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ABSTRACT 
Background: The global burden of kidney disease continues to rise but important gaps 
exist in our understanding of the prevalence of CKD and its complications globally and 
by region. Scarcity of evidence to guide public health decisions about CKD presents a 
serious challenge. There is a critical need to identify patterns of disease prevalence, risk 
factors and potential treatments. 
Methods: This thesis, based on contemporary evidence, has reported various 
epidemiological indices in kidney disease at a global and regional level, and explored 
whether regional dietary patterns might be associated with improved clinical outcomes. 
This research programme has utilised a series of quantitative methodologies, including 
meta-analysis of published randomised control trials (RCTs) and observational studies.  
Results: This research programme included a pooled analysis of disparate data sources 
to estimate the global burden of ESKD, the development of a novel collaboration 
among leading researchers in the field of nephrology in Asia: the Asian Renal 
Collaboration (ARC). Through a series of meta-analyses and pooled data analyses, the 
main findings of this thesis are that 1) 2.62 million people received RRT in 2010, but 
at least that many more did not have access to it and died prematurely due to ESKD,  2) 
370 million adults have earlier stage CKD in Asia, 3) renal anaemia prevalence 
increased with progressively worsening CKD and treatment  patterns varied 
dramatically,  4) a major shortage of evidence in exploring the Mediterranean diet as a 
potential therapeutic intervention for CKD, 5) potential beneficial effects of the 
Mediterranean diet on cardiovascular outcomes, 6) a lack of systematic data recording 
system in most countries in Asia.  
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Conclusion: This thesis highlights the importance of kidney disease as a global and 
regional problem, and the urgent need for a standardised data collection system for 
kidney disease to inform public health and clinical strategies. It also highlights the need 
for improved access to treatment for ESKD, and for methods to standardise evidence 
based care for the complications of kidney disease. Future research and resources to 
develop methods for prevention, early detection, and delay progression of CKD will 
also be key. The Mediterranean diet has shown moderate beneficial effects for multiple 
determinants of vascular risk, exploring the role of the Mediterranean diet in the onset 
and progression of CKD may be an important area of future research. 
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CHAPTER 1: Introduction  
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The human kidneys  
The kidneys are the waste filtering and disposal system of the human body. The kidneys 
perform a wide range of essential functions either independently or in combination with 
other organ systems. These include blood filtration and waste disposal, electrolyte and 
blood pressure homeostasis, and regulation of body fluid status. While a person could 
live a perfectly normal life with only one functioning kidney, the loss of both kidneys 
would lead to a rapid accumulation of wastes and death within a few days’ time.  
 
Acute kidney injury versus chronic kidney disease 
Kidney disease is a common condition worldwide1 that can arise rapidly or over a long 
period of time. Moreover, it’s a significant burden on national health budgets as the 
condition is extremely resource intensive to treat2 3. 
 
Acute kidney injury (AKI) refers to abrupt, usually reversible, loss of kidney function. 
AKI has a wide array of established risk factors as well as unidentified underlying 
aetiological factors, those contribute to the high rate of morbidity and mortality 4-6. This 
also leads to wide-ranging disease severity, from mild biochemical disturbances to 
severe renal impairment requiring artificial support in the form of acute dialysis.  
 
Definition of AKI has been controversial for last few decades. In fact, this has been a 
major impediment to the advancements of AKI management and improving outcomes 
in patients with AKI. Various observational studies since 1980s have reported outcomes 
in patients with AKI but had used varying inclusion criteria and definitions of AKI7 8. 
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A more recent review of those observational studies assessing pre-operative risk factors 
for post-operative AKI conducted in 1994, showed that none of the included 28 studies 
used same definition for AKI 9. This critical lack of a consensus agreement on definition 
had led to much uncertainty regarding the true magnitude of AKI, its risk factors and 
outcome of people with AKI.  
 
In recognition of this limitation, Acute Kidney Injury Network (AKIN) published a 
consensus definition of AKI10. The consensus definition defined AKI as: 
“An abrupt (within 48 hours) reduction in kidney function currently defined as an 
absolute increase in serum creatinine more than or equal to 0.3mg/dl (26.4 mmol/l), a 
percentage increase in serum creatinine of 50% (1.5 fold from baseline), or reduction 
in urine output (documented oliguria or <0.5 ml/kg per hour > 6 hours)” 10. 
 
Chronic kidney disease (CKD), the main focus of this thesis, is persistent reduction in 
kidney function or kidney damage lasting for more than three months. The National 
Kidney Foundation (NKF) Kidney Disease Quality Outcome Initiative (KDOQI) 
defined CKD as: 
“ Kidney damage for more than or equal to 3 months as defined by structural or 
functional abnormalities of the kidney, with or without decreased glomerular filtration 
rate, manifested  by either pathologic abnormalities or markers of damage (based on 
blood, urine or imaging tests) or glomerular filtration rate < 60 ml/min/1.73m2 with or 
without kidney damage” 11. 
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Chronic kidney disease 
Chronic kidney disease is the reduction of kidney function or kidney damage lasting 
over an extended time period. Onset of CKD can be rapid or gradual that develops over 
a period of time. Progression of CKD is highly variable while some individual’s kidney 
function may return to baseline others may either have stable but deranged kidney 
function or progress to end stage kidney disease (ESKD) requiring renal replacement 
therapy (RRT) to sustain life. General risk factors for cardiovascular disease such as 
obesity, diabetes mellitus, hypertension, and dyslipidaemia are also considered to be 
the risk factors for onset and progression of CKD. These risk factors also observed in 
higher rates in individuals with CKD compared to general population12.   
 
CKD is a life threatening multifaceted condition leading to substantial co-morbidity 
burden such as anaemia, metabolic bone disease and cardiovascular disease, which may 
in turn contribute to acceleration of the disease progression or premature death.  
Individuals with early CKD are more likely to die with a cardiovascular cause than 
kidney failure, in fact cardiovascular disease is the major cause of death in this group13 
14.   
Diagnosis and management of CKD imposes a substantial burden on the individual, 
family and the community as a whole. It is also a significant burden on national health 
budgets in most countries across the world. Although accurate national estimates are 
unavailable for many countries, some high income countries like Australia and the 
United States of America have estimated current costs and modelled for future costs 2 3 
15 16. 
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In Australia the total cost attributable solely to CKD in 2012, was estimated to be $4.1 
billion, made up of $2.5 billion in direct healthcare costs, $700 million in direct non-
healthcare costs, and $900 million in government subsidies2. The best available 
evidence on cost per person per year on dialysis was $79,072 for hospital 
haemodialysis, $49,137 for home haemodialysis and $53,112 for peritoneal dialysis3. 
 
CKD also negatively impacts on individual’s quality of life, particularly in those with 
advanced stages of the disease. In addition to having a significant negative impact on 
their own survival and long term outcomes, intense reductions in quality of life may 
impact on carer’s wellbeing as these individuals are often dependent on support from 
personal carers such as their family member or close friends17-19. 
 
CKD has a wide spectrum, ranging from minor urinary abnormalities to ESKD. 
Accurate assessment of kidney function is crucial to the kidney disease staging and 
appropriate management. The glomerular filtration rate (GFR), the rate of fluid filtered 
through the kidney, is a reliable marker of the level of kidney function. GFR can either 
be accurately assessed with urinary creatinine or isotopic clearance, or estimated 
(eGFR) based on serum creatinine level. The selection of the most appropriate 
measurement of renal function depends on the clinical question being asked, the 
accuracy required and the inconvenience to the patient. Serum creatinine and estimated 
glomerular filtration rate (eGFR) yield a reasonable estimation of renal function with 
minimal cost and inconvenience. Isotopic measurement of glomerular filtration rate can 
be used when greater accuracy is required, when renal function is poor or muscle mass 
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is significantly outside the normal range. In routine clinical practice estimated 
glomerular filtration rate (eGFR) is widely used. 
 
There are number of formulae such as the Cockcroft-Gault formula, Modification of 
Diet in Renal Disease (MDRD) formula and more recently Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula, have been developed and widely 
accepted to calculate the eGFR. The Cockcroft-Gault formula is used to estimate the 
creatinine clearance, and then estimates the eGFR20. The Modification of Diet in Renal 
Disease (MDRD) formula, developed by the MDRD study group, estimates the GFR 
based on 4 or 6 variables21. However, several limitations were identified in MDRD 
method, including its inability to adjust for individual’s body mass22 and 
underestimation of eGFR in people with higher GFR23. To address these uncertainties, 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently developed a 
new formula that produces more precise estimates of eGFR, particularly in people with 
GFR > 60ml/min/1.73m2 24. CKD-EPI formula is now widely used and has been 
validated to be a superior method compared to the MDRD formula25.  
The National Kidney Foundation (NKF) Kidney Disease Quality Outcome Initiative 
(KDOQI) stratified CKD into five stages based on GFR. The table 1 shows the 
classification of chronic kidney disease according to NKF-KDOQI. 
Table 1: National Kidney Foundation Kidney Disease Quality Outcome Initiative 
(NKF-K/DOQI) stages of chronic kidney disease (CKD) 
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Table taken from NKF 200211 , GFR: glomerular filtration rate  
 
Epidemiology of chronic kidney disease  
Chronic kidney disease (CKD) affects a substantial proportion of subjects in population 
representative surveys, although the proportion of people with reduced eGFR has been 
reported to vary from less than 2% in China26 to over 15% in Thailand27, with 
Australia28 and USA29 reporting intermediate levels. Similar variations in the 
prevalence of end stage kidney disease (ESKD) have also been reported, with the 
highest rates in the world reported by Taiwan and Japan30. The reasons for this 
substantial variation in prevalence appear multifactorial.  
 
In a cross-sectional survey of a nationally representative sample of 47,204 Chinese 
adults the adjusted prevalence of eGFR <60mL/min/1·73m2 was reported to be 1·7% 
(95%CI 1·5-1·9) and of albuminuria was 9·4% (8·9-10·0). The overall prevalence of 
chronic kidney disease was reported to be 10·8% (10·2-11·3)26.  
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In Thailand, the prevalence of stage 3 and 5 chronic kidney disease were estimated from 
a representative sample of individuals aged 35 years and above using a stratified, 
multistage, cluster-sampling method using the Cockroft-Gault and the simplified 
Modification of Diet in Renal Disease (MDRD) formulae. The prevalence of stage 3 
disease among individuals aged 35 years and above was estimated to be about 20% 
using the Cockroft-Gault formula and about 13% from the MDRD formula. Stage 
3disease was present in about 0.9% and 0.6% of this population using the respective 
formulae 27. 
 
The Australian Obesity and Lifestyle Study (AusDiab) which screened 11247 
Australian adults >25 years, examined the associations between age, gender, diabetes 
mellitus, and hypertension, and indicators of kidney damage. Proteinuria was detected 
in 2.4% (95% CI: 1.6-3.1), haematuria in 4.6% (95% CI: 3.8-5.4), and reduced GFR by 
Cockcroft-Gault formula (<60 ml/min/1.73 m2) in 11.2% (95% CI: 8.6-13.8). 
Approximately 16% had at least one indicator of kidney damage28. CKD prevalence 
was much greater in older compared to younger Australians and among indigenous 
compared to non-indigenous Australians.  
 
A study examining the prevalence of CKD in the United States, based on cross-
sectional analysis of the most recent National Health and Nutrition Examination 
Surveys (NHANES), a nationally representative sample of noninstitutionalized adults 
aged 20 years or older (15488 in NHANES 1988-1994 and 13233 in NHANES 1999-
2004) reported the prevalence of CKD stages 1 to 4 increased from 10.0% (95% 
confidence interval [CI], 9.2-10.9) in 1988-1994 to 13.1% (95% CI, 12.0-14.1) in 1999-
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2004. The prevalence of CKD stages in 1988-1994 and 1999-2004, respectively, were 
1.7% (95% CI, 1.3-2.2) and 1.8% (95% CI, 1.4-2.3) for stage 1; 2.7% (95% CI, 2.2-
3.2) and 3.2% (95% CI, 2.6-3.9) for stage 2; 5.4% (95% CI, 4.9-6.0) and 7.7% (95% 
CI, 7.0-8.4) for stage 3; and 0.21% (95% CI, 0.15-0.27) and 0.35% (95%CI, 0.25-0.45) 
for stage 4. Moderately reduced GFR, defined as eGFR 30-59 ml/min/1.73 m2, 
increased from 5.4% to 7.7%29. 
 
Systematic data collection subsequent to establishing large national data registries has 
significantly advanced our knowledge of kidney disease. Currently, number of large 
nationally representative databases exist, not only in North America and Europe 
(United States Renal Data System (USRDS), Canadian Organ Replacement Register, 
European Renal Association – European Dialysis and Transplant Association (ERA-
EDTA) registry)  but also in Asia (Australian and New Zealand Dialysis and Transplant 
Registry, Taiwan Renal registry, Japan Society of Dialysis and Transplant database, 
Insan Memorial Dialysis Registry in South Korea, Singapore Renal Registry) and other 
parts of the world (Caribbean Renal Registry). These registries report the various 
epidemiological indices related to CKD such as incidence, prevalence and outcomes of 
people with CKD, particularly in ESKD. 
ANZDATA registry showed that 2654 people started renal replacement therapy in 
2015, with an overall incidence rate of 112 per million population31. At the end of 2015, 
23,012 people were receiving renal replacement therapy with an overall prevalence of 
968 per million population. The prevalence of both dialysis and transplantation 
continues to grow in Australia, although the growth in dialysis prevalence has slowed 
in recent years31. 
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More than half of the population of the world lives in the Asia-Pacific region. While a 
number of studies have reported the prevalence of CKD and ESKD in individual 
countries26-28, the CKD or ESKD prevalence across the region (and globally) has not 
been systematically assessed and documented, leading to suboptimal recognition of the 
importance of kidney disease as a public health problem. Reducing this burden of 
kidney disease requires a clear recognition of key aetiological factors and their 
consistency across a range of populations including Asians. Previous studies have 
identified blood pressure32, glucose32 and socio-economic status33 as key predictors of 
the risk of major renal outcomes. A number of trials of blood pressure34-36 and glucose 
lowering37-39 have been undertaken, with substantial Asian populations enrolled. 
However, there may well be other unrecognised aetiological factors applicable to 
kidney disease such as regional diets40, exposure to chemicals used in agriculture41-43 
and heavy metals44 45. To date, there has been no systematic effort to document the 
burden of different stages of chronic kidney disease, aetiological factors or outcome 
globally or across the Asia Pacific region. 
 
Overview of the thesis 
This thesis attempts to address the current gaps in knowledge regarding the prevalence 
of kidney disease globally, but with a focus on the Asia Pacific region and potential 
region based therapeutic interventions.  
 
Defining the burden of CKD  
1. Worldwide access to renal replacement therapy (Chapter 2) 
2. Asian Renal Collaboration Project  (Chapter 3) 
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3. CKD prevalence in Asia (Chapter 4) 
4. Prevalence of renal anaemia in Asia (Chapter 5) 
5. Impact of CKD on quality of life (Appendix 1) 
 
Potential regional strategies to reduce the burden of CKD 
1. Effects of Mediterranean diet on kidney outcomes (Chapter 6) 
2. Effects of the Mediterranean diet on cardiovascular outcomes (Chapter 7) 
Based on the findings of this thesis, I propose directions for future research regarding 
defining and reducing the kidney disease burden.  
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CHAPTER 2: Worldwide access to treatment for end stage kidney disease: a 
systematic review  
  
13 
 
Rationale 
Renal replacement therapy (RRT), through either dialysis or renal transplantation, is a 
lifesaving yet high-cost therapy for people with end-stage kidney disease (ESKD). 
Despite the heavy disease burden and expected sharp rise, neither the prevalence of 
ESKD nor the use of RRT are well quantified in large parts of the world. To develop 
service provision strategies it is important to understand the current disease burden, 
availability of RRT, and to develop projections of future need. In this study we 
quantified the current global burden of ESKD, use of RRT and estimated future trends.  
 
Publication details 
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao M, Lv J, Garg 
AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide 
access to treatment for end-stage kidney disease: a systematic review. Lancet 
2015;385(9981):1975-82. 
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Abstract 
Introduction 
End-stage kidney disease (ESKD) is a leading cause of morbidity and mortality 
worldwide. The prevalence of ESKD and the worldwide use of renal replacement 
therapy (RRT) are expected to rise sharply over the next decade, but neither are well 
quantified. 
 
Methods 
We systematically searched MEDLINE for observational studies and renal registries, 
and contacted national experts, to obtain RRT prevalence data. Poisson regression was 
used to estimate the prevalence of RRT for countries without reported data. Estimates 
of the gap between required and actual RRT were made along with projections to 2030. 
 
Results 
In 2010, 2.62 million people received RRT worldwide.  The number of patients 
requiring RRT was estimated to be between 4.9 (4.4-5.4, conservative model) and 9.7 
(8.5-11, high model) million suggesting that at least 2.3 million people died prematurely 
because RRT could not be accessed.  The largest treatment gaps were observed in lower 
income countries, particularly in Asia and Africa.  Global use of RRT is projected to 
more than double to 5.4 million (3.9-7.6) by 2030 with the most growth in Asia. 
 
Conclusion 
The large number of people receiving RRT and the substantial number without access 
to it show the need to both develop low-cost treatments and implement effective 
population-based prevention strategies. 
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Introduction 
Renal replacement therapy (RRT), through either dialysis or renal transplantation, is a 
lifesaving yet high-cost therapy for people with end-stage kidney disease (ESKD). It 
has been available in high-income countries for more than 50 years, with rapid growth 
in the number of people being treated over this time. The use of dialysis to treat ESKD 
varies considerably between regions, likely due to differences in population 
demographics, the prevalence of ESKD and factors influencing access to and provision 
of RRT16 46. 
 
It has been suggested that the prevalence of ESKD may rise sharply over the next few 
decades, driven by population aging and an increasing prevalence of diabetes mellitus 
and hypertension1 16 47. The demographic transition driving this is expected to occur 
predominantly in developing rather than developed regions, challenging the economic 
capacity of many countries to provide RRT to an increasing number of people with 
ESKD48-50. 
 
To develop service provision strategies for people with ESKD it is important to 
understand the current burden of the condition, availability of RRT, and to develop 
projections of future need. In this study we quantified the current global burden of 
ESKD, use of RRT and estimated future trends.  
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Methods 
Data sources and searches 
We systematically searched the literature describing the prevalence of ESKD in 
countries around the world according to the MOOSE group consensus statement for the 
conduct of meta-analyses of observational studies51. We defined ESKD as kidney 
failure requiring ongoing maintenance dialysis or a kidney transplant for survival, and 
RRT as any form of maintenance dialysis, either haemodialysis or peritoneal dialysis, 
or kidney transplantation, excluding short term dialysis methods for acute kidney injury 
such as continuous venovenous haemofiltration/ haemodialysis/ haemodiafiltration and 
acute peritoneal dialysis. We also collected separate data on dialysis prevalence. All 
completed studies, review articles and registries reporting the epidemiology of ESKD 
and/or RRT, after the year 2000, were eligible for inclusion. Two authors (TL and TN) 
independently conducted the literature search using a standardised approach.  Because 
of the paucity of data on the incidence of ESKD it was decided to restrict this analysis 
to prevalence data.  
 
Relevant studies were identified by searching MEDLINE via Ovid (from 1950 through 
August 2013) using relevant text words and medical subject headings that included all 
spellings of renal replacement therapy, renal dialysis, kidney transplantation, 
haemodialysis, peritoneal dialysis, renal transplant, incidence, prevalence, and 
epidemiology without language restriction (Appendix 2.1). Reference lists from 
identified reports and review articles were manually scanned to identify any other 
relevant studies. We also performed Google and Google Scholar searches using 
individual country names for relevant information such as conference proceedings and 
individual country or regional registries. Additionally, we contacted experts in the field 
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for more recent unpublished data from regions where reliable data were unavailable or 
available data were out of date. Taiwan and Hong Kong were assessed separately from 
China because they use different renal registry systems from those used on the 
mainland. 
 
Life expectancy at birth, the median age of the population and population size by 5-
year age groups for the year 2010 were obtained from the United Nations Department 
of Economic and Social Affairs website, along with future projections for each 
country52. Information on gross national income (GNI) and the forecast annual change 
in gross domestic product (GDP) for each country (out to 2018) were obtained from the 
World Bank website53 and the International Monetary Fund website54 respectively. The 
relevant data for Taiwan were obtained from the Frederick S Pardee Centre for 
International Futures55. Data regarding prevalence of diabetes and hypertension were 
found in the website of the Global Health Observatory Data Repository56.  
 
Data extraction  
We obtained published reports for each renal registry, review article and individual 
study (Supplementary table 1) and extracted standard information. For the prevalence 
of dialysis and renal transplantation, when available, ESKD registries were considered 
the primary information source for data extraction, otherwise individual articles were 
used. The most recent available data were used.  We categorised data sources to high, 
good or moderate quality. The formalised national registries were considered high 
quality, published national and regional surveys were considered good quality, while 
all other sources were considered of moderate quality (Supplementary table 1).  
 
21 
 
Statistical analysis 
We used the SAS software package (SAS Institute Inc., Cary, NC) to perform all 
statistical analyses. Two-sided values of p <0.05 were considered statistically 
significant in all analyses. 
 
a) Estimation of the number of people receiving RRT 
The actual numbers of patients receiving RRT in each country were collected where 
available, or were estimated by multiplying the prevalence of RRT by the total 
population in each country.  For 71 countries and Hong Kong, the prevalence of RRT 
was based on combined data about renal transplantation and dialysis and for 52 
countries and Taiwan it was based on dialysis only. For the 76 countries and Macao 
without reported prevalence data, a national estimate was made using a multivariable 
Poisson regression and generalized estimating equation (GEE) (Model 1, Appendix 
2.2).   This model used the information available from the 123 countries (125 data) with 
prevalence data in conjunction with life-expectancy at birth and gross national income 
to derive a national estimate57. Global estimates were made by summing numbers across 
the 199 countries. 
 
b) Estimation of numbers requiring RRT  
It is widely recognised that access to RRT is limited in many countries and reported 
numbers using RRT are likely to under-estimate requirements. To estimate the total 
number of people requiring RRT we used age-specific prevalence data for RRT from 
20 high-income countries (Table 3). For four of these countries (USA, Taiwan, Korea, 
Singapore) RRT is known to be provided to almost all individuals requiring it.  For at 
least some of the remaining 16 countries it has been reported that about one half of 
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people requiring RRT receive it 58 59. We developed high and low estimates of the total 
national requirement for RRT in every country by applying estimated age-specific 
prevalence data on RRT to the population of every country in the world. This was again 
done using Poisson regression models with GEE (Model 2, Appendix 2.3).  The model 
developed using the data drawn from the 4 countries where RRT uptake is high was 
used to provide an upper estimate of the likely need for RRT in each country.  The 
model developed using the data drawn from the 16 countries where RRT uptake is 
known to be incomplete was used to provide a lower estimate of the likely need for 
RRT in each country (Supplementary figure 1). Once again, global estimates were made 
by summing numbers across the 199 countries. 
 
c) Estimating the future number of people receiving RRT  
Future projections of national prevalence of RRT for each country were calculated by 
applying an estimate of the annual percentage change in GNI to the baseline figures 
obtained which was extrapolated from the annual percentage change of GDP from 2010 
to each year. Beyond 2018, the annual percentage change of GNI up to 2018 was 
projected to continue. The national projections were calibrated using the baseline 
prevalence of RRT in a similar way to that done for risk equations (Appendix 2.3)60. 
The number of patients receiving RRT for each year was calculated by multiplying the 
estimated prevalence of RRT for each year by the total population projected for each 
year based upon data obtained from the United Nations Department of Economic and 
Social Affairs. Global estimates were made by summing data across countries. 
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Role of funding source 
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or manuscript preparation and the decision to submit. TL, TN, VJ, JK and VP had 
access to all data. VP was responsible for the decision to submit the manuscript.  
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Results 
Search results 
Our search strategy identified 3611 articles of which 68 were selected for full text 
review. We also identified 9 potential articles from other sources such as conference 
proceedings, input from the experts in the field and Google and Google Scholar 
searches using individual country names. We included 18 articles in this study after full 
text review of these 77 reports (Figure 1). These included 13 renal registries, of which 
four reported regional data for a total of 42 countries and six reported individual country 
data (Supplementary table 1). Additionally, experts in the area provided unpublished 
data regarding the number of people undergoing RRT for a number of countries - 
namely India, Pakistan, Bangladesh, Thailand61, China 62and African countries63. In 
total, we obtained prevalence data on dialysis for 123 countries (125 data elements) 
representing 93% of the global population.  
 
Characteristics of countries included studies 
When categorised geographically, data were available for countries in all 6 major 
regions but covered a variable proportion of the included countries for each region. 
Dialysis prevalence data were obtained for 31 African countries (81% of population in 
Africa), 28 Asian countries (94%), 35 European countries (98%), 25 Latin American 
and Caribbean countries (98%), 2 North American countries (100%) and 2 countries in 
Oceania (74%). In addition, we obtained age-specific dialysis prevalence rates from 20 
high-income countries in Europe, North America, Japan, Taiwan, Singapore, and 
Oceania (11.6% of global population) (Supplementary table 2).  
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Data quality  
The completeness and robustness of the data capture and reporting used for data 
extraction varied considerably. High quality reports were available for 57 countries 
(including Hong Kong and Taiwan), good quality reports for 62 countries and moderate 
quality reports from six countries. Even within the high quality reports there were 
noticeable differences in catchment area (national vs. regional), data collection and 
reporting methods (mandatory vs. voluntary) and level of internal and external 
validation. Age specific RRT prevalence data of 20 countries were derived from high 
quality reports. 
 
Global number of patients receiving dialysis and RRT 
In total, 2.62 million people received RRT in 2010. 2.05 million (78%) were treated 
with dialysis and the remainder received a transplant (Table 2). Actual data were 
available for 99% of these people, from the 123 countries with available data, whereas 
the prevalence in the 77 countries without available data was estimated by using Model 
1 (Figure 2). To develop Model 1, the predictors of RRT prevalence were found to be 
GNI and life expectancy (both p<0.0001) but not the prevalence of diabetes or 
hypertension (both p> 0.2) (Supplementary figure 2, Appendix 2.2). The validity of 
model 1, developed based on data from 20 high-income countries, was evaluated by 
assessing the consistency of actual and estimated number of patients receiving dialysis 
in the 123 countries for which data were available (R2=0.80, interclass correlation 
coefficient (1,1)=0.86) (Supplementary figure 3). 
The prevalence of RRT varied widely both within and across geographical regions, 
ranging from 80 per million population (pmp) in Africa to 1,840 pmp in North America 
(Figure 2 and 3). The absolute number of people receiving RRT was highest in Asia 
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(0.97 million) and North America (0.64 million). With regard to income levels, the 
prevalence of RRT increased steeply with higher income levels (Figure 3). The majority 
of RRT recipients (92.8%) were in high (1.63 million) and upper-middle (0.80 million) 
income countries, with only 7.2% of the RRT recipients living in lower middle income 
(0.17 million) and low income (0.02 million) countries  (Figure 4).  
 
Global number of patients requiring RRT 
The number of patients requiring RRT was calculated using age-standardised data from 
the 20 high-income countries for which age specific prevalence estimates were 
available. The prevalence of patients undergoing RRT steadily increased with age, but 
there were two groups of countries with a manifestly different patterns in older ages: 4 
countries (USA, Japan, Taiwan and Singapore) had a very high prevalence of RRT, 
particularly in the elderly, whereas the remaining 16 countries had a more modest 
prevalence (Supplementary Figure 1 and Table 3). 
 
In total, the numbers of patients requiring RRT in 2010 was estimated to be 4.90 (95% 
CI, 4.44-5.43) million when using the model derived from the data in 16 countries 
(conservatively-estimated model) in which implementation of RRT is likely to be 
partial. The estimate was 9.70 (8.55-11.02) million when using the model derived from 
data in the four countries (high-estimate model) with near-complete levels of RRT use 
(Table 2). This analysis suggests that between 47% (2.3 million patients) and 73% (7.1 
million patients) of those requiring RRT globally did not receive it. By region, Asia 
was estimated to have the highest number of people in need of RRT, but the number 
actually receiving this therapy ranged from 17% to 34% across the two models. Africa 
had the lowest access to RRT of all ranging between 9 and 16%. Middle and Eastern 
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Africa had remarkably lower access compared to rest of the continent with only 1-3% 
in need of treatment receiving RRT (supplementary table 3).  
 
Future projections of the number of patients undergoing RRT  
Based on data describing demographic projections and the forecast rate of economic 
growth, it is estimated that the projected number of people receiving RRT will more 
than double from 2.62 million people in 2010 to 5.44 (95% CI, 3.90-7.64) million 
worldwide in 2030. The largest absolute growth in the number of people receiving RRT 
is projected for Asia rising from 0.97 million in 2010 to 2.16 (1.57-3.01) million by 
2030. The number of people receiving RRT is also forecast to increase rapidly in Africa, 
from 0.08 to 0.24 (0.17-0.35) million, as well as Latin America and the Caribbean (2.5-
fold), from 0.37 to 0.90 (0.66-1.23) million, by 2030 (Figure 5).   
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Discussion 
In this study we have used the best available data to calculate the number of people 
receiving RRT in 2010, finding that approximately 2.62 million people received this 
life sustaining treatment around the world. Additionally, our findings have suggested 
that at best only a half or less of all people requiring RRT around the world currently 
have access to it so that at least 2.3 million people died prematurely due to lack of 
access to therapy. The majority of this burden of preventable deaths was experienced 
in low and middle-income countries. Further modelling suggests that the number of 
people undergoing RRT will more than double to 5.4 million by 2030, mostly in 
developing regions such as Asia and Africa, however the number of people without 
access to RRT will remain substantial. These data highlight a pressing need to develop 
low cost RRT alternatives to reduce disparities in accessing the therapy, as well as the 
importance of developing, implementing and evaluating cost-effective ESKD 
prevention strategies. 
 
These estimates build on and extend previous estimates of the global ESKD burden, 
where the number of people estimated to be receiving RRT have increased steadily 
from 1.1 million people during the 1990s64, 1.8 million in 200465, 1.9 million in 200566 
and now 2.62 million in 2010. Our data suggest this trend is likely to continue, driven 
by change in demographics, especially aging of the global population, as well as 
improvements in access to dialysis in countries with growing economies. Importantly, 
these estimates do not take account of any future changes in the prevalence in ESKD 
potentially driven by projected increases in diabetes48 or hypertension50 or due to 
changes in urbanisation, diet and physical activity49, as relationships between these 
parameters and RRT prevalence were not apparent in our analysis. Nonetheless, these 
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variables are highly likely to be captured in the model due to the high degree of 
collinearity with life expectancy and economic development. The lack of an observed 
association may also be the result of the aggregate nature of the data obtained, which 
may obscure relationships that would be apparent if more granular data were available. 
Any increases in the prevalence of diabetes and hypertension may thus be additional to 
those estimated in this analysis, and likely bring with them further preventable deaths 
and additional health-care costs. 
 
The most important finding of this analysis is that there are a large number of people in 
need of RRT around the world who do not currently receive it. One previous study used 
national rates of diabetes mellitus and hypertension to estimate incidence rates of ESKD 
and access to RRT, and suggested that more than 1.2 million premature deaths occurred 
as a result of untreated ESKD related to diabetes and hypertension66.  However we did 
not find a strong relationship between these risk factors and the prevalence of RRT at a 
national level, but instead found age, life expectancy and economic development were 
the strongest drivers.  While economic factors have been previously reported to be 
predictors of RRT prevalence47 67 68, the observation regarding the relationship between 
average life expectancy and RRT prevalence is novel. The strong predictive ability of 
our model for the prevalence of RRT suggests that this approach is robust.   
 
The large number of deaths occurring due to the lack of access to treatment sets a 
demanding task for the nephrology community, as well as the broader healthcare and 
research communities. While documenting the magnitude of the problem is a necessary 
first step, the size of the gap demands a combined advocacy, healthcare delivery and 
research approach46. First, governments should be made aware of the number of 
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preventable deaths in their jurisdictions, and lobbied to increase access to dialysis for 
affected individuals where this is affordable in the context of the broader health needs 
of their population. Second, effective population-based approaches to prevention of 
ESKD such as blood pressure control69, renin angiotensin system blockade and 
management of key risk factors including diabetes and obesity70, as well as acute kidney 
injury (AKI)71 must be refined and tested. Innovative models of preventive care should 
be piloted in low and middle-income countries, especially in areas where access to 
physicians is low72. There is evidence from countries including the United Kingdom, 
Chile, Uruguay and Taiwan to suggest that multifaceted preventative strategies might 
stabilise or even reduce RRT incidence rates, and lead to cost savings73-76. These models 
should be implemented more widely and rigorously evaluated. Third, more cost-
effective dialysis techniques must be developed and made available. For the foreseeable 
future, current dialysis modalities costing tens of thousands of dollars per patient per 
annum will remain unaffordable for many of the countries where access to RRT is 
lowest. Considering the increase in the expected number of patients requiring treatment, 
dialysis provision will represent a substantial financial burden for even the most 
affluent countries in the years ahead. Finally, barriers to receiving a kidney transplant 
must be identified and removed, as this is the most cost-effective form of RRT, and 
produces the best outcomes47.  Professional bodies such as the International Society of 
Nephrology have a key role to play in this effort.  
 
Our study has several strengths. We collected contemporary data from 123 countries 
(almost double the most recent report)66 including 93% of the global population using 
a comprehensive and systemic approach, with conservative estimates used wherever 
possible. This study reports estimates of RRT use around the world, and uses the most 
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reliable available methods to develop estimates of premature deaths due to lack of 
access to RRT. It also expands on previous studies by identifying a new association 
with life expectancy.  
 
A number of limitations must also be considered, primarily as a consequence of 
variability in the datasets used and their quality and reliability. The available data were 
not complete for some countries, and the two largest countries in the world, China and 
India, do not have comprehensive national registries. Nonetheless, we have obtained 
data from the most reliable available sources and believe that any variability in the 
reliability of estimates for these countries would have a modest impact on the results at 
most. We were unable to identify sufficient RRT incidence data to allow meaningful 
analysis of incidence rates. Since we considered national dialysis prevalence as equal 
to total RRT prevalence where renal transplantation data were unavailable, the number 
of patients receiving RRT would likely be slightly underestimated in this study. We 
also recognise that there is a much larger number of patients with kidney failure (eGFR 
<15ml/min/1.73m2) as defined by the Kidney Disease: Improving Global Outcomes 
(KDIGO) group77 than the number requiring RRT, as the indications for RRT are 
neither clear nor uniform. The models required a series of assumptions but each was 
well supported by the available data and while strong predictive ability was achieved, 
substantial variation was still observed. We developed two different models of expected 
RRT need, and have focused on the more conservative of these to minimise the risk of 
overestimation. Finally, our estimates do not take account of ongoing changes such as 
urbanisation and westernisation, and their association with rapidly increasing rates of 
diabetes and hypertension, so the estimates here may be conservative and underestimate 
the future burden of disease. 
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Conclusion 
The number of people receiving RRT is projected to grow from 2.62 million in 2010 to 
5.4 million by 2030. Between 2.3 and 7.1 million people who could have been kept 
alive with RRT in 2010 died prematurely due to a lack of access to RRT. Most of these 
deaths occurred in low and middle income countries in Asia, Africa and Latin America. 
The predicted growth in the prevalence of ESKD demands the development of 
affordable RRT modalities as well as the implementation of effective and affordable 
early detection and prevention programs for chronic kidney disease.  
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Panel: research in context 
Systematic review 
We systematically searched MEDLINE for observational studies, review articles and 
registry reports describing dialysis and/or RRT prevalence published up to August 31, 
2013, using all spellings and synonyms of the search terms “renal replacement therapy”, 
“renal dialysis”, “kidney transplantation”, “haemodialysis”, “peritoneal dialysis”, 
“renal transplant”, “incidence”, “prevalence” and “epidemiology” without language 
restriction. We also performed Google and Google Scholar searches using individual 
country names and contacted national experts for more recent unpublished data. In total, 
we obtained prevalence data on dialysis for 123 countries (125 data elements) 
representing 93% of the global population. 
 
Interpretation  
Despite the heavy disease burden and expected sharp rise, neither the prevalence of 
ESKD nor the use of RRT are well quantified in large parts of the world. We found that 
more than 2.6 million people are receiving RRT globally, an estimate which is several 
years more current and based on much more data than previous analyses. Our projection 
model estimates that the total number of people receiving RRT globally will more than 
double by 2030, with the greatest growth in Asia.  
It also suggests, based on a newly identified association with life expectancy as well as 
the recognised association with economic development, that only one quarter to one 
half of people requiring RRT receive this therapy. These findings highlight the need for 
programs focused on prevention as well as improving access to RRT. 
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Appendix 2.1 
MEDLINE search strategy  
1. exp Renal Replacement Therapy/ 
2. exp Renal Dialysis/ 
3. exp Kidney Transplant/ 
4. h?emodialysis.tw 
5. peritoneal dialysis.tw 
6. renal transplant$.tw 
7. exp Incidence/ 
8. exp Prevalence/ 
9. exp Epidemiology/ 
10. exp Cross-Sectional Studies/ 
11. exp Cohort Studies/ 
12. exp Follow-Up Studies/ 
13. or/1-6 
14. or/7-9 
15. or/10-12 
16. and/13-15 
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Appendix 2.2 
Development of model 1 
To estimate the global number of patients undergoing RRT we first investigated the 
association of several factors including life expectancy at birth, GNI per capita, 
prevalence of diabetes and hypertension with prevalence of dialysis among 123 
countries (125 data) with reported RRT prevalence data for 2010. Seven countries, with 
populations of less than 1 million, did not have data for GNI available, so the average 
value of GNI in low-income countries (US$500) was used. As shown in Figure 2, the 
prevalence of dialysis was significantly associated with longer life-expectancy at birth 
and higher log-transformed GNI per capita (both p<0.001), but there was no such 
association with national prevalence of diabetes or hypertension (both p values>0.20) 
(Supplementary Figure 2). Life-expectancy at birth and log-transformed GNI were 
included in the multivariable model for estimating the prevalence of dialysis for each 
country (Model 1) as follow:  
 
Prevalence of dialysis (pmp) = exp(-18.534+0.079*Life expectancy at birth [years, 
p=0.02] + 0.514*Log (GNI) [US$, p<0.001])*106  (Model 1) 
 
To evaluate the validity of this formula, we assessed the consistency between the actual 
and estimated number of cases (where actual data was available) using the coefficient 
of determination (i.e. R-square) and interclass correlation coefficient among 123 
countries (125 data). As a consequence, the estimated numbers of patients with RRT 
were well consistent with the actual number (R-square=0.80, Interclass correlation 
coefficient=0.86) (Supplementary Figure 3). Median age of population was also 
significantly associated with prevalence of dialysis (beta=0.121, p<0.001). However, 
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life expectancy was used to estimate prevalence of dialysis for the countries without 
available data, because median age and life expectancy at birth was strongly correlated 
each other (r=0.78) and the model including life expectancy at birth was more fitted 
than the model including median age of population. 
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Appendix 2.3 
Development of model 2 
For countries with available data in 2010 that has been reported, the intercept of the 
estimation model for individual countries was calibrated with actual prevalence data in 
2010, assuming the original coefficient of unity. 
 
   Actual prevalence in 2010 = exp (μ + [α + β1* life expectancy in 2010 + β2*GNI in 2010])  
   = exp(μ)* estimated prevalence in 2010 = θ *Estimated prevalence in 2010, 
where μ is constant for the calibration, the formula of square brackets is the formula for 
the estimated prevalence and θ= exp(μ). 
 
Thus,  
   θ= exp(μ) = Actual prevalence in 2010/ Estimated prevalence in 2010 
   Calibrated prevalence in yeari = θ *estimated prevalence in yeari  
    = exp(μ + [α + β1* life expectancy in yeari + β2*GNI in  yeari])   
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Figure 1: Identification process for eligible studies  
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Figure 2: Global number of patients receiving renal replacement therapy in 2010 
                   
41 
 
Figure 3: Prevalence of patients receiving renal replacement therapy and their numbers according to regions. 
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Figure 4: Prevalence of patients receiving renal replacement therapy and their numbers according to income levels 
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Figure 5: Trend in the estimated number of patients undergoing RRT from 2010 to 2030  
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Supplementary figure 1: Association between age and prevalence of patients receiving RRT in 20 high-income countries with available age-
specific data  
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Supplementary figure 2: Association between risk factors and prevalence of patients receiving dialysis in 123 countries  
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Supplementary figure 3: The consistency between the actual and estimated number of patients receiving dialysis in 123 countries  
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Table 2: Estimated number of patients receiving renal replacement therapy worldwide and by region or income levels in 2010  
 Number of 
population   
(x 1000) 
Patients receiving 
dialysis 
 Patients receiving 
RRTa) 
 Patients requiring RRT calculated by 
conservatively-estimated model 
 Patients requiring RRT calculated 
by high-estimated model 
Estimated 
number 
(x 1000) 
Prevalence 
(pmp) 
 
Estimated 
number 
(x 1000) 
Prevalence 
(pmp) 
 
Estimated 
number 
(x 1000) 
Prevalence 
(pmp) 
%Gap  
Estimated 
number 
(x 1000) 
Prevalence 
(pmp) 
%Gap 
World 6,915,149 2,050 296  2,618 379  4,902 709 -47%  9,701 1,403 -73% 
Region               
Africa 1,031,079 81 79  83 80  515 499 -84%  949 921 -91% 
Asia 4,165,440 909 218  968 232  2,875 690 -66%  5,632 1,352 -83% 
Europe 739,963 327 442  532 719  759 1,026 -30%  1,600 2,162 -67% 
Latin America and 
the Caribbean 
595,872 276 463  373 626  401 673 -7%  785 1,318 -53% 
Northern America 346,373 441 1,275  637 1,840  323 934 97%b)  673 1,942 -5% 
Oceania 36,420 15 405  25 695  30 824 -16%  61 1,682 -59% 
               
Income level c)               
Low income 793,525 16 20  16 20  408 514 -96%  757 955 -98% 
Lower-middle income 2,496,046 170 68  172 69  1,486 595 -88%  2,833 1,135 -94% 
Upper-middle income 2,520,598 688 273  803 318  1,903 755 -58%  3,783 1,501 -79% 
High income 1,104,980 1,176 1,064  1,628 1,473  1,106 1,001 47%  2,327 2,106 -30% 
Abbreviations: RRT, renal replacement therapy; pmp, per million population 
a) In countries without available information of renal transplantation, number of RRT were estimated to be same as number of dialysis. 
b) In conservatively-estimated model, estimated prevalence of patients receiving RRT was lower than actual one in 4 countries with high prevalence-namely-USA, Japan, Taiwan 
and Singapore. 
c) Income levels were categorized according to the World Bank income groups in 2010: low income, GNI per capita ≤$1,005; Lower-middle income, $1,006-$3,975; Upper-middle 
income, $3,976-$12,275; High income, ≥$12,276. 
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Table 3: Estimated age-specific prevalence (95% confidence interval) of patients with end-stage kidney disease on the basis of the data from 20 
high-income countries  
 
High-estimated model 
(USA, Japan, Taiwan and Singapore) 
 Conservatively-estimated model 
(Other 16 counties) a) 
Age categories Prevalence, pmp (95% CI)  Prevalence, pmp (95% CI) 
0-19 years 309.5 (285.3 to 335.7)  214.1 (177.8 to 257.7) 
20-24 years 561.3 (512.1 to 615.1)  352.8 (311.5 to 399.6) 
25-29 years 705.7 (640.9 to 777.1)  427.6 (386.3 to 473.3) 
30-34 years 887.2 (801.8 to 981.9)  518.2 (478.6 to 561.1) 
35-39 years 1115.6 (1002.8 to 1241.2)  628.0 (592.1 to 666.1) 
40-44 years 1402.6 (1253.8 to 1569.2)  761.1 (729.7 to 793.8) 
45-49 years 1763.6 (1567.3 to 1984.5)  922.3 (890.3 to 955.5) 
50-54 years 2217.4 (1958.8 to 2509.9)  1117.8 (1070.3 to 1167.3) 
55-59 years 2788.1 (2448.0 to 3175.2)  1354.7 (1275.0 to 1439.3) 
60-64 years 3505.2 (3058.6 to 4017.1)  1641.7 (1513.4 to 1780.8) 
65-69 years 4407.3 (3821.5 to 5083.3)  1989.4 (1793.7 to 2206.8) 
70-74 years 5541.4 (4773.9 to 6432.4)  2411.0 (2124.5 to 2736.4) 
75-79 years 6967.5 (5962.9 to 8141.3)  2922.0 (2515.5 to 3394.2) 
≥80 years 10050.8 (8510.1 to 11869.3)  3973.9 (3294.5 to 4793.5) 
Abbreviation: pmp, per million population; CI, confidence interval  
a) Data from Australia, New Zealand, Austria, Belgium, Denmark, Finland, France, Greece, Iceland, Norway, Spain, Sweden, the Netherlands, United Kingdom, Canada 
and Saudi Arabia were included in the analysis 
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Supplementary table 1: Data source and quality  
Country 
Year of 
data 
Data source of dialysis prevalence Data source of renal transplantation prevalence 
Quality of 
available data 
AFRICA  
Ethiopia 2007 Perit Dial Int 2010; 30:23–28  Good 
Kenya 2007 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Madagascar 2007 Perit Dial Int 2010; 30:23–28  Good 
Mauritius 2007 Perit Dial Int 2010; 30:23–28  Good 
Mozambique 2007 Perit Dial Int 2010; 30:23–28  Good 
Rwanda ? Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Uganda 2007 Perit Dial Int 2010; 30:23–28  Good 
Tanzania 2007 Perit Dial Int 2010; 30:23–28  Good 
Zambia 2007 Perit Dial Int 2010; 30:23–28  Good 
Zimbabwe 2007 Perit Dial Int 2010; 30:23–28  Good 
Angola 2007 Perit Dial Int 2010; 30:23–28  Good 
Cameroon 2012 Provided by Dr. Halle Marie Patrice  Moderate 
Congo 2007 Perit Dial Int 2010; 30:23–28  Good 
Gabon 2007 Perit Dial Int 2010; 30:23–28  Good 
Algeria 2007 Perit Dial Int 2010; 30:23–28  Good 
Egypt 2008 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Libya 2007 Perit Dial Int 2010; 30:23–28  Good 
Morocco 2007 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6 Good 
Sudan 2007 Perit Dial Int 2010; 30:23–28  Good 
Tunisia 2008 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6 Good 
Botswana 2007 Perit Dial Int 2010; 30:23–28  Good 
Namibia 2007 Perit Dial Int 2010; 30:23–28  Good 
South Africa 2007 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
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Benin 2007 Perit Dial Int 2010; 30:23–28  Good 
Côte d'Ivoire 2007 Perit Dial Int 2010; 30:23–28  Good 
Ghana 2007 Perit Dial Int 2010; 30:23–28 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Mali 2007 Perit Dial Int 2010; 30:23–28  Good 
Mauritania 2007 Perit Dial Int 2010; 30:23–28  Good 
Nigeria 2007 Perit Dial Int 2010; 30:23–28 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Senegal 2007 J Am Soc Nephrol 2012; 23:533–544 Clin Nephrol. 2010 Nov;74 Suppl 1:S13-6. Good 
Togo 2007 Perit Dial Int 2010; 30:23–28  Good 
ASIA 
China 2012 Provided by Dr. Minghui Zaho & Dr Jicheng Lv  Moderate 
(Taiwan) 2009 Taiwan Renal registry  High 
(Hong Kong SAR) 2009 USRD2011 USRD2011 High 
Japan 2012 JSDT database (In Japanese) Japan society of transplantation (2007)a High 
Republic of Korea 2011 Insan Memorial Dialysis Registry Insan Memorial Dialysis Registry High 
Bangladesh 2012 Provided by Prof Vivek Jha USRD2008 Moderate 
India 2012 Provided by Prof Vivek Jha  Moderate 
Iran 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Nepal 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Pakistan 2012 Provided by Prof Vivek Jha  Moderate 
Brunei Darussalam 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Indonesia 2006 Ethnicity & Disease 2009;19, S1-33-36 Ethnicity & Disease 2009;19, S1-33-36 Good 
Malaysia 2009 USRD2011 USRD2011 High 
Philippines 2008 USRD2011 USRD2011 High 
Singapore 2008 Singapore renal registry Singapore renal registry High 
Thailand 2012 Prof Vivek Jha USRD2011 Moderate 
Viet Nam 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Cyprus 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Georgia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
51 
 
Israel 2009 USRD2011 USRD2011 High 
Jordan 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Kuwait 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Lebanon 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Oman 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Qatar 2006 J Am Soc Nephrol 2012; 23:533–544  Good 
Saudi Arabia 2008 Saudi Med J 2011; 32, 339-346 Saudi Med J 2011; 32, 339-346 Good 
Syrian Arab Republic 2005 J Am Soc Nephrol 2012; 23:533–544  Good 
Turkey 2009 USRD2011 USRD2011 High 
United Arab Emirates 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Yemen 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
EUROPE Good 
Belarus 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
Bulgaria 2003 J Am Soc Nephrol 2012; 23:533–544  Good 
Czech Republic 2009 USRD2011 USRD2011 High 
Hungary 2008 J Am Soc Nephrol 2012; 23:533–544 USRD2008 Good 
Poland 2008 USRD2011 USRD2011 High 
Romania 2011 ERA-EDTA ERA-EDTA High 
Russian Federation 2009 USRD2011 USRD2011 High 
Slovakia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Ukraine 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Denmark 2011 ERA-EDTA ERA-EDTA High 
Estonia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Finland 2011 ERA-EDTA ERA-EDTA High 
Iceland 2011 ERA-EDTA ERA-EDTA High 
Ireland 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Latvia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Lithuania 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
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Norway 2011 ERA-EDTA ERA-EDTA High 
Sweden 2011 ERA-EDTA ERA-EDTA High 
United Kingdom 2011 ERA-EDTA ERA-EDTA High 
Bosnia and Herzegovina 2011 ERA-EDTA ERA-EDTA High 
Croatia 2009 USRD2011 USRD2011 High 
Greece 2011 ERA-EDTA ERA-EDTA High 
Italy 2008 J Am Soc Nephrol 2012; 23:533–544 USRD2008 Good 
Portugal 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Serbia 2004 J Am Soc Nephrol 2012; 23:533–544  Good 
Slovenia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Spain 2011 ERA-EDTA ERA-EDTA High 
TFYR Macedonia 2008 J Am Soc Nephrol 2012; 23:533–544  Good 
Austria 2011 ERA-EDTA ERA-EDTA High 
Belgium 2011 ERA-EDTA ERA-EDTA High 
France 2011 ERA-EDTA ERA-EDTA High 
Germany 2006 USRD2008 USRD2008 High 
Luxembourg 2006 USRD2008 USRD2008 High 
Netherlands 2011 ERA-EDTA ERA-EDTA High 
Switzerland 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
LATIN AMERICA AND THE CARIBBEAN  
Bahamas 2006 Caribbean Renal Registry Caribbean Renal Registry High 
Barbados 2006 Caribbean Renal Registry Caribbean Renal Registry High 
Cuba 2006 SLANH SLANH High 
Dominican Republic 2006 SLANH SLANH High 
Jamaica 2006 Caribbean Renal Registry Caribbean Renal Registry High 
Puerto Rico 2006 SLANH SLANH High 
Trinidad and Tobago 2006 Caribbean Renal Registry Caribbean Renal Registry High 
Virgin Islands 2007 J Am Soc Nephrol 2012; 23:533–544  Good 
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Costa Rica 2006 SLANH SLANH High 
El Salvador 2006 SLANH SLANH High 
Guatemala 2006 SLANH SLANH High 
Honduras 2006 SLANH SLANH High 
Mexico 2009 USRD2011 USRD2011 High 
Nicaragua 2006 SLANH SLANH High 
Panama 2006 SLANH SLANH High 
Argentina 2006 SLANH SLANH High 
Bolivia 2006 SLANH SLANH High 
Brazil 2006 SLANH SLANH High 
Chile 2009 USRD2011 USRD2011 High 
Colombia 2009 USRD2011 USRD2011 High 
Ecuador 2006 SLANH SLANH High 
Paraguay 2006 SLANH SLANH High 
Peru 2006 SLANH SLANH High 
Uruguay 2009 USRD2011 USRD2011 High 
Venezuela 2006 SLANH SLANH High 
NORTH AMERICA  
Canada 2010 Canadian Organ Replacement Register Canadian Organ Replacement Register High 
United States of America 2010 USRD2012 USRD2012 High 
OCEANIA  
Australia 2011 ANZDATA ANZDATA High 
New Zealand 2011 ANZDATA ANZDATA High 
Data derived from formalised national registries were considered high quality; published national and regional surveys were considered good quality while all other sources 
were considered moderate quality 
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Supplementary table 2: Characteristics of 123 countries (125 data) enrolled in this study 
Country 
Prevalence 
of dialysis 
(pmp) 
Prevalence 
of 
RRT(pmp) 
N of 
dialysis a) 
N of RRTa) 
Age-
specific 
datac) 
N of 
population 
(x1000) 
Median 
age (years) 
Life 
expectancy 
at birth 
(years) 
GNI per 
capita 
(US$) 
Prevalence 
of diabetes 
(%) 
Prevalence of 
hypertension 
(%) 
AFRICA  
Ethiopia 5.3 NA 460 NA NA 87,095 17.5 59.3 370 5.9 35.2 
Madagascar 3.6 NA 75 NA NA 21,080 18 62.2 420 6.4 41.8 
Mozambique 0.4 NA 10 NA NA 23,967 17.2 48.4 430 6.9 44.9 
Uganda 1.0 NA 35 NA NA 33,987 15.5 55.2 460 5.3 41.2 
Zimbabwe 2.7 NA 35 NA NA 13,077 18.5 47.3 460 7.7 39 
Togo 5.6 NA 35 NA NA 6,306 18.7 54.7 460 7.5 39.5 
Rwanda 2.8 4.4b) 30 48 NA 10,837 17.8 59.8 510 5.1 41.4 
Tanzania 0.2 NA 10 NA NA 44,973 17.4 56.6 530 7.2 39.2 
Mali 2.5 NA 35 NA NA 13,986 16.5 52.7 660 7.8 34.7 
Benin 26.3 NA  250 NA  NA 9,510 18.1 58.2 710 5.6 38.7 
Kenya 9.3 9.6b) 380 393 NA 40,909 18.5 57.2 800 6.2 37 
Mauritania 66.5 NA 240 NA NA 3,609 19.5 60.7 980 6.8 39.2 
Senegal 11.4 11.4b) 148 148 NA 12,951 17.9 62.2 1040 8.9 40.4 
Zambia 2.6 NA 35 NA NA 13,217 16.5 50.9 1080 6.1 40.1 
Cameroon 23.6 NA 487 NA NA 20,624 18 52.7 1140 8.8 36.9 
Sudan 79.9 83.6b) 2,850 2,981 NA 35,652 18.7 60.9 1200 7.2 40.1 
Côte d'Ivoire 24.2 NA 460 NA NA 18,977 18.8 48.7 1210 8.1 41.5 
Nigeria 7.1 7.6b) 1,130 1,209 NA 159,708 17.9 50.2 1240 8.5 42.8 
Ghana 3.1 NA 75 NA NA 24,263 20.2 60 1260 8.8 36.4 
Congo 8.5 NA 35 NA NA 4,112 18.9 55.7 2210 6.8 40 
Egypt 517.8 525.7b) 40,430 41,046 NA 78,076 24.4 69.9 2550 6.5 35 
Morocco 185.7 186.2b) 5,875 5,892  NA 31,642 26.2 69.7 2870 9.9 41.2 
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Angola 14.8 NA 290 NA NA 19,549 16 49.6 3870 6.9 38.2 
Tunisia 759.2 767.2b) 8,071  8,156 NA 10,632 29 74.6 4150 11.4 38.5 
Algeria 274.1 NA 10,160 NA NA 37,063 26 70.3 4210 8 38 
Namibia 16.1 NA 35 NA NA 2,179 20.3 60.1 4430 7.8 43.4 
Libya 355.9 NA 2,150 NA NA 6,041 25.6 74.2 4855 11.8 42.6 
Botswana 38.1 NA 75 NA NA 1,969 22 46.5 5990 7.5 40.8 
South Africa 74.8 84.0b) 3,851 4,324 NA 51,452 25.2 52.2 6100 10.6 42.2 
Mauritius 666.3 NA 820 NA NA 1,231 33.3 72.8 7950 10.4 44.9 
Gabon 96.4 NA 150 NA NA 1,556 20.5 61.3 8220 8.5 41.3 
ASIA 
Nepal 11.7 NA 314 NA NA 26,846 21.3 65.9 540 8.4 34 
Bangladesh 34.7 36.1b) 5,240 5,458 NA 151,125 24 68.4 690 8.4 33.7 
Pakistan 53.3 NA 9,230 NA NA 173,149 21.6 65.7 1050 11.7 35.3 
Viet Nam 49.8 NA 4,437 NA NA 89,047 28.5 75.1 1160 6.9 33 
Yemen 108.7 NA 2,474 NA NA 22,763 18.2 62 1220 9.1 34.1 
India 49.2 NA  59,345 NA  NA 1,205,625 25.5 64.9 1290 10 32.5 
Philippines 105.0 110.0 9,812 10,279 NA 93,444 22.3 67.8 2060 5.8 32.7 
Indonesia 23.0 23.4 5,532 5,632 NA 240,676 26.9 69.6 2500 6.3 37.4 
Syrian Arab 
Republic 
155.1 NA 3,339 NA NA 21,533 21.9 75 2610 10.6 33.8 
Georgia 179.2 NA 787 NA NA 4,389 37 73.5 2680 12.7 51.4 
Jordan 446.3 NA 2,881 NA NA 6,455 22.5 73 4140 14.4 28.8 
China 169.1 NA 230,000 NA NA 1,359,821 34.6 74.4 4240 9.4 38.2 
Thailand 297.6 323.5b) 19,760 21,478 NA 66,402 35.4 73.3 4580 10.2 48.1 
Iran  227.0 NA 16,900 NA NA 74,462 27 72.3 8065 8.3 33.7 
Malaysia 762.0 827.0 21,546 23,384 NA 28,276 26.1 74 8130 10.5 34.7 
Lebanon 694.1 NA 3,013 NA NA 4,341 28.5 78.2 8360 11.5 39 
Turkey 717.0 819.0 51,723 59,081 NA 72,138 28.3 73.4 9980 9 32.8 
Saudi Arabia 463.0 874.0 12,621 23,824 Available 27,258 26.1 74.3 16720 17.9 33.1 
Oman 262.5 NA 736 NA NA 2,803 25.1 74.9 19120 9.7 34.5 
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Republic of 
Korea 
972.4 1,224.80 47,118 59,346 NA 48,454 37.8 80 19720 6.3 30.6 
 (Taiwan) 2,445.7 NA 56,300 NA Available 23020 37.6 80.3 21000 NA NA 
Brunei  1,235.0 NA 495 NA NA 401 29.5 77.5 24826 5.8 28.2 
Israel 704.0 1,087.0 5,224 8,066 NA 7,420 30.1 80.8 27270 10 35.8 
Cyprus 22.9 NA 25 NA NA 1,104 34.2 79 28570 9.4 40.5 
(Hong Kong) 620.0 1,078.0 4,371 7,599 NA 7,050 41.1 82.4 32292 NA NA 
United Arab 
Emirates 
200.8 NA 1,695 NA NA 8,442 28 75.9 35270 10.2 27.5 
Japan 2,358.2 2,482.3b) 300,327 316,133 Available 127,353 44.9 82.7 42190 7.7 43.9 
Singapore 1,144.3 1,488.8 5,812 7,562 Available 5,079 37.3 81.2 42530 6.9 36.8 
Kuwait 303.2 NA 907 NA NA 2,992 28.4 73.8 44730 11.9 29.1 
Qatar 559.4 NA 979 NA NA 1,750 31.6 77.6 73440 9.5 33.8 
EUROPE  
Ukraine 77.2 NA 3,557 NA NA 46,050 39.4 67.9 2990 11.5 53.6 
Macedonia 622.4 NA 1,308 NA NA 2,102 36.1 74.4 4320 7.3 34.3 
Bosnia and 
Herzegovina 
613.7 704.7 2,360 2,710 NA 3,846 38.6 75.5 4640 12 51.7 
Serbia 305.5 NA 2,947 NA NA 9,647 37.8 73.3 5550 10.4 51.7 
Belarus 221.3 NA 2,100 NA NA 9,491 38.9 69.3 5990 11.2 50.6 
Bulgaria 323.3 NA 2,389 NA NA 7,389 42.4 73 6320 11.3 51.4 
Romania 575.3 624.2 12,576 13,646 NA 21,861 38.5 73.1 7950 10.4 49.1 
Russian 
Federation 
135.0 173.0 19,388 24,846 NA 143,618 38 67.2 10000 11.6 47.6 
Lithuania 381.5 NA 1,171 NA NA 3,068 38.7 71.3 11620 11.8 53.4 
Latvia 206.6 NA 432 NA NA 2,091 41.2 71.5 11850 11.2 52.9 
Poland 408.0 650.0 15,585 24,829 NA 38,199 38 75.5 12390 8.6 50.3 
Hungary 579.8 883b) 5,807 8,843 NA 10,015 39.9 73.8 12860 10.8 51 
Croatia 669.0 930.0 2,902 4,034 NA 4,338 41.9 76.1 13550 10.9 53.7 
Estonia 213.4 NA 277 NA NA 1,299 40.5 73.6 14150 9.7 54.1 
Slovakia 273.7 NA 1,487 NA NA 5,433 37.2 74.7 16030 10.6 48.7 
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Czech 
Republic 
549.0 908.0 5,794 9,583 NA 10,554 39.5 76.8 18380 11.8 48.1 
Portugal 919.2 NA 9,734 NA NA 10,590 41 78.7 21870 7.9 47.9 
Slovenia 721.2 NA 1,482 NA NA 2,054 41.5 78.6 23910 11.1 52.1 
Greece 699.6 1,102.9 7,772 12,253 Available 11,110 41.8 79.8 26410 10.8 42.6 
Spain 525.3 1,127.1 24,259 52,051 Available 46,182 40.2 81.2 31450 11.3 41.7 
Iceland 252.8 664.6 80 211 Available 318 34.9 81.4 33900 9.9 37.2 
Italy 621.9 839.9b) 37,629 50,823 NA 60,509 43.3 81.5 35520 9.1 46.1 
United 
Kingdom 
551.9 1,122.6 34,254 69,677 Available 62,066 39.8 79.6 38410 8.3 43.5 
France 513.8 1,085.2 32,488 68,619 Available 63,231 40 80.9 42280 6.8 42.7 
Ireland 354.4 NA 1,583 NA NA 4,468 34.3 79.6 42380 7.4 42.4 
Germany 808.0 1,114.0 67,078 92,481 NA 83,017 44.3 79.8 43280 10.6 47.2 
Belgium 665.2 1,581.8 7,278 17,307 Available 10,941 41.1 79.5 45990 9.6 41.2 
Austria 393.8 1,001.4 3,308 8,414 Available 8,402 41.8 80.1 47070 7.1 43.8 
Finland 277.2 802.6 1,488 4,308 Available 5,368 42 79.5 47130 10.3 49.2 
Netherlands 384.9 961.3 6,396 15,972 Available 16,615 40.8 80.2 48580 6.3 42.4 
Sweden 411.6 929.8 3,862 8,724 Available 9,382 40.7 81.1 50860 8.8 46 
Denmark 446.3 850.4 2,477 4,721 Available 5,551 40.6 78.6 59590 8.9 41 
Luxembourg 87.0 522.0 44 265 NA 508 38.9 79.5 71860 9.4 40.7 
Switzerland 382.8 NA 2,998 NA NA 7,831 41.6 81.8 73350 8.6 40.4 
Norway 244.0 874.1 1,194 4,276 Available 4,891 38.7 80.6 86850 11.1 46.8 
LATIN AMERICA AND THE CARIBBEAN 
Nicaragua 31.5 34.2 183 199 NA 5,822 22 72.9 1430 7.7 34.3 
Bolivia 112.2 139.3 1,139 1,415 NA 10,157 21.7 65.6 1760 8.7 34.3 
Honduras 127.0 128.7 968 981 NA 7,621 20.9 72.1 1850 7.5 33.7 
Guatemala 201.9 227.5 2,895 3,263 NA 14,342 18.8 70.3 2750 11.7 32.3 
Paraguay 85.0 94.2 549 608 NA 6,460 23.1 71.8 2820 9.6 36.8 
El Salvador 420.1 447.3 2,612 2,781 NA 6,218 23.1 71.3 3350 9.9 31.9 
Ecuador 199.9 215.7 2,999 3,235 NA 15,001 25.2 75 4330 9 36.8 
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Jamaica 126.9 132.7 348 364 NA 2,741 27 72.2 4570 11.4 39.9 
Peru 201.0 244.0 5,882 7,141 NA 29,263 25.5 73.1 4600 5.5 31.7 
Colombia 392.0 454.0 18,206 21,086 NA 46,445 26.8 72.9 5460 5.9 37 
Cuba 193.2 261.6 2,179 2,952 NA 11,282 38.4 78.3 5631 12.4 43.6 
Dominican 
Republic 
115.2 136.2 1,154 1,365 NA 10,017 25 72.2 6570 18.2 46.8 
Costa Rica 33.0 231.6 154 1,082 NA 4,670 28.4 78.8 6860 9.5 35.6 
Panama 250.4 330.5 921 1,216 NA 3,678 27.1 76.4 7710 10.5 36.6 
Mexico 856.0 1,314.0 100,911 154,903 NA 117,886 26 76.3 8590 13.1 33.9 
Argentina 601.2 729.9 24,275 29,471 NA 40,374 30.3 75.3 8911 11.1 36.7 
Brazil  387.1 505.1 75,574 98,608 NA 195,210 29 72.4 9520 9.7 40 
Uruguay 746.0 1,019.0 2,515 3,436 NA 3,372 33.7 76.4 10110 11.5 45.7 
Chile 918.0 1,109.0 15,744 19,020 NA 17,151 32.1 78.6 10720 10.6 43.2 
Venezuela  379.2 471.7 11,012 13,701 NA 29,043 26.1 73.7 11520 10 38 
Trinidad and 
Tobago 
409.1 NA 543 NA NA 1,328 31.9 69.3 15740 12 38.9 
Puerto Rico 990.2 1,148.9 3,673 4,262 NA 3,710 34.7 77.9 16300 NA NA 
Bahamas 661.7 694.6 239 250 NA 360 30.9 74.3 21320 12.7 39.4 
Barbados 657.3 660.9 184 185 NA 280 36.2 74.5 25791 14.6 43.2 
Virgin Islands 1,441.5 NA 153 NA NA 106 39.3 78.9 35147 NA NA 
NORTH AMERICA  
Canada 679.7 1,153.6 23,196 39,369 Available 34,126 39.7 80.5 43250 11.1 33.6 
United States 
of America 
1,339.5 1,914.6 418,271 597,838 Available 312,247 37.1 78.1 47230 12.3 33.8 
OCEANIA  
New Zealand 540.8 870.8 2,362 3,804 Available 4,368 36.6 80.2 28310 11.3 36.8 
Australia 511.4 919.6 11,457 20,604 Available 22,404 36.8 81.7 46320 9.4 36.4 
Abbreviations: RRT, renal replacement therapy; NA, not available;  RRT was defined as dialysis or renal transplantation. 
a) Numbers of patients receiving dialysis or RRT were calculated by multiplying prevalence of dialysis or RRT, which were obtained from the data source shown in supplementary table 1, by number of population in 
2010 for each country. 
b) Prevalence of RRT was estimated on the basis of proportion of dialysis among RRT reported by different data sources as shown in supplementary table  
c) Availability of age-specific prevalence of patients undergoing dialysis among 20 high-income countries          
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Supplementary table 3: Actual or estimated number of patients receiving renal replacement therapy for each country in 2010 
Country 
Actual or estimated 
number of patients 
receiving dialysis in 
2010 
Actual or estimated number of 
patients receiving RRT in 2010 
b) 
(% of dialysis among RRT) 
 
Patients requiring RRT calculated by 
conservatively-estimated model  
  
Patients requiring RRT calculated by 
high-estimated model  
 
Estimated number of  
patients requiring RRT 
%Gap  
Estimated number of  
patients requiring RRT 
%Gap 
AFRICA 
Burundi 72 a) 72 b)  (100)  4,188 -98%  7,556 -99% 
Comoros 21 a) 21 b)  (100)  331 -94%  604 -97% 
Djibouti 32 a) 32 b)  (100)  441 -93%  820 -96% 
Eritrea 110 a) 110 b)  (100)  2,561 -96%  4,573 -98% 
Ethiopia 460 460 b)  (100)  41,425 -99%  75,897 -99% 
Kenya 380 393  (96.7)  19,018 -98%  34,455 -99% 
Madagascar 75 75 b)  (100)  9,987 -99%  18,192 -99% 
Malawi 156 a) 156 b)  (100)  6,913 -98%  12,570 -99% 
Mauritius 820 820 b)  (100)  948 -14%  1,887 -57% 
Mayotte 84 a) 84 b)  (100)  94 -11%  169 -50% 
Mozambique 10 10 b)  (100)  11,348 -99%  20,755 -99% 
Réunion 77 a) 77 b)  (100)  625 -88%  1,245 -94% 
Rwanda 30 48  (62.5)  4,924 -99%  8,872 -99% 
Seychelles 29 a) 29 b)  (100)  67 -57%  133 -78% 
Somalia 64 a) 64 b)  (100)  4,401 -99%  7,980 -99% 
South Sudan 183 a) 183 b)  (100)  4,826 -96%  8,855 -98% 
Uganda 35 35 b)  (100)  14,575 -99%  26,055 -99% 
Tanzania 10 10 b)  (100)  21,082 -99%  38,435 -99% 
Zambia 35 35 b)  (100)  5,822 -99%  10,457 -99% 
Zimbabwe 35 35 b)  (100)  6,290 -99%  11,623 -99% 
Angola 290 290 b)  (100)  8,628 -97%  15,473 -98% 
Cameroon 487 487 b)  (100)  9,773 -95%  17,864 -97% 
Central African 
Republic 
36 a) 36 b)  (100)  2,192 -98%  4,062 -99% 
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Chad 139 a) 139 b)  (100)  5,085 -97%  9,110 -98% 
Congo 35 35 b)  (100)  2,026 -98%  3,729 -99% 
Democratic Republic 
of the Congo 
370 a) 370 b)  (100)  28,744 -99%  52,124 -99% 
Equatorial Guinea 36 a) 36 b)  (100)  360 -90%  664 -95% 
Gabon 150 150 b)  (100)  865 -83%  1,648 -91% 
Sao Tome and 
Principe 
10 a) 10 b)  (100)  86 -88%  159 -93% 
Algeria 10,160 10,160 b)  (100)  22,170 -54%  42,094 -76% 
Egypt 40,430 41,046  (98.5)  47,751 -14%  91,728 -55% 
Libya 2,150 2,150 b)  (100)  3,520 -39%  6,656 -68% 
Morocco 5,875 5,892  (99.7)  19,526 -70%  37,372 -84% 
Sudan 2,850 2,981   (95.6)  17,352 -83%  31,797 -91% 
Tunisia 8,071 8,156  (99.0)  7,395 9%  14,498 -44% 
Western Sahara 20 a) 20 b)  (100)  287 -93%  530 -96% 
Botswana 75 75 b)  (100)  1,016 -93%  1,878 -96% 
Lesotho 25 a) 25 b)  (100)  1,037 -98%  1,943 -99% 
Namibia 35 35 b)  (100)  1,106 -97%  2,043 -98% 
South Africa 3,851 4,324  (89.1)  31,524 -86%  60,459 -93% 
Swaziland 26 a) 26 b)  (100)  577 -96%  1,057 -98% 
Benin 250 250 b)  (100)  4,484 -94%  8,145 -97% 
Burkina Faso 262 a) 262 b)  (100)  6,912 -96%  12,400 -98% 
Cape Verde 90 a) 90 b)  (100)  283 -68%  544 -83% 
Côte d'Ivoire 460 460 b)  (100)  9,286 -95%  16,990 -97% 
Gambia 37 a) 37 b)  (100)  747 -95%  1,341 -97% 
Ghana 75 75  (100)  12,371 -99%  22,901 -99% 
Guinea 147 a) 147 b)  (100)  5,288 -97%  9,687 -98% 
Guinea-Bissau 23 a) 23 b)  (100)  771 -97%  1,409 -98% 
Liberia 61 a) 61 b)  (100)  1,896 -97%  3,457 -98% 
Mali 35 35 b)  (100)  6,317 -99%  11,412 -99% 
Mauritania 240 240 b)  (100)  1,783 -87%  3,270 -93% 
Niger 221 a) 221  (100)  7,166 -97%  12,929 -98% 
Nigeria 1,130 1,209  (93.5)  74,873 -98%  135,623 -99% 
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Senegal 148 148  (100)  6,051 -98%  11,004 -99% 
Sierra Leone 38 a) 38 b)  (100)  2,699 -99%  4,873 -99% 
Togo 35 35 b)  (100)  2,962 -99%  5,365 -99% 
ASIA 
China 230,000 230,000 b)  (100)  1,067,779 -78%  2,129,216 -89% 
  (Taiwan) 56,300 56,300 b)  (100)  NA   NA  
  (Hong Kong) 4,371 7,599  (57.5)  6,909 10%  14,336 -47% 
  (Macao) 394 a) 394 b)  (100)  436 -10%  869 -55% 
Dem. People's 
Republic of Korea 
1,175 a) 1,175 b)  (100)  18,374 -94%  36,362 -97% 
Japan 300,327 316,133  (95.0)  154,098 105%  334,040 -5% 
Mongolia 216 a) 216 b)  (100)  1,555 -86%  2,910 -93% 
Republic of Korea 47,118 59,346  (79.4)  42,404 40%  86,198 -31% 
Other non-specified 
areas 
2,394 a) 2,394 b)  (100)  20,347 -88%  41,507 -94% 
Kazakhstan 2,474 a) 2,474 b)  (100)  11,021 -78%  21,582 -89% 
Kyrgyzstan 292 a) 292 b)  (100)  3,111 -91%  5,914 -95% 
Tajikistan 377 a) 377 b)  (100)  3,932 -90%  7,281 -95% 
Turkmenistan 531 a) 531 b)  (100)  2,926 -82%  5,532 -90% 
Uzbekistan 2,046 a) 2,046 b)  (100)  16,099 -87%  30,525 -93% 
Afghanistan 623 a) 623 b)  (100)  12,306 -95%  21,958 -97% 
Bangladesh 5,240 5,458  (96.0)  86,483 -94%  163,527 -97% 
Bhutan 57 a) 57 b)  (100)  407 -86%  769 -93% 
India 59,345 59,345 b)  (100)  736,468 -92%  1,407,458 -96% 
Iran 16,900 16,900 b)  (100)  46,265 -63%  88,477 -81% 
Maldives 94 a) 94 b)  (100)  184 -49%  347 -73% 
Nepal 314 314 b)  (100)  15,073 -98%  28,522 -99% 
Pakistan 9,230 9,230 b)  (100)  93,759 -90%  175,846 -95% 
Sri Lanka 3,208 a) 3,208 b)  (100)  15,216 -79%  30,120 -89% 
Brunei Darussalam 495 495 b)  (100)  250 98%  474 4% 
Cambodia 918 a) 918 b)  (100)  8,349 -89%  15,943 -94% 
Indonesia 5,532 5,632  (98.2)  148,986 -96%  284,912 -98% 
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Lao People's 
Democratic Republic 
352 a) 352 b)  (100)  3,291 -89%  6,108 -94% 
Malaysia 21,546 23,384  (92.1)  17,389 34%  33,184 -30% 
Myanmar 3,042 a) 3,042 b)  (100)  32,901 -91%  63,037 -95% 
Philippines 9,812 10,279  (95.5)  50,954 -80%  95,158 -89% 
Singapore 5,812 7,562  (76.9)  4,304 76%  8,682 -13% 
Thailand 19,760 21,478  (92.0)  53,571 -60%  107,365 -80% 
Timor-Leste 91 a) 91 b)  (100)  495 -82%  902 -90% 
Viet Nam 4,437 4,437 b)  (100)  61,061 -93%  119,953 -96% 
Armenia 585 a) 585 b)  (100)  2,412 -76%  4,899 -88% 
Azerbaijan 1,693 a) 1,693 b)  (100)  6,089 -72%  11,807 -86% 
Bahrain 642 a) 642 b)  (100)  730 -12%  1,343 -52% 
Cyprus 25 25 b)  (100)  950 -97%  1,943 -99% 
Georgia 787 787 b)  (100)  4,133 -81%  8,603 -91% 
Iraq 4,560 a) 4,560 b)  (100)  15,192 -70%  27,914 -84% 
Israel 5,224 8,066  (64.8)  5,939 36%  12,124 -33% 
Jordan 2,881 2,881 b)  (100)  3,346 -14%  6,166 -53% 
Kuwait 907 907 b)  (100)  1,656 -45%  3,034 -70% 
Lebanon 3,013 3,013 b)  (100)  3,118 -3%  6,178 -51% 
Oman 736 736 b)  (100)  1,434 -49%  2,614 -72% 
Qatar 979 979 b)  (100)  1,005 -3%  1,817 -46% 
Saudi Arabia 12,621 23,824  (53.0)  14,993 59%  27,776 -14% 
State of Palestine 654 a) 654 b)  (100)  1,871 -65%  3,390 -81% 
Syrian Arab Republic 3,339 3,339 b)  (100)  11,369 -71%  21,144 -84% 
Turkey 51,723 59,081  (87.5)  49,186 20%  96,317 -39% 
United Arab Emirates 1,695 1,695 b)  (100)  3,949 -57%  6,806 -75% 
Yemen 2,474 2,474 b)  (100)  10,489 -76%  19,001 -87% 
EUROPE 
Belarus 2,100 2,100 b)  (100)  9,163 -77%  19,070 -89% 
Bulgaria 2,389 2,389 b)  (100)  8,017 -70%  16,994 -86% 
Czech Republic 5,794 9,583  (60.5)  10,663 -10%  22,339 -57% 
Hungary 5,807 8,843  (65.7)  10,338 -14%  21,789 -59% 
Poland 15,585 24,829  (62.8)  36,846 -33%  76,720 -68% 
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Republic of Moldova 328 a) 328 b)  (100)  3,112 -89%  6,354 -95% 
Romania 12,576 13,646  (92.2)  21,247 -36%  44,278 -69% 
Russian Federation 19,388 24,846  (78.0)  135,349 -82%  280,110 -91% 
Slovakia 1,487 1,487 b)  (100)  4,998 -70%  10,294 -86% 
Ukraine 3,557 3,557 b)  (100)  45,899 -92%  96,046 -96% 
Channel Islands 229 a) 229 b)  (100)  163 40%  344 -33% 
Denmark 2,477 4,721  (52.5)  5,681 -17%  11,985 -61% 
Estonia 277 277 b)  (100)  1,358 -80%  2,875 -90% 
Finland 1,488 4,308  (34.5)  5,726 -25%  12,164 -65% 
Iceland 80 211  (38.0)  282 -25%  583 -64% 
Ireland 1,583 1,583 b)  (100)  3,822 -59%  7,820 -80% 
Latvia 432 432 b)  (100)  2,220 -81%  4,706 -91% 
Lithuania 1,171 1,171 b)  (100)  3,000 -61%  6,275 -81% 
Norway 1,194 4,276  (27.9)  4,823 -11%  10,145 -58% 
Sweden 3,862 8,724  (44.3)  10,006 -13%  21,331 -59% 
United Kingdom 34,254 69,677  (49.2)  63,458 10%  134,248 -48% 
Albania 822 a) 822 b)  (100)  2,509 -67%  5,067 -84% 
Bosnia and 
Herzegovina 
2,360 2,710  (87.1)  3,605 -25%  7,451 -64% 
Croatia 2,902 4,034  (71.9)  4,600 -12%  9,734 -59% 
Greece 7,772 12,253  (63.4)  12,210 0%  26,064 -53% 
Italy 37,629 50,823  (74.0)  69,271 -27%  148,891 -66% 
Malta 296 a) 296 b)  (100)  416 -29%  864 -66% 
Montenegro 178 a) 178 b)  (100)  556 -68%  1,143 -84% 
Portugal 9,734 9,734 b)  (100)  11,289 -14%  23,963 -59% 
Serbia 2,947 2,947 b)  (100)  9,173 -68%  19,056 -85% 
Slovenia 1,482 1,482 b)  (100)  2,148 -31%  4,527 -67% 
Spain 24,259 52,051  (46.6)  48,566 7%  103,007 -49% 
TFYR Macedonia 1,308 1,308 b)  (100)  1,838 -29%  3,749 -65% 
Austria 3,308 8,414  (39.3)  8,899 -5%  18,868 -55% 
Belgium 7,278 17,307  (42.1)  11,591 49%  24,660 -30% 
France 32,488 68,619  (47.3)  66,206 4%  140,975 -51% 
Germany 67,078 92,481  (72.5)  94,325 -2%  201,949 -54% 
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Luxembourg 44 265  (16.7)  488 -46%  1,018 -74% 
Netherlands 6,396 15,972  (40.0)  16,779 -5%  35,259 -55% 
Switzerland 2,998 2,998 b)  (100)  8,233 -64%  17,433 -83% 
LATIN AMERICA AND THE CARIBBEAN  
Antigua and Barbuda 37 a) 37 b)  (100)  62 -40%  121 -70% 
Aruba 55 a) 55 b)  (100)  88 -38%  178 -69% 
Bahamas 239 250  (95.3)  260 -4%  510 -51% 
Barbados 184 185  (99.5)  241 -23%  492 -62% 
Cuba 2,179 2,952  (73.8)  10,226 -71%  21,036 -86% 
Curaçao 13 a) 13 b)  (100)  138 -91%  287 -95% 
Dominican Republic 1,154 1,365  (84.6)  6,330 -78%  12,289 -89% 
Grenada 26 a) 26 b)  (100)  69 -62%  136 -81% 
Guadeloupe 52 a) 52 b)  (100)  411 -87%  849 -94% 
Haiti 295 a) 295 b)  (100)  5,370 -95%  10,086 -97% 
Jamaica 348 364  (95.6)  1,915 -81%  3,803 -90% 
Martinique 48 a) 48 b)  (100)  395 -88%  831 -94% 
Puerto Rico 3,673 4,262  (86.2)  3,326 28%  6,889 -38% 
Saint Lucia 49 a) 49 b)  (100)  131 -62%  261 -81% 
Saint Vincent and the 
Grenadines 
25 a) 25 b)  (100)  74 -67%  145 -83% 
Trinidad and Tobago 543 543  (100)  1,018 -47%  2,025 -73% 
Virgin Islands 153 153 b)  (100)  100 54%  206 -25% 
Belize 61 a) 61 b)  (100)  165 -63%  309 -80% 
Costa Rica 154 1,082  (14.2)  3,201 -66%  6,270 -83% 
El Salvador 2,612 2,781  (93.9)  3,895 -29%  7,610 -63% 
Guatemala 2,895 3,263  (88.7)  7,450 -56%  14,000 -77% 
Honduras 968 981  (98.7)  4,094 -76%  7,708 -87% 
Mexico 100,911 154,903  (65.1)  74,996 107%  145,363 7% 
Nicaragua 183 199  (92.1)  3,221 -94%  6,090 -97% 
Panama 921 1,216  (75.8)  2,457 -51%  4,813 -75% 
Argentina 24,275 29,471  (82.4)  32,038 -8%  65,156 -55% 
Bolivia  1,139 1,415  (80.5)  5,679 -75%  10,744 -87% 
Brazil 75,574 98,608  (76.6)  135,975 -27%  267,231 -63% 
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Chile 15,744 19,020  (82.8)  13,422 42%  26,991 -30% 
Colombia 18,206 21,086  (86.3)  29,919 -30%  57,902 -64% 
Ecuador 2,999 3,235  (92.7)  9,528 -66%  18,510 -83% 
French Guiana 20 a) 20 b)  (100)  138 -85%  261 -92% 
Guyana 71 a) 71 b)  (100)  416 -83%  772 -91% 
Paraguay 549 608  (90.3)  3,796 -84%  7,265 -92% 
Peru 5,882 7,141  (82.4)  18,446 -61%  35,684 -80% 
Suriname 113 a) 113 b)  (100)  349 -68%  679 -83% 
Uruguay 2,515 3,436  (73.2)  3,037 13%  6,326 -46% 
Venezuela  11,012 13,701  (80.4)  18,451 -26%  35,638 -62% 
NORTH AMERICA 
Canada 23,196 39,369  (58.9)  33,439 18%  69,907 -44% 
United States of 
America 
418,271 597,838  (70.0)  289,979 106%  602,669 -1% 
OCEANIA 
Australia 11,457 20,604  (55.6)  20,904 -1%  43,493 -53% 
New Zealand 2,362 3,804  (62.1)  3,992 -5%  8,281 -54% 
Fiji 118 a) 118 b)  (100)  532 -78%  1,013 -88% 
New Caledonia 179 a) 179 b)  (100)  192 -7%  386 -53% 
Papua New Guinea 312 a) 312 b)  (100)  3,422 -91%  6,258 -95% 
Solomon Islands 31 a) 31 b)  (100)  261 -88%  480 -93% 
Vanuatu 31 a) 31 b)  (100)  125 -76%  232 -87% 
Guam 15 a) 15 b)  (100)  114 -86%  224 -93% 
Kiribati 9 a) 9 b)  (100)  54 -84%  101 -91% 
Micronesia 12 a) 12 b)  (100)  55 -78%  104 -88% 
French Polynesia 160 a) 160 b)  (100)  187 -14%  365 -56% 
Samoa 28 a) 28 b)  (100)  106 -74%  203 -86% 
Tonga 18 a) 18 b)  (100)   61 -71%   118 -85% 
Abbreviations: RRT, renal replacement therapy; NA, not assessed 
In countries without available information of renal transplantation, number of RRT were considered to be same as number of dialysis. 
Gap for Taiwan was not estimated, because age-distribution was not available in the database of United Nation. 
a) Numbers of patients receiving dialysis were estimated by the model built in this study 
b) In countries without available information of renal transplantation, number of RRT were considered to be same as number of dialysis 
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Rationale 
The incidence and prevalence of kidney disease and associated complications are increasing in 
Asia. There is limited information available regarding the prevalence, prognostic implications 
and treatment patterns in this region. There is a need to maximise the value of available data 
through consolidating existing information, bring together the expertise of local investigators, 
and identify priority areas for future studies. This chapter describes the Asian Renal 
Collaboration (ARC), an initiative offering a unique opportunity to obtain accurate information 
from a large number of subjects in Asia. 
“ARC project is currently underway across Asia. Executive Committee led by the study 
director at the George Institute, University of Sydney drives the project. The protocol has been 
published and several other projects are already underway. While current focus of the project 
is to consolidate available data in Asia, there may be opportunities to conduct prospective 
observational studies in the future to capture data on CKD prevalence, outcomes and 
associations in Asia. GlaxoSmithKline PLC is funding the project but the funding body has no 
role in protocol design, data collection, project selection and analysis or manuscript 
preparation.” 
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List of abbreviations used in the protocol 
 
ARC Asian Renal Collaboration 
CKD Chronic kidney disease 
CVD Cardiovascular disease 
eGFR Estimated glomerular filtration rate 
ESA Erythropoiesis-stimulating agent 
ESCHDCP Eastern Stroke and Coronary Heart Disease Collaborative Project 
ESKD End-stage kidney disease 
HD Haemodialysis 
KDOQI Kidney Disease Outcomes Quality Initiative 
MACE Major adverse cardiovascular event  
MI Myocardial infarction 
MOOSE Meta-analysis of observational studies 
PD Peritoneal dialysis 
PI Principal investigator 
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Protocol summary 
Introduction 
The incidence and prevalence of chronic kidney disease (CKD), end stage kidney disease 
(ESKD) and associated complications such as cardiovascular disease, mineral and bone 
disorders and anaemia are rapidly increasing in Asia. Taiwan has one of the highest incidences 
of ESKD in the world (361 per million population in 2001) followed closely by Japan (288 per 
million populations)78. Despite the high prevalence and incidence of CKD, there is limited 
consolidated information available regarding the overall prevalence of different aspects of 
CKD, the prognostic implications and treatment patterns in this region. A need exists to 
maximise the value of available data through the establishment of a collaboration aiming to 
leverage existing information, bring together the expertise of local investigators, and identify 
priority areas for future studies.   
The Asian Renal Collaboration (ARC) is an initiative offering a unique opportunity to obtain 
accurate information from a large number of subjects about the prevalence, manifestations and 
risk factors of CKD in Asia. ARC will also provide insight into many important clinical 
endpoints including progression of CKD and associated complications such as cardiovascular 
disease, mineral and bone disorder, anaemia, and mortality.  
 
Objectives 
To understand the epidemiology and the impact of chronic kidney disease (CKD) in Asia, as 
defined by the United Nations, by pooling existing data (individual patient and summary level 
data), to describe: 
 Prevalence of CKD in Asian populations 
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 Prevalence of risk factors, complications and patterns of treatment in CKD patients in Asia 
 Clinical outcomes in CKD patients in Asia 
Wherever possible, these analyses will be completed overall, as well as by country, stage of 
disease and cause of the disease. 
 
Study Design 
The Asian Renal Collaboration (ARC) will bring together data from studies conducted in Asia 
through collaborative systematic review and meta-analysis. The types of studies to be included 
are: 
 Prevalence of CKD in Asian populations; cross-sectional surveys or baseline data for 
longitudinal studies that have been conducted in general Asian populations and describe 
the prevalence of one or more of CKD indicators (reduced estimated glomerular filtration 
rate and/or proteinuria/albuminuria) 
 Prevalence of risk factors, complications and patterns of treatment for CKD patients in 
Asia; cross-sectional surveys or baseline data for longitudinal studies that have been 
conducted in people with CKD and describe prevalence of risk factors, complications and 
patterns of treatment 
 Clinical outcomes in CKD patients in Asia; longitudinal studies that have been conducted 
in people with CKD and describe clinical outcomes of interest 
 
Groups to be compared will be defined by: 
 Stages of CKD 
 Non-dialysis patients vs dialysis dependent patients 
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 Diabetes vs non-diabetes 
 Anaemic vs non-anaemic 
 ESA treated vs not treated 
The collection of datasets from participating countries will be coordinated centrally by the 
coordinating centre, the George Institute for Global Health, Sydney, Australia. Regarding the 
longitudinal cohort, all existing forms of data from the participating countries will be 
acceptable for collection. Data processing procedures will be performed using a pre-developed 
standardised data collection form.   
The estimated number of included cohorts is 30 with an estimated subject number of 
approximately 2.2 million.  
 
Study Endpoints/Assessments 
The study endpoints will include 3 main sections: 
1. Prevalence of CKD in Asian populations 
This aspect will use cross-sectional studies conducted in community-based population, 
particularly representative population of countries. The definitions and manifestations of 
CKD to be collected will include: 
 Reduced eGFR 
 Presence of albuminuria/proteinuria 
 CKD stages I-V (defined by KDOQI) 
 ESKD (defined by treated ESKD – dialysis, HD and PD and transplant) 
 Renal transplant recipients 
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The total burden of kidney disease in Asia will be calculated overall, by country, and by 
each of the parameters listed above. The descriptive statistic used will be prevalence per 
million population. 
 
2. Prevalence of risk factors, complications and patterns of treatment for CKD patients 
in Asia 
This analysis will use all data describing characteristics of participants with CKD to 
describe: 
 Clinical characteristics – age, gender, ethnicity, country, cause of CKD, co-morbidities 
(e.g. smoking, diabetes, cardiovascular disease, stroke, peripheral vascular disease, 
blood pressure etc), catheter use   
 Dialysis type and duration  
 Laboratory characteristics – Serum albumin, calcium, phosphate, haemoglobin, 
haematocrit, ferritin, transferrin saturation, C-reactive protein etc 
 Treatment pattern – Oral iron, IV iron, ESA, antihypertensive medications, phosphate 
binders, Vitamin D, and other treatments 
 Prevalence of anaemia defined by haemoglobin (Hb) <10 g/dl or on ESA therapy 
 Quality of life 
Prevalence of risk factors and complications will be calculated according to CKD stages. 
Additionally, associations of risk factors with anaemia in CKD patients will be addressed. 
3. Clinical outcomes in CKD patients in Asia 
This analysis will focus on longitudinal data and will describe the risk of clinical outcomes 
in CKD patients: 
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 Kidney outcomes 
o Deterioration in at least 1 stage of CKD 
o Progression to ESKD 
o Doubling of serum creatinine 
o eGFR decline by 30% over 2 years 
 Cardiovascular outcomes 
o Major cardiovascular events (Coronary heart disease, stroke, or cardiovascular 
mortality) 
o Coronary heart disease (Myocardial infarction or hospitalization from angina) 
o Stroke 
o Cardiovascular mortality 
o Hospitalization from heart failure 
o Any other atherosclerotic disease (eg. peripheral arterial disease and aneurysm) 
o Thromboembolic events (vascular access related and non-vascular access related) 
 Mortality 
o All-cause mortality 
o Cause-specific mortality (Appendix 3.1) 
Hazard ratios of clinical outcomes will be estimated by means of Cox proportional hazard 
regression model according to baseline CKD status including anaemia, risk factors and 
presence/absence of CKD complications across the region.  
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Introduction  
Chronic kidney disease (CKD) is prevalent around the world and its incidence continues to rise 
at a rapid rate. Individuals with CKD have a reduced life expectancy, and those who progress 
to end-stage kidney disease (ESKD) have mortality rates that are increased 20-fold compared 
with age and sex matched individuals with normal kidney function79.The number of patients 
initiating renal-replacement therapy is also increasing in most countries 80 81, particularly in 
Asia, placing a substantial burden on healthcare systems.  
During the past few decades, epidemiological studies have provided much valuable 
information about CKD, its progression to ESKD and its associations with complications such 
as anaemia, cardiovascular disease and mortality. Cross-sectional data indicate that the 
prevalence of CKD in the general population is between 6- 20%27 28 82-84. Collaborative 
overviews (or meta-analyses), in which data from a number of cohort studies are combined 
provide useful information that is additional to that provided by the studies individually32 85-87. 
They also provide the opportunity to compare the results of different subsets of studies (for 
example, from different geographical regions). Such overviews can also use information from 
repeat measurements of risk factors to adjust estimates of association for “regression dilution” 
– the bias that occurs when associations are estimated from risk factor measurements that are 
subject to random error (e.g. measurements of blood pressure or cholesterol made on a single 
occasion). The Chronic Kidney Disease Prognosis Consortium (CKD-PC) has been also tasked 
with compiling the available data from existing cohort studies, which arise from either general, 
high-risk, or CKD populations among the world and provided a more comprehensive 
evaluation of the associations between kidney measures and clinical outcomes88. 
However, most of this evidence has come from studies conducted in European and North 
American populations and comparatively little has come from studies of Asian populations. 
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Patterns of disease and risk factors also differ markedly in many Asian populations from those 
in Europe and North America (e.g. higher incidence of IgA nephropathy, lower blood 
cholesterol and body mass index in Eastern Asia), as well as varying substantially within the 
region itself 89-91. Developed countries in Asia have some of the highest rates of ESKD in the 
world. The high incidence and prevalence of kidney disease in Asia has been identified as a 
major public health issue by the International Society of Nephrology, the Asian Pacific Society 
of Nephrology, and other groups92.  
Several collaborative meta-analyses among Asian countries have already launched in the area 
of cardiovascular disease. The Eastern Stroke and Coronary Heart Disease Collaborative 
Project (ESCHDCP) was a collaboration that examined the effects of diastolic blood pressure 
and total cholesterol on risk of stroke and cardiovascular disease in China and Japan93. 
ESCHDCP demonstrated that the association between blood pressure and stroke appeared to 
be about 50% stronger in these Eastern populations than in comparable Western populations, 
while the relationships of blood pressure and cholesterol with coronary heart disease in these 
Eastern populations were broadly similar in size and shape to those typically seen in Western 
populations. The Asia Pacific Cohort Studies Collaboration has similarly combined a large 
number of datasets to derive estimates of the strength of the relationship between a large 
number of risk factors with cardiovascular and other outcomes. On the contrary, there is few 
collaborations focused on kidney disease in Asians. Therefore, it is imperative that information 
specific to Asian populations and kidney outcomes are also obtained to improve our 
understanding of the challenges in managing this complex condition.  
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Rationale 
The incidence and prevalence of chronic kidney disease (CKD), end stage kidney disease 
(ESKD) and associated complications such as anaemia, are rapidly increasing in Asia. Taiwan 
has one of the highest incidences of ESKD in the world (361 per million population in 2001) 
followed closely by Japan (288 per million populations)78. Despite the high prevalence and 
incidence of CKD, there is limited consolidated information available regarding the overall 
prevalence of different aspects of CKD, and the prognostic implications and treatment patterns 
in this region. A need exists to maximise the value of available data through the establishment 
of a collaboration aiming to leverage existing information, bring together the expertise of local 
investigators, and identify priority areas for future studies.   
The Asian Renal Collaboration (ARC) is an initiative offering a unique opportunity to obtain 
accurate information from a large number of subjects about the prevalence, manifestations and 
risk factors of CKD in Asia. ARC will provide also insight into many important clinical 
endpoints including progression of CKD, CKD complications such as anaemia, cardiovascular 
disease and mortality. The large number of participants will also facilitate the discernment of 
important differences in the magnitude of associations between CKD stages, geographical 
regions, and between patient subgroups.  
From the evidence generated by this project, it will be possible to produce estimates of the 
likely eventual effects on CKD of changes in levels of exposures in population, (for example, 
those that may occur as a consequence of efforts to reduce population blood pressure levels or 
reduce anaemia), as well as the impact on other outcomes (such as cardiovascular disease) of 
initiatives aiming to prevent CKD and/or its complications. The study will also provide reliable 
evidence about one of the long-term consequences of diabetes in this region, the prevalence of 
which is increasing rapidly94. 
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The results will be of substantial relevance to health authorities in the region and international 
agencies with responsibility for decisions about strategies for the prevention of renal disease in 
the populations of Asia. 
 
Objectives 
The study will build a new collaboration and collect available data from Asia, as defined by 
the United Nations. The collaboration will involve the analyses of data from individual 
participants on a broad range of risk factors and disease outcomes.  
Specifically, the study aims to understand the epidemiology and the impact of chronic kidney 
disease (CKD) in Asia, by pooling existing data (individual patient and summary level data). 
This project will describe: 
 Prevalence of CKD in Asian populations  
 Prevalence of risk factors and complications, patterns of treatment in CKD patients in Asia 
 Clinical outcomes in CKD patients in Asia  
Wherever possible, these analyses will be completed overall, as well as by country, stage of 
disease and cause of disease. 
 
Target audience  
The Asian Renal Collaboration (ARC) provides a unique opportunity to obtain accurate 
information about the prevalence, manifestations and risk factors of CKD in the populations of 
Asia. Results of this study are of utmost importance to governments, economists, nephrologists, 
those involved in disease prevention and general physicians.  
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The results of the study will be disseminated by manuscripts in peer-reviewed publications in 
the fields of general medicine and nephrology and by presentations at international meetings. 
Summary reports will be shared with the sponsors.  
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Methods 
1.  This study will be conducted according to the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines51. Studies will be identified through a systematic 
search of the literature including abstracts and proceedings of meetings, as well as 
electronic databases such as MEDLINE and EMBASE. In addition, personal enquiry 
among collaborators and experts in the region will identify studies that have not yet been 
reported. 
2.  Key leaders in CKD epidemiology in the Asian region will be part of this new 
collaboration - the Asian Renal Collaboration (ARC). The principal investigators (PIs) of 
all eligible studies will be invited to participate in ARC. In addition, data from dialysis 
registries will also be sought. The Asia Pacific Society of Nephrology and the Asian Forum 
for Chronic Kidney Disease Initiative will be approached to endorse and support the study. 
3.  The collaboration will be formed using a model based on the highly successful Asia Pacific 
Cohort Studies Collaboration32, a regional epidemiological collaboration led and managed 
from the George Institute that focused on cardiovascular disease. 
4.  The collaboration will be overseen by an executive group. The Group will meet twice 
during the first year, and will 
 Oversee the collaboration  
 Be responsible for inviting steering committee members based on expertise and existing 
study datasets 
 Prepare for, and present at meetings. 
5.  A steering group will be formed and will incorporate members of the executive group, the 
principal investigators of studies that have collected relevant data, and 1-2 representatives 
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of the funding body (Glaxo Smith Kline). The executive group will identify and invite 
these individuals to join the steering committee (Appendix 3.3)  
The steering committee will: 
 Collect and provide data to form the basis of relevant analyses 
 Provide proposals for analyses to be undertaken by the collaboration  
 Consider and approve proposals for analysis and publication 
 Review and comment on the results of analyses 
 Review and comment on draft publications  
6.  A secretariat will be established at the George Institute, and will support the collaboration. 
This will include  
 Facilitating communications 
 Organizing and preparing meetings and teleconferences 
 Collating and cleaning datasets 
 Undertaking analyses under the guidance of the steering committee 
 Preparing initial drafts of manuscripts  
 Hosting fellows and trainees from institutions involved in the collaboration who wish 
to undertaken analyses of collaboration data (funding permitting)  
7.  De-identified individual patient data will be sought from participating studies including 
baseline parameters and subsequent outcomes for longitudinal studies. If individual data 
is not available, tabular summary data will be sought using a standardized data template 
(Appendix 3.2). 
8.  Guidelines for definitions of variables (e.g. hypertension, diabetes, and smoking) will be 
circulated to minimize heterogeneity. 
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9.  Data will be pooled and analysed by the secretariat at the coordinating centre (The George 
Institute for Global Health). 
10.  Primary analyses will be determined by the steering committee. Additional analyses can 
be suggested by steering committee members and will take place following approval by 
the committee. 
Study design 
This study is a collaborative overview (meta-analysis) of observational studies with 
participants who reside in Asia. The study will be conducted through the formation of a 
collaboration – the Asian Renal collaboration (ARC) – which will develop a detailed analysis 
plan incorporating the studies to be included, the variables to be collected, the parameters and 
relationships to be assessed, and the publications to be generated.  
Data on individual participants are sought from each collaborating study. If individual 
participant data is not available, the estimations analysed in each site of study will be obtained.  
Study population 
Study populations are defined separately for the three parts of the study. 
1. Prevalence of CKD in Asian populations  
Studies are potentially eligible for inclusion in this project if they satisfy the following 
criteria: 
 A study population from the Asia (defined here as South Asia, Southeast Asia and East 
Asia) 
 At least 500 adult (18 years or older) participants recorded or planned;  
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 Cross-sectional study or baseline data of longitudinal study that describe the prevalence of 
CKD in community-based population  
2. Prevalence of risk factors and complications, patterns of treatment, and clinical 
outcomes in CKD patients in Asia 
Studies are potentially eligible for inclusion in this project if they satisfy the following 
criteria: 
 A study population from the Asia-Pacific region (defined here as South Asia, Southeast 
Asia and East Asia) 
 At least 500 adult (18 years or older) participants recorded or planned;  
 Cross-sectional study or baseline data of longitudinal study that describe prevalence of risk 
factors and complications and patterns of treatment in people with CKD 
3. Clinical outcomes in CKD patients in Asia 
Studies are potentially eligible for inclusion in this project if they satisfy the following 
criteria: 
 A study population from the Asia-Pacific region (defined here as South Asia, Southeast 
Asia and East Asia) 
 At least 500 adult (18 years or older) participants recorded or planned;  
 Longitudinal studies that describe clinical outcomes of interest, at least date of death or the 
age at death recorded during follow-up, in people with CKD 
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Outcome definitions 
Individual participant data will be sought from each study on the date of occurrence of each of 
the following outcomes:  
1. Prevalence of CKD in community-based Asian populations  
o Reduced eGFR 
o Presence of albuminuria/proteinuria 
o CKD stages (defined by KDIGO) 
o ESKD (defined by treated ESKD – dialysis, HD and PD and transplant) 
o Transplant recipients  
2. Prevalence of risk factors and complications and patterns of treatment in CKD 
patients in Asia 
o Clinical characteristics – age, gender, cause of CKD, co-morbidities (eg. diabetes, 
cardiovascular disease, stroke, peripheral vascular disease), blood pressure, etc. 
o Dialysis type and duration 
o Laboratory characteristics – serum albumin, calcium, phosphate, haemoglobin, iron 
stores, etc. 
o Treatment pattern – iron, ESA, antihypertensive medications, phosphate binders, 
Vitamin D, and other treatments 
o Prevalence of anaemia defined by haemoglobin (Hb) <10 g/dl or on ESA therapy 
o Quality of life  
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3. Clinical outcomes in CKD patients in Asia 
Kidney outcomes 
o Deterioration in at least 1 stage of CKD 
o Progression to ESKD 
o Doubling of serum creatinine 
o eGFR decline by 30% over 2 years 
Cardiovascular outcomes  
o Major cardiovascular events (coronary heart disease, stroke, or cardiovascular 
mortality) 
o Coronary heart disease (myocardial infarction or hospitalization from angina) 
o Stroke 
o Cardiovascular mortality 
o Hospitalization from heart failure 
o Any other atherosclerotic disease (e.g. peripheral arterial disease and aneurysm) 
o Thromboembolic events (Vascular access related and non-vascular access related) 
Mortality 
o All-cause mortality 
o Cause-specific mortality (Appendix 3.1) 
Precise details of the diagnostic criteria used for the definition of outcomes (eg. major 
cardiovascular events), and data on the completeness of follow-up will also collected for 
individual studies. It is anticipated that definitions for outcomes may vary across included 
studies. Definition of outcomes will be standardized whenever possible. Quality assessment of 
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outcome ascertainment will be conducted and subgroup analyses will take place in order to 
assess for potential bias. 
Exposure definitions 
Data on demographic factors will be requested for each of the studies: date of birth or age at 
baseline, gender, ethnicity, occupation and education levels 
The exposures that will be collected include well-established risk factors for renal disease, 
anaemia and cardiovascular disease. Table 4 gives a list of these risk factors. For those risk 
factors measured on multiple occasions, all recorded data will be sought. The information of 
treatment will be also requested. 
It is anticipated that the methods used to measure exposure will vary across included studies 
(eg. fasting glucose versus non-fasting glucose). Methods and classifications will be 
standardized whenever possible. Full details of risk factor collection methods (including 
laboratory methods) will be sought from all studies. Quality assessment of exposure 
ascertainment will be conducted and subgroup analyses will take place in order to assess for 
potential bias. 
Confounders and effect modifiers 
This study will be of observational study design including cross-sectional data and longitudinal 
data. Therefore, the study is open to a range of biases inherent to non-randomised data. These 
biases may include, but are not limited to, selection bias, misclassification bias, and 
confounding. However, all efforts will be made to collect all available data to minimise the 
effect of confounding.  
Data collection and management 
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A standardised central data request form will be developed to collect the relevant data from 
each of the involved studies. Data may be provided to the coordinating centre in any a format 
convenient to the collaborator. Some unique identifier should be available for each individual 
in submitted data sets but this can be anonymous. All data provided to the coordinating centre 
will be carefully checked for completeness and consistency. Computer-generated reports on 
the data will be referred back to the principal investigator of each collaborating study for review 
and confirmation in order to ensure that the individual study results are incorporated correctly 
into the overview. Any data queries that may arise will be discussed and resolved in confidence 
with the responsible collaborating investigator. The data provided for inclusion in the Asian 
Renal Collaboration will be held in strict confidence by the coordinating centre. All data will 
be stored securely by the data manager in the coordinating centre.  
The data from each study will remain the sole property of the principal investigators of that 
study and will not be used for any presentation or publication without the consent of the 
collaborating investigators from the studies involved. GSK has no access to central data base 
or individual study data. 
Validation procedures 
As this study is proposed to be a collaborative meta-analysis based on previously collected data 
from participating sites/countries, there will be no requirements of validating clinical outcomes 
(e.g. adjudication of relevant clinical outcomes). However, general data validation procedures 
of each of the collected datasets (e.g. checking the plausibility of data) will be performed 
centrally as the data is being collected. 
 
Data analysis 
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The prevalence of CKD will be estimated for each of Asian countries as a first aim of the study 
“Prevalence of CKD in Asian populations”. 
For the second aim of the study “Prevalence of risk factors and complications and patterns of 
treatment in CKD patients in Asia”, the principal analyses of the associations of CKD stages 
with risk factors and complication will be performed. For the third aim of the study “Clinical 
outcomes in CKD patients in Asia”, the risks of clinical outcomes according to baseline CKD 
status, risk factors and presence/absence of CKD complications across the region will be 
estimated. Analyses will be adjusted for potential confounding factors and stratified by 
potential effect modifiers. Similar methods will be used to estimate the relationship between 
CKD and its complications, and other outcomes such as cardiovascular events and death. 
Associations in pre-specified subject subgroups (Table 5) will be determined. Analyses will be 
conducted to determine whether any subgroup differences are due to confounding effect 
modification (eg. different age distributions in the cohorts) or different diagnostic practices 
between countries. In addition to exploring heterogeneity of the associations between these 
subgroups, tests will also be performed to explore heterogeneity between individual studies 
(adjusting for major confounders). 
Sensitivity analyses taking account of factors including completeness of follow-up, methods of 
assessing outcomes and availability of repeat measurements risk factors will be performed to 
determine the robustness of the findings. 
The effects of regression dilution bias will be controlled in each individual cohort using repeat 
measurements of risk factors data from that cohort (or if repeat measurements are not available, 
data on re-measurement from other similar cohorts)95. 
Essential analyses 
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1. Prevalence of CKD in Asian populations  
 Reduced eGFR 
 Presence of albuminuria/proteinuria 
 CKD stages (defined by KDIGO) 
 ESKD (defined by treated ESKD – dialysis, HD and PD and transplant) 
i. This aspect will use cross-sectional studies, particularly those that are representative of the 
population.  
ii. The total burden of kidney disease in Asia will be calculated overall and by country.  
iii. The descriptive statistic used will be crude or age- and sex-standardized prevalence per 
million population. 
2. Prevalence of risk factors and complications and patterns of treatment in CKD 
patients in Asia 
 Clinical characteristics - age, gender, cause of CKD, co-morbidities, blood pressure, etc 
 Laboratory characteristics - iron stores, albumine, calcium, phosphate, haemoglobin, 
etc. 
 Treatment pattern - Iron, ESA, antihypertensive medication, Vitamin D, and other 
treatments 
 Prevalence of anaemia defined by haemoglobin (Hb) <100 g/L or on ESA therapy 
 Scale for quality of life 
i. This analysis will use all data describing characteristics of participants with CKD. The 
analysis will be also performed in participants with anaemia by CKD stage 
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ii. Analyses of the associations of CKD stages with risk factors (Table 4) and its 
complications will be performed using a linear regression model for continuous outcomes 
(e.g. age, systolic blood pressure) or a logistic regression model for binary outcomes (e.g. 
gender, presence of hypertension and diabetes).  
iii. Analyses will be adjusted for potential confounding factors and stratified by potential 
effect modifiers.  
3. Clinical outcomes in CKD patients in Asia 
 Kidney outcomes 
o Increase in CKD stage 
o Progression to ESKD 
o Doubling serum creatinine 
 Cardiovascular outcomes  
o Major cardiovascular events (Coronary heart disease, stroke, or cardiovascular 
mortality) 
o Coronary heart disease (Myocardial infarction or hospitalization from angina) 
o Stroke 
o Cardiovascular mortality 
o Hospitalization from Heart failure 
o Any other atherosclerotic disease  
 Mortality 
o All-cause mortality 
o Cause-specific mortality 
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i. This analysis will focus on longitudinal data and will describe the risk of clinical outcomes 
in CKD patients. 
ii. Hazard ratios of clinical outcomes according to baseline CKD status including anaemia, 
risk factors and presence/absence of CKD complications across the region will be 
estimated by means of a stratified Cox proportional hazard regression model. 
iii. Associations in pre-specified subject subgroups (Table 5) will be determined. 
Heterogeneity between subgroups will be explored.  
iv. Sensitivity analyses taking into account factors such as completeness of follow-up, 
methods of assessing outcomes and availability of repeat measurements risk factors will 
be performed to determine the robustness of the findings. 
v. The effects of regression dilution bias will be controlled in each individual cohort using 
repeat measurements of risk factors data from that cohort (or if repeat measurements are 
not available, data on re-measurement from other similar cohorts). Linear mixed model 
will be used to estimate attenuation coefficient. 
Exploratory analyses 
Although the primary and essential analysis is as described above, there are also plans to use 
the data collected from this study to conduct subsequent exploratory analyses. The aim of these 
post-hoc analyses is to detect specific association between potential risk factors and clinical 
outcomes in the developed large cohort. Such exploratory analyses will be defined and 
performed as required. Exploratory analyses may be suggested by steering committee members 
and will be undertaken following committee’s approval.  
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General considerations for data analyses 
Potential confounders will be assessed and controlled for by stratification according to pre-
specified subgroups listed in Table 5 or multivariable-adjusted analyses. 
Data handling conventions 
Participants were censored at their date of death or, for those still alive at the end of follow-up, 
the date of their last visit. 
 
Sample size and power/precision calculation 
This study is a systematic review and meta-analysis and it is therefore not necessary or possible 
to determine the level of precision of the estimates, as such a formal sample size calculation is 
not required.  However, from an initial review of the literature, it is anticipated that ARC will 
include 30 cohorts with approximately 2.2 million subjects. The large number of subjects will 
enable accurate estimation. 
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Study limitations 
The great strengths of the ARC will be the large amount of raw data and the strong 
collaboration between lead researchers in Asia. The study will leverage existing studies from 
a very large number of subjects in different countries and will consider a broad range of 
clinically important kidney endpoints such as progression of CKD, complications of CKD, 
hospitalisation, cardiovascular outcomes and mortality. The large number of subjects will mean 
that precise estimates will be achieved and inclusion of repeat measurements of exposure will 
enable adjustment for regression dilution bias.  
The main limitations of ARC relate to the use of existing data and non-standardization of data 
collection methods. All the included cohorts will have begun prior to the establishment of the 
Collaboration, without a common protocol. This has the potential to introduce bias when 
analysing continuous exposure variables, and makes analysis of categorical variables crude or 
impractical. Outcome variables will have similar issues; for example, progression of CKD may 
be defined in different ways and may be verified using different techniques in different studies.  
Subgroup analyses according to study quality will be conducted to assess for potential bias. 
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Study management  
Ethical approval and subject consent 
Individual studies will have obtained ethical approval and subject consent from their relevant 
institutions prior to participation in the collaboration. Thus, no further ethical approval or 
subject consent will be sought from individual participants. For the process of central data 
collection and analysis, a separate ethics submission will be made to the University of Sydney. 
 
Subject confidentiality 
All data provided to the collaboration by the principal investigators of individual studies will 
be provided in a de-identified format to ensure confidentiality of subjects. The George Institute 
for Global Health is an independent not-for-profit organization, which has extensive 
knowledge and experience in coordinating large-scale, international, multi-centre clinical 
research. In order to ensure the integrity and security of collected data, the George Institute has 
appropriate infrastructure established to cover all aspects including: data collection, handling, 
processing, and storage. 
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Study reporting and publications 
A report of the development of the collaboration and the study protocol will be drafted. A 
separate statistical analysis plan will also be drafted aimed at publication in a relevant medical 
journal, if necessary. Investigators will be encouraged to publish their own analyses before any 
collaboration report is released. All reports from this project will be sent to all collaborating 
investigators for comments and approval. The results of the study will be disseminated by 
manuscripts in peer-reviewed publications in the fields of general medicine and nephrology 
and by presentations at international meetings. All publications will be submitted in the name 
of the Asian Renal Collaboration with a defined writing committee for each based on 
established scientific principles. 
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Resourcing needs 
A study team will be established at the George Institute for Global Health that will oversee and 
implement all aspects of the collaboration. 
The team will consist of: 
 Study Director: a senior nephrologist who will take overall responsibility for all aspects of 
the collaboration 
 Senior statistician: a leading expert in statistics and epidemiology who will take primary 
responsibility for relevant aspects of data analysis 
 Senior Research Fellow: a person with renal training and relevant expertise who will 
undertake the analyses and manage the project under the supervision of the study director 
and senior statistician 
 Project Manager: an experienced person who will manage study timelines, budgets and 
deliverables 
 Administrative support: as required 
In addition, the study will require 2 meetings, one at study commencement and another once 
data is available. Flow diagram of the project is shown in Figure 6. 
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Table 4: List of risk factors 
Risk factors  Contents 
Age 
 
Gender Men and women 
Ethnicity  
 
Occupation 
 
Education level 
 
History of stroke and coronary heart 
disease 
y/n 
Cause of kidney disease 
 
Blood pressure Systolic blood pressure, diastolic blood 
pressure 
Diabetes Presence/absence of diabetes, Fasting glucose, 
HbA1c 
Blood lipids total cholesterol, HDL and LDL cholesterol, 
triglycerides 
Body parameters Height, weight, and body mass index 
Electrocardiogram abnormality Left ventricular hypertrophy, atrial fibrillation 
Smoking status Current, past, never 
Alcohol consumption Standard drinks/week 
Exercise y/n 
Laboratory markers 
 
Kidney function Serum creatinine, eGFR (estimated by CKD-
EPI formula) 
Albuminuria Presence/absence of 
microalbuminuria/microalbuminuria  
Urinary albumin-to-creatinine ratio  
Daily albumin excretion 
Proteinuria Presence/absence of proteinuria  
Urinary protein-to-creatinine ratio  
Daily protein excretion 
Haematology Haemoglobin, white cell count, platelets 
Iron status Serum iron, serum transferrin, serum ferritin 
Biochemistry Urea, electrolytes, calcium, phosphate 
Endocrinology Parathyroid hormone, Vitamin D 
Treatment 
 
Erythropoietin stimulating agent y/n, type, dose, mode of administration 
Iron therapy y/n, type, dose, mode of administration 
Anti-hypertensive medications y/n, type, dose 
Anti-diabetic medications y/n, type, dose 
Antithrombotic medications y/n, type, dose 
Cholesterol lowering drugs y/n, type, dose 
Phosphate binders y/n, type, dose 
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Calcium and Vitamin D therapy y/n, type, dose 
Calcimimetics y/n, type, dose 
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Table 5: Pre-specified subgroups 
Risk factors Subgroups 
Gender Men and women 
Country Asian countries 
Age groups By decade, or aged <65 and ≥65 years  
Periods of follow-up Median follow up 
Stage of CKD CKD stages 1-5 
Diabetes status Present/absent, type 1/type 2 diabetes 
Hypertensive status Present/absent, JNC 7 categories 
Smoking status Current, past, never 
Status of hyperlipidaemia Present/absent 
Body mass index (BMI) Median BMI, WHO categories BMI 
Anaemia Hb<100/Hb>100, treated with ESA or iron/no 
treatment 
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Figure 6: Flow of the project  
 
 
 
 
 
 
 
 
 
 
 
 
Systematic review of the literature to identify 
cohort studies conducted in Asia
Principal investigators from each study are 
invited to participate in the  ARC
Request for data
ARC cohort (>2.2 million participants)
Analysis
 prevalence of CKD in Asia
 Prevalence of risk factors and 
complications in CKD patients in Asia
 Clinical outcomes in CKD patients in Asia
Formation of the Asian Renal Collaboration 
(ARC)
Flow of the project
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Appendix 3.1 
Definition of clinical outcomes 
Cardiovascular outcomes 
i. Stroke (ICD-10: I60-I69)  
ii. Subarachnoid haemorrhage (ICD-10: I60) 
iii. Haemorrhagic stroke (ICD-10: I61-I62) 
iv. Ischaemic stroke (ICD-10: I63-I66) 
v. Coronary heart disease (ICD-10: I20-I25) 
vi. Quality of life  
 
Cause-specific mortality 
    Cardiovascular diseases 
i. All cardiovascular diseases (ICD-10: I00-I78) 
ii. Coronary heart disease (ICD-10: I20-I25) 
iii. Pulmonary circulatory disease (ICD-10:I26-I28) 
iv. Sudden death (ICD-10: I46.9) 
v. Heart failure (ICD-10: I50) 
vi. Stroke (ICD-10: I60 - I69)  
vii. Subarachnoid haemorrhage (ICD-10: I60) 
viii. Haemorrhagic stroke (ICD-10: I61-I62) 
ix. Ischaemic stroke (ICD-10: I63-I66) 
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     Other specific causes 
i. All neoplasms (ICD-10: C00-C97) 
ii. Oesophageal cancer (ICD-10: C00-C14) 
iii. Stomach cancer (ICD-10: C16) 
iv. Colorectal cancer (ICD-10: C18-C21) 
v. Liver cancer (ICD-10: C22) 
vi. Lung cancer (ICD-10: C33-C34) 
vii. Breast cancer (ICD-10: C50) 
viii. Liver disease (ICD-10: K70-77) 
ix. Kidney disease (ICD-10: N00-N19) 
x. Lung disease (ICD-10; J00-J99) 
 105 
 
Appendix 3.2 
Data Request (If available) 
1 Demographic factors 
1.1 Date of birth or age at baseline 
1.2 Gender 
1.3 Ethnicity  
1.4 Occupation (for whole cohort or individually, if available) 
1.5 Education level 
1.6 Some unique (but anonymous) identifier in case queries arise 
 
2 Baseline survey data (coded in whatever way the study has used) 
Details of the coding conventions, preferably accompanied by a copy of the questionnaire or 
data coding or data entry forms used in the study.  
2.1 Date or year of the baseline survey 
2.2 History of stroke and coronary heart disease 
2.3 Cause of kidney disease 
2.4 Systolic and diastolic blood pressure 
2.5 Diabetes (types 1 and 2) 
2.6 Lipid parameter (serum total, HDL- and LDL cholesterol and triglycerides) 
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2.7 Body parameters (height, weight, body mass index) 
2.8 Electrocardiogram abnormality (left ventricular hypertrophy and atrial fibrillation) 
2.9 Smoking status 
2.10 Alcohol consumption 
2.11 Exercise 
2.12 serum creatinine, eGFR 
2.13 Urinary albumin-to-creatinine ratio or daily albumin excretion 
2.14 Presence of proteinuria, urinary protein-to-creatinine ratio, or daily protein excretion 
2.15 Haematology (haemoglobin, white cell count and platelets) 
2.16 Iron status (serum iron, serum transferrin and serum ferritin) 
2.17 Biochemistry (urea, electrolytes, calcium and phosphate) 
2.18 Parathyroid hormone and vitamin D  
 
3. Treatment 
3.1 Erythropoietin stimulating agent (y/n, type, dose, mode of administration) 
3.2 Iron therapy (use or not, type, dose, mode of administration) 
3.3 Anti-hypertensive medications (y/n, Type, dose) 
3.4 Antithrombotic medications (y/n, Type, dose) 
3.5 Cholesterol lowering drugs (y/n, Type, dose) 
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3.6 Phosphate binders (y/n, Type, dose) 
3.7 Calcium and vitamin D therapy (y/n, Type, dose) 
3.8 Calcimimetics (y/n, Type, dose)  
 
4 Repeat survey(s) data 
Please provide data from any repeat survey(s) in a format as similar as conveniently possible 
to that for the baseline survey.  
 
5 Events 
5.1 Date last known to be alive (if not recorded as dead) 
5.2 Date of event or, if date not available age at event, for all non-fatal events of these 
types: 
a) Kidney outcomes 
1) Increase in CKD stage 
2) Progression to ESKD 
3) Doubling serum creatinine 
b) Cardiovascular outcomes  
1) Major cardiovascular events (coronary heart disease, stroke, or cardiovascular 
mortality) 
 108 
 
2) Coronary heart disease (myocardial infarction or hospitalization from angina) 
3) Stroke 
4) Cardiovascular mortality 
5) Hospitalization from heart failure 
6) Any other atherosclerotic disease (e.g. peripheral arterial disease and aneurysm) 
5.3 Date of death (or, age at death, if date not available) 
5.4 Underlying cause of death [preferably coded according to some specified version or 
other (e.g. 7th, 8th, 9th or 10th) of the 4-digit International Classification of 
Diseases, but if a 4-digit ICD code is not available then whatever code the study 
already uses] 
5.5 Stroke investigated by CT/MRI (y/n) 
5.6 Autopsy (y/n) 
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Appendix 3.3  
Roles and Responsibilities of collaboration members 
Study Director(s) 
 Study design  
 Protocol development 
 Executive committee recruitment and management 
 Prepare and chair meetings  
 Overall study oversight 
 Interpretation of study results and report writing 
 Manuscript writing 
 
Executive Committee  
 Review and comment on protocol  
 Identify studies and investigators in each country 
 Lead and present at meetings 
 Support investigators and facilitate national interpretation 
 Contribute to draft manuscripts and reports 
 Disseminate study results at conclusion 
 
Steering Committee  
 Review and comment on protocol  
 Participate in meetings 
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 Provide datasets for analysis 
 Facilitate national interpretation 
 Contribute to draft manuscripts and reports 
 Disseminate study results at conclusion 
 
Senior Research Fellow  
 Oversight of study activities at day-to-day level 
 Liaise with the sponsor and provide regular status updates 
 Liaise with each of the principal investigators to collect relevant data 
 Clean data to prepare a consistent dataset 
 Conduct analyses with guidance from director and statistician 
 Write first draft of protocol and reports under supervision of director 
 Experience and Qualifications: Medical or science graduate with a minimum of 3 years 
epidemiology experience at a high level, and a strong preference for regional experience 
 
Lead statistician 
 Review study design and protocol  
 Oversee development statistical analysis plan  
 Coordinate statistical analyses  
 Write statistical report and assist with scientific publication  
 Participate in steering committee 
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Appendix 3.4 
Signatures 
I have read and approve this protocol.  
Name (print) __________________________________________________________ 
Signature:  ____________________________________________________________ 
Date of Signature (dd/mmm/yyyy):__________________________________________ 
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CHAPTER 4: Prevalence of chronic kidney disease in Asia – a systematic review 
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Rationale 
Chronic kidney disease is a significant cause of morbidity and mortality. Recent 
epidemiological studies have provided valuable information on CKD, its progression and 
complications. However, most of the evidence has been generated from studies conducted 
either in Europe or North America while evidence regarding Asian populations is more limited. 
This review consolidates available data to estimate CKD prevalence across Asia. 
 
 
Author contribution 
Thaminda Liyanage involved in study concept design, conducted literature search, data 
collection, analysis where necessary, and led the manuscript preparation; currently managing 
the journal submission process under the guidance of steering committee. Tadashi Toyama 
conducted literature search, data collection and analysis where necessary. Toshiharu Ninomiya 
conducted analysis where necessary. Min Jun, Masafumi Fukagawa, Kearkiat Praditpornsilpa, 
Mark Woodward, Hooi Lai Seong, Hong Zhang, Luxia Zhang, Kunitoshi Iseki, Ming-Yen Lin, 
Heide A. Stirnadel-Farrant, Helen Monaghan contributed to study concept design and critical 
revision and editing of manuscripts. Vlado Perkovic and Vivekanand Jha oversaw the concept 
design, data collection, analysis and contributed to critical revision and editing of manuscripts.   
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Abstract 
Background 
The burden of chronic kidney disease (CKD) is growing rapidly around the world, especially 
in Asia. However, there is limited information on the overall regional prevalence of CKD, as 
well as the variations in national prevalence within the region. We aimed to consolidate 
available data, highlight limited availability and quantify estimates of this disease burden. 
Methods 
We systematically searched Medline for observational studies and contacted national experts 
to obtain CKD prevalence data. We estimated the prevalence of CKD for countries without 
reported data, assuming countries with similar levels of risk factors have similar CKD 
prevalence. Thus, we applied average-linkage clustering based on standardized risk factors and 
used random effects models. 
Results 
We obtained CKD prevalence for 16 countries (and Taiwan) and made estimates for nine 
countries. A total of 364.2 million (95% confidence interval 343.3-385.2) adults have CKD in 
Asia and 116.1 million (100.5-131.7) have advanced CKD (stages 3-5). The overall prevalence 
of CKD in the region is 13.2% (12.4-13.9%) and the prevalence of advanced CKD is 4.2% 
(3.6-4.8%). The prevalence of advanced CKD varies widely within the region from 1.8% (1.7-
1.9%) in China to 11.6% (11.0-12.2%) in Iran. Countries in Eastern Asia reported relatively 
higher prevalence (>13%) compared to other subregions in Asia. The greatest number of people 
living with CKD are in China [150.2 million (146.9-153.6)] and India [139.4 million (131.4-
147.4)].  
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Conclusions 
The large number of people with CKD, and the substantial number with advanced forms of the 
disease, shows the need for urgent collaborative action in the region to combat CKD and its 
complications.  
Keywords 
Asia, chronic kidney diseases, prevalence, cohort study, risk factors 
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Introduction 
Chronic kidney disease (CKD) is a significant cause of morbidity and mortality around the 
world16. Individuals with CKD have a reduced life expectancy: those who progress to end-
stage kidney disease (ESKD) have 20 times the mortality rate compared with age- and sex-
matched individuals with normal kidney function79. The global prevalence of end stage kidney 
disease (ESKD) is expected to rise sharply in the coming decades, with the largest growth in 
Asia1 16 46 96. This will place a substantial and growing burden on healthcare systems in most 
countries - especially in Asia16 80 96.  
 
Epidemiological studies conducted over last few decades have provided much valuable 
information about CKD, its progression to ESKD and its complications. Cross-sectional data 
indicate that the prevalence of CKD in the general population varies between 6 and 20% 
globally16 27 28 82-84. However, most of the evidence has been generated from studies conducted 
either in Europe or North America while evidence regarding Asian populations is more limited. 
Moreover, studies conducted in Asia tend to be smaller, regional and have not been 
consolidated to date. 
 
We conducted this systematic review and meta-analysis to consolidate available data, assess 
the availability of high quality data, and to estimate CKD prevalence in countries where no 
reported data exist as part of the wider effort by the Asian Renal Collaboration97.  
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Materials and methods 
Data Sources and Searches 
We performed a systematic review and meta-analysis of CKD prevalence using the published 
literature, as well as data collected from individual researchers by the Asian Renal 
Collaboration, according to the MOOSE guidelines51. 
 
CKD prevalence 
We conducted a systematic literature search to identify published literature on the prevalence 
of CKD in countries and regions within Asia, South, Southeast and East Asia, according to  
United Nations Population Division classification98. MEDLINE was searched via Ovid from 
1946 to September, 2017, without language restriction. The search terms used appear in 
appendix 4.1, consisting of keywords related to Asian countries, kidney function, and 
proteinuria.  References of relevant literature were manually searched to obtain other relevant 
information. We also conducted google and google scholar searches using individual country 
names, and contacted authors and experts in the field to obtain the most appropriate prevalence 
data on CKD. The literature search, data extraction and quality assessment were conducted 
independently by two authors (TL and TT) using a standardised approach. Disagreements in 
extracted data were adjudicated by a third reviewer (VP). 
 
Risk factors 
National estimates of life expectancy at birth, gross national income (GNI), prevalence of 
diabetes, hypertension (blood pressure ≥140/90 mmHg), and obesity (body mass index ≥30 
kg/m2) were obtained from the WHO Global Health Observatory data repository. These data 
covered all 26 Asian countries (see Table 6) except Taiwan56. We obtained data for Taiwan 
from published data in the literature.   
Population data 
To estimate the number of patients with CKD, we used national population data reported by 
the United Nations52. We obtained population data for Taiwan from their National Statistics 
website99. 
Study Selection and Data Extraction 
Studies were eligible for inclusion if they satisfied the following criteria: 1. A study population 
from Asia (defined as South, Southeast and East Asia); 2. At least 500 adult participants (18 
years or older) recorded or planned; 3. Cross-sectional study or baseline data of longitudinal 
study that describes the prevalence of CKD in a community-based population. Outcomes were 
defined as all CKD (stage 1 – 5; eGFR ≥60 ml/min/1.73 m2 with proteinuira, or eGFR <60 
ml/min/1.73 m2) or advanced CKD (stage 3 – 5; eGFR <60 ml/min/1.73 m2). 
Data Synthesis and Analysis 
We obtained national CKD prevalence from the available literature and ARC collaborators. 
Where more than one study reporting CKD prevalence for a given country was available we 
included the study that had the strongest design and reporting, was recent, and had the broadest 
population representation.  A study that was based on the general population and used random 
sampling with weighting according to the population structure was considered representative 
and used where available, otherwise the study with the largest sample size was used. We used 
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one representative study for each country to avoid excessive weight being allocated to countries 
with multiple studies during analysis. When relevant information were not available, we 
contacted authors for any missing data, as well as to recalculate eGFR using the CKD-EPI 
equation. Where the overall national CKD prevalence was unavailable, for the purpose of this 
calculation we used advanced CKD prevalence (CKD stages 3-5) as the overall CKD 
prevalence for that country.  
 
To allow estimates to be developed for countries which lacked specific data, we assumed that 
countries with the same levels of risk factors have similar CKD prevalence. First, we divided 
Asian countries into clusters based on similarity in risk factors obtained from the WHO data 
repository. Life expectancy at birth, GNI per capita, prevalence of diabetes, prevalence of 
hypertension, and prevalence of obesity were identified as CKD risk factors and standardized 
to z scores (0-1). Next, we conducted agglomerative average-linkage hierarchical clustering of 
countries using the standardized risk factors 100. Clusters were verified for their similarity in 
prevalence of the risk factors. Using the available prevalence data, we applied random effects 
models (due to study heterogeneity) to estimate the prevalence of CKD for each country in 
different clusters that did not report prevalence. 
We estimated the prevalence of all CKD (stages 1–5) as well as advanced CKD (stages 3-5) 
for the entire Asia as well as for each geographical subregion in Asia. The absolute number of 
individuals was calculated by multiplying the prevalence by the total population of the country. 
All analyses were performed using Stata (version 14.1; StataCorp, College Station, TX). 
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Results 
Our search strategy identified 1672 articles from which 68 were selected for full text review. 
We also identified one potential article from web searches using individual country names. We 
included 17 articles26 101-114 in this systematic review after review of these 69 full text reports.  
Additionally, we updated data for two countries (China and South Korea) with inputs from 
study authors and experts in the discipline who provided unpublished individual patient level 
data. In total, we obtained prevalence data on CKD for 16 countries (and Taiwan) representing 
97.1% of the adult population in Asian region. 
 
When classified geographically, data were available for countries in all three sub-regions of 
Asia (Southern Asia, Eastern Asia and South-Eastern Asia) but covered a variable proportion 
of included countries for each region. We obtained CKD prevalence data for four countries 
(and Taiwan) in Eastern Asia (98.6% of the adult East Asian population), six countries in South 
Asia (98.6%) and six countries in South-Eastern Asia (88%). Additionally, we obtained 
individual patient level data on CKD and its complications for China and South Korea. The 
completeness and robustness of data capture and reporting in studies used for data extraction 
varied considerably. Among the included studies, noticeable differences existed in catchment 
areas (national vs regional), sample size, age cut off, formula used to estimate glomerular 
filtration rate (eGFR) and also in the definition of CKD (Table 7). 
 
In the absence of reliable published data, we estimated the prevalence of CKD and advanced 
CKD in nine countries (Afghanistan, Bhutan, Brunei, Cambodia, Laos, Maldives, Myanmar, 
North Korea and Timore-Leste), with a total population of 80.6 million representing 2.9% of 
the total population of Asia. We classified 25 countries and Taiwan into 7 clusters based on 
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known CKD risk factor profile (life expectancy at birth, per capita gross national income, 
prevalence of diabetes mellitus, hypertension and body mass index >30 kg/m2) in each country 
(Table 6). Afghanistan, Bangladesh, Cambodia, India, Indonesia, Laos, Myanmar, Nepal, 
North Korea, Philippines, Timor-Leste and Viet Nam were considered a single cluster as all 
these countries shared common risk factor profiles. Similarly, Bhutan and Pakistan formed one 
cluster while China, Maldives, Sri Lanka and Thailand formed another. Japan, Korea, 
Singapore and Taiwan were in another cluster as were Brunei and Malaysia. However, 
Mongolia and Iran were considered individually as these two countries had very different risk 
factor profiles to the other Asia countries (Figure 8). We estimated CKD prevalence for 
countries without reported data by applying random effects model to the available prevalence 
data within a cluster. Estimates were made for one country in Eastern Asia (North Korea), three 
countries in Southern Asia (Afghanistan, Bhutan, and Maldives) and five countries in South-
Eastern Asia (Brunei, Cambodia, Laos, Myanmar, and Timor-Leste). 
 
In total, 364.2 million (95% confidence interval 343.3-385.2) adults had CKD in the Asia –this 
included 116.1 million (100.5-131.7) with more advanced CKD (stages 3-5). The overall 
prevalence of CKD in the region was 13.2% (12.4-13.9%) and the prevalence of advanced 
CKD was 4.2% (3.6-4.8%). The prevalence of CKD varied widely within the region ranging 
from 2.6% (0.7-4.6%) in the Philippines to 17.2% (16.2-18.2) in India.  Advanced CKD also 
ranged from 1.8% (1.7-1.9%) in China to 11.6% (11.0-12.2%) in Iran. The absolute number of 
people with CKD was highest in China [150.2 million (146.9-153.6)] and India [139.4 million 
(131.3-147.4)]. Similarly, the absolute number of people with advanced CKD was also highest 
in China [19.1 million (17.8-20.3)] and India [47.8 million (42.8-52.8)], closely followed by 
Japan [11.4 million (11.3-11.5)]. In Southern Asia, CKD prevalence varied between 7.2% (7.0-
7.4) in Sri Lanka to 17.2% (16.2-18.2) in India. In South-Eastern Asia, the prevalence ranged 
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from 2.6% (0.7-4.6%) in the Philippines to 14.4% (13.2-15.6) in Thailand. All six countries in 
Eastern Asia reported a higher prevalence (>13%) compared to the other geographical 
subregions in Asia (Table 8). 
 
A sensitivity analysis using all available data for a given country from multiple sources, in 
contrast to single representative study for each country, we estimated 353.3 million (274.9-
431.8) had CKD and 109.3 million (85.2-133.4)  had more advanced CKD in Asia. The overall 
prevalence of CKD in the region was 12.8% (9.9-15.6%) and the prevalence of advanced CKD 
was 4.0% (3.1-4.8%) (Supplementary table 4). 
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Discussion 
In this systematic review, we used the best available data to estimate the overall prevalence 
and the absolute number of people with CKD in Asia, finding almost 364 million people had 
CKD with an overall prevalence rate of 13.2%. Additionally our findings suggest, 116 million 
of those people have more advanced forms of CKD (stages 3-5). The highest burden of CKD 
as well as advanced CKD was observed in China and India – the two countries with largest 
populations in the region. These data highlight the need to reliably and consistently collect data 
on CKD prevalence, and demonstrate a pressing need for the early detection and treatment of 
CKD, as well as the importance of development, implementation, and assessment of cost 
effective kidney disease prevention strategies. 
 
Although the prevalence of CKD has been reported in individual countries, regional estimates 
on CKD burden in Asia are not currently available.  However, global CKD prevalence was 
estimated to be 497.5 million in 2010, with nearly half of affected individuals having more 
advanced stages of CKD (stages 3-5) and three quarters living in low or middle income 
countries115.  These estimates were based on 33 reports from 32 countries and only represented 
48.6% of the global adult population. National CKD prevalence has been reported by number 
of countries around the world, including some countries in the Asian region. Based on 
nationally representative studies, in the United States CKD prevalence in men was 10.6% and 
in women 13.0%116, in the United Kingdom 13% for both men and women117 and in Canada 
12.4% in men and 12.7% in women118. Only a limited number of countries in Asia have 
reported national CKD prevalence based on studies involving nationwide sampling. Most other 
countries around the world have gathered CKD prevalence information to some extent but they 
are neither uniform nor comprehensive.  
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This study has several strengths. Our findings build on and extend on previous estimates on 
CKD burden in Asian region. We obtained contemporary data from 16 countries plus Taiwan, 
including 97.1% of the regional population, using a comprehensive and systematic approach.  
This study reports estimate of CKD prevalence in the region, used clustering rather than flat 
rates to estimate CKD prevalence in countries without reported data, and used conservative 
estimates wherever possible. Moreover, this is the first comprehensive report on regional CKD 
prevalence to our knowledge. 
 
Some limitations should also be considered, mainly due to limited data availability, variability 
in the datasets used (age cut off, formula used to calculate eGFR and definition of CKD) and 
their quality and reliability. There were highly variable prevalence reports for CKD within the 
same country as well as between countries, despite having similar risk factor profiles. The 
available data were not complete for some countries, and the two countries with the largest 
populations in the region, China and India, do not have comprehensive data on national studies 
or CKD registries. Nonetheless, we obtained data from the most reliable available sources and 
believe that any variability in reliability of estimates for these countries would have a small 
effect on the results at most. Because we deemed advanced CKD prevalence equals to overall 
CKD prevalence where overall CKD prevalence data were unavailable, the total number of 
patients with CKD in the region is probably slightly underestimated in this study.  Most studies 
used only a single creatinine measurement to calculate eGFR but no follow up measurement in 
three months to confirm CKD. This may overestimate CKD prevalence due to high false 
positive rates. Furthermore, the model we used needed a series of assumptions, but each was 
well supported by the available data.   
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The large number of affected individuals in the region and the many complications of CKD set 
a demanding task for the nephrology community and the health-care and research communities 
in general. Although documentation of the magnitude of the issue is a necessary first step, the 
results highlight the importance of consistent approaches to data collection regarding CKD, 
and the value of longitudinal assessments to understand changes over time. In addition, the 
value of screening for CKD, and of interventions proven to prevent progression of CKD as 
well as other complications should be tested using innovative models of care, with a focus on 
low-income and middle-income countries, especially in areas where access to physicians is 
low72. Regional and global professional bodies such as the Asian Pacific Society of 
Nephrology, the International Society of Nephrology and other organisations have a key role 
to play in this effort. 
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Conclusion 
CKD is major health concern in Asia affecting substantial proportion of its population. Our 
study results highlight the need for a collaborative action in the region to combat CKD and its 
complications including ESRD, CVD and death. 
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Appendix 4.1 
Search strategy 
# Search terms   
1 exp China/  
2 exp Hong Kong/  
3 exp Macau/  
4 exp Taiwan/  
5 exp "Democratic People's Republic of Korea"/  
6 exp Japan/  
7 exp Mongolia/  
8 exp "Republic of Korea"/  
9 exp Afghanistan/ 
10 exp Bangladesh/  
11 exp Bhutan/  
12 exp India/ 
13 exp Iran/  
14 maldives.mp. or exp Indian Ocean Islands/  
15 exp Nepal/  
16 exp Pakistan/  
17 exp Sri Lanka/  
18 exp Brunei/  
19 exp Cambodia/  
20 exp Indonesia/  
21 exp Laos/  
22 exp Malaysia/  
23 exp Myanmar/  
24 exp Philippines/ 
25 exp Singapore/  
26 exp Thailand/  
27 timor.mp.  
28 exp Vietnam/  
29 chronic renal failure.mp. or exp Kidney Failure, Chronic/  
30 Glomerular Filtration Rate/  
31 exp Proteinuria/  
32 exp Hematuria/  
33 exp Creatinine/  
34 exp Anemia/  
35 exp Erythropoietin/  
36 exp Iron/  
37 exp Ferritins/  
38 exp Transferrin/ 
39 exp Prevalence/  
40 exp Epidemiology/  
41 exp Cross-Sectional Studies/  
42 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 415807 
43 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38  
44 39 or 40 or 41   
45 42 and 43 and 44  
46 limit 45 to yr="2000 -Curre
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Table 6: Baseline characteristics of each East and South Asian country according to clusters categorized by the burden of risk factors 
Cluster Countries 
Life expectancy at birth 
(years) 
GNI per capita 
(US$) 
Prevalence of 
diabetes*(%) 
Prevalence of BP 
≥140/90 mmHg (%) 
Prevalence of BMI ≥30 
kg/m2 (%) 
1 
Afghanistan 58.4 680 9.6 29.0 2.9 
Bangladesh 68.4 1080 9.4 25.6 3.6 
Nepal 65.9 730 9.4 26.6 3.3 
India 65.0 1610 9.5 25.4 4.9 
Cambodia 69.5 1010 8.2 24.4 3.2 
Laos 65.8 1600 8.6 24.1 3.5 
Indonesia 70.0 3650 8.7 23.3 6.0 
Philippines 67.8 3440 7.3 22.1 5.1 
Myanmar 64.2 1270 7.1 23.7 2.9 
Timor-Leste 64.5 3120 7.4 26.7 2.2 
North Korea 68.4 1400 5.6 21.0 2.4 
Viet Nam 75.1 1890 6.5 22.2 3.6 
2 
China 74.4 7380 9.5 18.8 6.9 
Maldives 75.6 7290 10.4 21.6 7.9 
Sri Lanka 73.4 3400 9.7 21.2 6.5 
Thailand 73.3 5410 9.7 21.3 8.5 
3 
Bhutan 65.7 2390 12.4 27.3 6.7 
Pakistan 65.7 1410 10.8 27.9 5.4 
4 
Japan 82.7 42000 7.5 16.9 3.3 
Korea 80.0 27090 7.9 10.8 5.8 
Singapore 81.0 55150 8.5 14.1 6.2 
Taiwan 80.0 21000 7.8 23.5 4.0 
5 
Brunei 77.5 36710 11.6 19.3 18.1 
Malaysia 74.0 10660 11.1 22.1 13.0 
6 Iran 74.2 15600 12.2 23.7 26.1 
7 Mongolia 66.1 4320 11.5 31.1 16.7 
Note: Diabetes was defined as fasting glucose ≥7.0 mmol/l (126 mg/dl), using glucose-lowering agents, and/or the presence of a history of diagnosis of diabetes 
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Table 7: Characteristics of the included studies 
Cluster Countries Formula Definition of 
proteinuria 
Age 
(years) 
Year Sample size  Prevalence 
(all CKD) 
Prevalence (CKD 
stage 3-5) 
Reference 
1 Afghanistan               
1 Bangladesh MDRD dipstick ≥1+ ≥18  2013 634 12.8% 6.0% Saudi J Kidney Dis Transpl. 24(3):534-41, 2013 May. 
1 Cambodia               
1 India MDRD dipstick ≥1+ ≥18  2013 5588 17.2% 5.9% BMC Nephrology. 14:114, 2013. 
1 Indonesia Chinese 
MDRD 
dipstick ≥1+ ≥18  2009 9412 7.5%   Nephrology. 14(7):669-74, 2009 Oct 
1 Laos                 
1 Myanmar               
1 Nepal MDRD dipstick ≥1+ ≥20  2013 3218 10.6% 6.3% J Nepal Med Assoc 2013;52(189):205-12 
1 Northe Korea               
1 Philippines MDRD   ≥20  2005 NA   2.6% NNHeS renal report http://goo.gl/XKADci 
1 Timor-Leste               
1 Viet Nam Cockcroft-
Gault 
dipstick ≥1+ ≥40  2008 8505 4.7% 3.1% Nephron Clinical Practice, 2008; 109(1):c25-32 
2 China CKD-EPI albuminuria 
and/or dipstick 
≥1+ 
≥20  2010 46968 14.2% 1.8% Lancet. 379(9818):815-22, 2012 Mar 3. 
2 Maldives 
       
2 Sri Lanka MDRD dipstick ≥1+ ≥20  2015 54081 7.2% 7.0% J Epidemiol. 2015;25(4):275-80 
2 Thailand MDRD albuminuria and 
/or hematuria 
≥18  2010 3459 14.4% 8.6% Nephrol Dial Transplant. 2010 May;25(5):1567-75 
3 Bhutan               
3 Pakistan MDRD   ≥40 2009 3,143   8.0% Nephrol Dial Transplant. 24(7):2111-6, 2009 Jul. 
4 Japan Japanese 
GFR 
dipstick ≥1+ ≥20 2009 574,024 13.2% 10.9% Clin Exp Nephrol. 13(6):621-30, 2009 Dec. 
4 Korea CKD-EPI dipstick ≥1+ ≥20 2011 5,428 17.4% 3.8% KNHANES 2011 
4 Singapore MDRD albuminuria ≥24 2010 4499 15.6% 5.3% Nephrol Dial Transplant (2010) 25: 2564–2570 
4 Taiwan MDRD dipstick ≥trace ≥20 2008 462293 11.9% 6.9% Lancet. 2008; 371: 2173–82 
5 Brunei                 
5 Malaysia CKD-EPI albuminuria ≥18 2011 876 9% 2.8% Kidney Int. 84(5):1034-40, 2013 Nov 
6 Iran MDRD 
 
≥18 2009-
2011 
9409 
 
11.6% Iranian Journal of Kidney Diseases 2014, 8, 109-115 
7 Mongolia MDRD dipstick ≥1+ ≥16 2010 997 13.9% 7.9% Am J Kidney Dis. 2010 Nov;56(5):915-27, Nephrology 
16,2011, 633-641 
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Table 8: Number of patients and prevalence for all CKD and CKD stage 3-5 in East and South Asian countries (based on single best study per 
country) 
Cluster Countries 
N of population aged ≥20 
years in 2015 
(x million) 
All CKD 
 
CKD stage 3–5 
Number of patients (95% CI) 
(x million) 
Prevalence (95% CI)  
(%) 
Number of patients (95% CI) 
(x million) 
Prevalence (95% CI)  
(%) 
 Afghanistan 14.368 1.509 (0.812 to 2.206) 10.5 (5.7 to 15.4) c)  0.762 (0.481 to 1.042) 5.3 (3.4 to 7.3) c) 
 Bangladesh 97.467 12.476 (9.941 to 15.01) 12.8 (10.2 to 15.4)  5.848 (4.046 to 7.65) 6.0 (4.2 to 7.8) 
 Nepal 15.944 1.69 (1.52 to 1.86) 10.6 (9.5 to 11.7)  1.004 (0.871 to 1.138) 6.3 (5.5 to 7.1) 
 India 810.276 139.367 (131.35 to 147.385) 17.2 (16.2 to 18.2)  47.806 (42.8 to 52.812) 5.9 (5.3 to 6.5) 
 Cambodia 9.082 0.954 (0.513 to 1.394) 10.5 (5.7 to 15.4) c)  0.481 (0.304 to 0.658) 5.3 (3.4 to 7.3) c) 
1 Laos 3.684 0.387 (0.208 to 0.565) 10.5 (5.7 to 15.4) c)  0.195 (0.123 to 0.267) 5.3 (3.4 to 7.3) c) 
 Indonesia 163.301 12.248 (11.379 to 13.117) 7.5 (7.0 to 8.0)  8.655 (5.471 to 11.839) 5.3 (3.4 to 7.3) c) 
 Philippines 58.404 1.518 (0.38 to 2.657) 2.6 (0.7 to 4.6) b)  1.518 (0.38 to 2.657) 2.6 (0.7 to 4.6) 
 Myanmar 34.066 3.577 (1.925 to 5.229) 10.5 (5.7 to 15.4) c)  1.805 (1.141 to 2.47) 5.3 (3.4 to 7.3) c) 
 Timor-Leste 0.555 0.058 (0.031 to 0.085) 10.5 (5.7 to 15.4) c)  0.029 (0.019 to 0.04) 5.3 (3.4 to 7.3) c) 
 North Korea 17.878 1.877 (1.01 to 2.744) 10.5 (5.7 to 15.4) c)  0.948 (0.599 to 1.296) 5.3 (3.4 to 7.3) c) 
 Viet Nam 64.898 1.533 (1.387 to 1.679) a) 4.7 (4.3 to 5.2) a)  1.003 (0.884 to 1.122) a) 3.1 (2.7 to 3.5) a) 
2 
China 1,060.004 150.225 (146.881 to 153.568) 14.2 (13.9 to 14.5)  19.063 (17.789 to 20.337) 1.8 (1.7 to 1.9) 
Maldives 0.231 0.028 (0.015 to 0.040) 11.9 (6.4 to 17.4)c)  0.013 (0.004 to 0.023) 5.8 (1.7 to 9.9) c) 
Sri Lanka 14.040 1.012 (0.981 to 1.042) 7.2 (7.0 to 7.4)  0.977 (0.947 to 1.007) 7.0 (6.7 to 7.2) 
Thailand 51.521 7.419 (6.816 to 8.022) 14.4 (13.2 to 15.6)  4.431 (3.949 to 4.912) 8.6 (7.7 to 9.5) 
3 
Bhutan 0.493 0.039 (0.035 to 0.044) 8.0 (7.1 to 8.9) b,c)  0.039 (0.035 to 0.044) 8.0 (7.1 to 8.9) c) 
Pakistan 103.475 0.003 (0.003 to 0.004) a,b) 8.0 (7.1 to 8.9) a,b)  0.003 (0.003 to 0.004) a) 8.0 (7.1 to 8.9) a) 
4 
Japan 104.341 13.773 (13.682 to 13.864) 13.2 (13.1 to 13.3)  11.373 (11.289 to 11.457) 10.9 (10.8 to 11.0) 
Korea 39.994 3.280 (3.106 to 3.453) 8.2 (7.8 to 8.6)  1.596 (1.505 to 1.687) 4.0 (3.8 to 4.2) 
Singapore 4.375 0.683 (0.636 to 0.729) 15.6 (14.5 to 16.7)  0.232 (0.203 to 0.261) 5.3 (4.6 to 6.0) 
Taiwan 17.526 2.086 (2.069 to 2.102) 11.9 (11.8 to 12.0)  1.209 (1.196 to 1.222) 6.9 (6.8 to 7.0) 
5 
Brunei 0.290 0.026 (0.021 to 0.032) 9.1 (7.2 to 11.0) b,c)  0.008 (0.005 to 0.011) 2.8 (1.7 to 3.9) c) 
Malaysia 20.124 1.825 (1.443 to 2.208) 9.1 (7.2 to 11.0)  0.563 (0.344 to 0.783) 2.8 (1.7 to 3.9) 
6 Iran 54.953 6.375 (6.019 to 6.73) 11.6 (11.0 to 12.2) b)  6.375 (6.019 to 6.73) 11.6 (11.0 to 12.2) 
7 Mongolia 1.895 0.263 (0.223 to 0.304) 13.9 (11.8 to 16.0)  0.15 (0.118 to 0.181) 7.9 (6.2 to 9.6) 
Total 2763.183  364.230 (343.259 to 385.200) d) 13.2 (12.4 to 13.9)   116.089 (100.503 to 131.675) d) 4.2 (3.6 to 4.8) 
 
a) Number of patients and prevalence among subjects aged 40 years or older, because of no available data for subjects aged 20-39 years 
b) Number of patients and prevalence for CKD stage 3-5 were used in place of those for all CKD, because of no available data for all CKD 
c) Prevalence of all CKD or CKD stage 3-5 which was estimated by using a random effects model with the data from the countries included in the same cluster.  
95% confidence intervals of the number of patients for total population were calculated as the sum of lower or higher values of 95% confidence intervals among countries
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Supplementary table 4: Number of patients and prevalence for all CKD and CKD stage 3-5 in East and South Asian countries (based on all 
available data per country) 
Cluster Countries 
N of population aged ≥20 
years in 2015 
(x million) 
All CKD 
 
CKD stage 3–5 
Number of patients (95% CI) 
(x million) 
Prevalence (95% CI) (%) 
Number of patients (95% CI) 
(x million) 
Prevalence (95% CI)  
(%) 
 Afghanistan 14.368 1.652 (1.401 to 1.904) 11.5 (9.7 to 13.2) c)  0.675 (0.381 to 0.97) 4.7 (2.7 to 6.8) c) 
 Bangladesh 97.467 12.476 (9.942 to 15.01) 12.8 (10.2 to 15.4)  5.848 (4.094 to 7.602) 6.0 (4.2 to 7.8) 
 Nepal 15.944 1.69 (1.515 to 1.865) 10.6 (9.5 to 11.7)  1.626 (0.399 to 2.854) 10.2 (2.5 to 17.9) 
 India 810.276 110.197 (62.796 to 157.599) 13.6 (7.8 to 19.5)  25.119 (17.421 to 32.816) 3.1 (2.1 to 4.0) 
 Cambodia 9.082 1.044 (0.885 to 1.203) 11.5 (9.7 to 13.2) c)  0.427 (0.241 to 0.613) 4.7 (2.7 to 6.8) c) 
1 Laos 3.684 0.424 (0.359 to 0.488) 11.5 (9.7 to 13.2) c)  0.173 (0.098 to 0.249) 4.7 (2.7 to 6.8) c) 
 Indonesia 163.301 18.78 (15.922 to 21.637) 11.5 (9.7 to 13.2) c)  12.248 (11.431 to 13.064) 7.5 (7.0 to 8.0) 
 Philippines 58.404 6.716 (5.694 to 7.738) 11.5 (9.7 to 13.2) c)  1.518 (1.226 to 1.811) 2.6 (2.1 to 3.1) 
 Myanmar 34.066 3.918 (3.321 to 4.514) 11.5 (9.7 to 13.2) c)  1.601 (0.903 to 2.299) 4.7 (2.7 to 6.8) c) 
 Timor-Leste 0.555 0.064 (0.054 to 0.074) 11.5 (9.7 to 13.2) c)  0.026 (0.015 to 0.037) 4.7 (2.7 to 6.8) c) 
 North Korea 17.878 2.056 (1.743 to 2.369) 11.5 (9.7 to 13.2) c)  0.84 (0.474 to 1.207) 4.7 (2.7 to 6.8) c) 
 Viet Nam 64.898 3.72 (3.154 to 4.287) a) 11.5 (9.7 to 13.2) a,c)  1.003 (0.873 to 1.132) a) 3.1 (2.7 to 3.5) a) 
2 
China 1,060.004 143.1 (130.38 to 155.821) 13.5 (12.3 to 14.7)  28.62 (22.79 to 34.45) 2.6 (2.2 to 3.0) 
Maldives 0.231 0.025 (0.012 to 0.038) 10.9 (5.4 to 16.4) c)  0.012 (0.006 to 0.018) 5.1 (2.1 to 8.1) c) 
Sri Lanka 14.040 1.011 (0.983 to 1.039) 7.2 (7.0 to 7.4)  0.983 (0.955 to 1.011) 7.0 (6.8 to 7.2) 
Thailand 51.521 6.801 (2.473 to 11.128) 13.2 (4.8 to 21.6)  2.937 (2.628 to 3.246) 5.7 (5.1 to 6.3) 
3 
Bhutan 0.493 0.082 (0.065 to 0.099) 16.6 (13.2 to 20.0) c)  0.093 (-0.013 to 0.199) 18.8 (-2.7 to 40.3) c) 
Pakistan 103.475 0.007 (0.006 to 0.009) a) 16.6 (13.2 to 20.0) a)  0.008 (-0.001 to 0.017) a) 18.8 (-2.7 to 40.3) a) 
4 
Japan 104.341 24.624 (21.494 to 27.755) 23.6 (20.6 to 26.6)  13.982 (11.06 to 16.903) 13.4 (10.6 to 16.2) 
Korea 39.994 3.28 (3.120 to 3.439) 8.2 (7.8 to 8.6)  2.04 (1.18 to 2.90) 5.1 (3.0 to 7.3) 
Singapore 4.375 0.56 (0.516 to 0.604) 12.8 (11.8 to 13.8)  0.494 (0.466 to 0.523) 11.3 (10.7 to 12.0) 
Taiwan 17.526 2.734 (1.446 to 4.022) 15.6 (8.3 to 23.0)  1.718 (0.482 to 2.953) 9.8 (2.8 to 16.9) 
5 
Brunei 0.290 0.026 (0.021 to 0.032) 9.1 (7.2 to 11.0) c)  0.026 (0.021 to 0.032) 9.1 (7.2 to 11.0) b) 
Malaysia 20.124 1.825 (1.443 to 2.208) 9.1 (7.2 to 11.0)  1.825 (1.443 to 2.208) 9.1 (7.2 to 11.0) b) 
6 Iran 54.953 6.375 (6.019 to 6.73) 11.6 (11.0 to 12.2) b)  6.375 (6.019 to 6.73) 11.6 (11.0 to 12.2) 
7 Mongolia 1.895 0.149 (0.117 to 0.181) 7.9 (6.2 to 9.5) b)  0.149 (0.117 to 0.181) 7.9 (6.2 to 9.5) 
 Total 2763.183  353.337 (274.882 to 431.791) d) 12.8 (9.9 to 15.6)  109.305 (85.235 to 133.375) d) 4.0 (3.1 to 4.8) 
 
a) Number of patients and prevalence among subjects aged 40 years or older, because of no available data for subjects aged 20-39 years 
b) Number of patients and prevalence for CKD stage 3-5 were used in place of those for all CKD, or vice versa, because of no available data. 
c) Prevalence of all CKD or CKD stage 3-5 which was estimated by using a random effects model with the data from the countries included in the same cluster.  
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Figure 7: Literature search 
 
 
 
 
 
 
 
 
 
 
 
 
 
Result of database search 
Abstract review 
n = 1672 
Full paper review 
n = 68 
Not reporting prevalence of CKD 
n = 1604 
Included 
n = 17 
Data collected from web 
n = 1 (Philippines) 
Included 
n = 16 
Not representative data of a country 
n = 52 
Included 
n = 17 
Two data updated using individual 
patient data 
n = 2 (China, South Korea) 
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Figure 8: The clusters categorized based on risk factors for each country (Dendrogram) 
 
As categorized variables, life expectancy at birth, GNI per capita, prevalence of diabetes, prevalence of BP ≥140/90 mmHg, prevalence of BMI ≥30 kg/m2 were used.
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CHAPTER 5: Prevalence of anaemia in patients with chronic kidney disease and the 
treatment patterns of renal anaemia across Asia 
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Rationale 
Anaemia is a frequent complication of CKD, and it is associated with greater mortality and 
morbidity. Anaemia is increasingly diagnosed in patients with early stages of CKD, in addition 
to patients with ESKD. Current evidence base suggests that the treatment of anaemia in both 
pre-dialysis and dialysis dependent populations remains suboptimal. There is an unmet need to 
understand the prevalence and treatment patterns of anaemia, particularly in Asia. This review 
describes and consolidates available data on anaemia prevalence and its treatment patterns in 
Asia. 
 
Author contribution 
Thaminda Liyanage involved in study concept design, conducted literature search, data 
collection, analysis, and led the manuscript preparation; currently managing the journal 
submission process under the guidance of steering committee. Tadashi Toyama conducted 
literature search, data collection and analysis where necessary. Toshiharu Ninomiya, Min Jun 
and Heide A Stirnadel-Farrant contributed to study concept design and critical revision and 
editing of manuscripts. Vlado Perkovic and Vivekanand Jha oversaw the concept design, data 
collection, analysis and contributed to critical revision and editing of manuscripts.   
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Abstract 
Introduction 
Chronic kidney disease (CKD) is a multisystem disorder, leading to a range of complications 
including anaemia. Anaemia accelerates CKD progression and is associated with increased 
mortality. There is limited understanding of the anaemia prevalence and treatment patterns in 
Asia. 
 
Methods 
We systematically searched MEDLINE and EMBASE for observational studies and renal 
registries, and contacted national experts in Asia through the Asian Renal Collaboration 
(ARC), to obtain anaemia prevalence and treatment data. A meta-analysis within each CKD 
category was conducted using random effects model to estimate summary statistics for anaemia 
prevalence. 
 
Results 
In general population studies available from South Korea and Taiwan, overall anaemia 
prevalence was estimated at 1.26%. In CKD patients, the anaemia prevalence in Japan varied 
from 2.7% - 19.7%. Among patients on maintenance dialysis, the prevalence was estimated to 
be 79.5% in Thailand, 72.5% in Japan, 77.7% in South Korea and 61.1% – 87.2% in India.  
Compared to those with CKD stage 1-2, the prevalence of anaemia was progressively higher 
within CKD categories 3, 4, and 5 (P for trend = 0.01) 
 
Conclusion 
Anaemia affects large number of individuals across Asia, with high prevalence in people with 
CKD and ESKD receiving dialysis.  
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Introduction 
Chronic kidney disease (CKD) is a rapidly growing multisystem disorder affecting people 
globally, with the highest burden seen in Asia 96 119-121. Anaemia, a frequent complication of 
CKD, is associated with increased mortality 122 as well as other adverse outcomes including 
neurocognitive impairment, sleep disturbances, CKD progression, cardiovascular 
comorbidities and reduced quality of life (QoL)123-128. Anaemia of CKD develops from a 
combination of erythropoietin (EPO) deficiency, decreased responsiveness to EPO, iron 
deficiency, chronic inflammation and shortened red blood cell survival.  
 
Clinical practice guidelines such as the European Best Practice Guidelines 129 and the Kidney 
Disease Improving Global Outcomes 130 recognize management of anaemia as an integral part 
of overall CKD management. Although most frequent in patients receiving dialysis, anaemia 
and its adverse effects have been recognized in patients with early and mid-stage CKD 131 132.  
 
Despite the availability of effective strategies to treat anaemia in CKD such as erythropoiesis-
stimulating agents (ESAs), iron therapy and blood transfusion, 133 the available evidence 
suggests that treatment of anaemia in the pre-dialysis as well as dialysis populations remains 
suboptimal 134-136. A study based on data from the Dialysis Outcomes and Practice Pattern 
Study (DOPPS) and Shanghai Renal Registry 2011 reported that in China, only 39% - 46% of 
patients on haemodialysis achieved a target Hb of 100-120g/L26. 
 
In contrast to the relatively abundant information regarding anaemia in patients with ESKD on 
dialysis that mostly comes from developed countries127, far less is known about the prevalence 
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and treatment of anaemia in Asia. Reliable data on the prevalence and management of anaemia 
are needed to understand and improve the care of people with CKD. 
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Materials and methods 
The protocol for the Asian Renal Collaboration (ARC) has been previously published 97. 
Briefly, ARC collates data from studies conducted in Asia through a pre-defined collaborative 
process based on a systematic review of the literature.  
 
Data sources and study selection 
Studies were identified through a systematic literature search including abstracts and 
proceedings of meetings, as well as electronic databases such as MEDLINE and EMBASE 
from inception to September, 2017. In addition, personal enquiry among collaborators and 
experts in the region was sought to obtain unpublished data. Where available, individual 
participant data (IPD) were sought from collaborating studies, otherwise summary level data 
were collected. 
All cross-sectional and longitudinal studies which 1) included adult (age ≥18 years) 
populations from Asia 2) reported the prevalence of anaemia and/or its treatment in subjects 
with CKD or in a community-based population and 3) had 500+ adult participants were eligible 
for inclusion.  
 
Data collection 
We used a standardised central data request form to collect relevant data from each of the 
involved studies (Chapter 3, appendix 3.2). We collected data on demographics, medical 
history and laboratory investigations. Medical history included presence of diabetes mellitus, 
hypertension or cardiovascular disease and laboratory investigations comprised of 
haemoglobin, total cholesterol, LDL, HDL, triglycerides and urine albumin/creatinine ratio. 
Hypertension was diagnosed in patients on the basis of the cut-off recommended by the 
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guidelines issued jointly by the WHO and the International Society of Hypertension (systolic 
blood pressure ≥140mm Hg and/or diastolic blood pressure ≥90 mm Hg in adults aged 18 years 
or older not taking antihypertensive agents, regularly using antihypertensive drugs or any use 
of antihypertensive medication in the past 2 weeks regardless of blood pressure, or a history of 
hypertension)137.  Diabetes mellitus was defined as requiring anti-diabetic drugs or meeting the 
diagnostic criteria for diabetes mellitus specified by the 1999 WHO and the Chinese Guideline 
for Diabetes Prevention and Treatment (characteristic symptoms and casual blood glucose, 
≥11.1mmol/L; fasting blood glucose, ≥7 mmol/L; or 2-hour oral glucose tolerance test, ≥11.1 
mmol/L)138. 
 
Definition of anaemia and CKD   
We defined anaemia according to the ARC protocol as haemoglobin (Hb) <100 g/L, or 
participants receiving erythropoietin simulation therapy 97. CKD stage was defined according 
to 2012 KDIGO Clinical Practice Guidelines where as ESKD was defined as receiving 
maintenance dialysis or having a functioning renal transplant130. 
 
Data Synthesis and Analysis 
Anaemia prevalence was extracted from the available literature and data received from 
collaborators to conduct a descriptive analysis of anaemia and its treatment modalities. We 
expressed continuous variables as mean ± standard deviation or median ± interquartile range 
(IQR) and categorical variables as numbers or proportions. Within each study and for each 
CKD category, the prevalence rate and 95% confidence intervals (CIs) for anaemia were 
calculated with CKD stages 1-2 as the reference group. A meta-analysis within each CKD 
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category was then conducted using random effects model. All analyses were performed using 
Stata (version 14.1; StataCorp, College Station, TX) 
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Results 
Studies and participants 
We included 14 datasets across six Asian countries with total of 502,974 participants in this 
analysis. We received one dataset each from Malaysia (32,159 participants), Thailand (52,641) 
and Taiwan (3,203); two datasets each from India (4,925) and South Korea (101,862), and 
seven were from Japan (308,184).  
 
Two studies were conducted in the general population, four studies among patients with CKD, 
while eight studies included patients receiving haemodialysis or peritoneal dialysis. We 
received individual patient level data (IPD) for six studies (2 from India and South Korea and 
one from Taiwan and Thailand) and summary level data for other eight studies (7 from Japan 
and 1 from Malaysia). Of the six countries included, no pre-dialysis CKD participants were 
available for India, Thailand and Malaysia. Similarly, no data were available for dialysis 
recipients in Taiwan (Table 9). 
 
Anaemia in patients with pre-dialysis CKD 
Six studies conducted in Japan (n=4), South Korea (n=1) and Taiwan (n=1) including 38,844 
participants reported data on the prevalence of anaemia among patients with pre-dialysis CKD. 
We included data on haemoglobin level for four CKD population-based studies from Japan, 
and one general population based study each from South Korea and Taiwan.  All four Japanese 
studies provided summary data, and three of these studies provided information on the use of 
erythropoiesis stimulating agents (ESA). The South Korean and Taiwanese studies did not have 
information on ESA use (Table 9).  
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General population studies 
A total of 32,198 participants (female 43.9%) with a mean age of 48.7+16.6 years were 
included in the two studies from South Korea and Taiwan. The patient characteristics are shown 
in Table 10. Although these data were from the general population, it showed that 3.5%, 0.2% 
and 0.1% had CKD Stage 3, 4 and 5 respectively based on estimated glomerular filtration rate 
(eGFR). Overall anaemia prevalence in adults living in South Korea and Taiwan was 1.26%, 
while adult CKD patients living in these two countries had higher anaemia prevalence at 
3.92%. Females appear to be underrepresented in anaemia group (16.5%) compared to males 
in these studies (Table 10).  
 
Pre dialysis CKD Studies 
A total of 6,646 CKD patients were included in Gonryo study, Nagoya study, Hisayama study 
and CKD JAC 2 study that reported anaemia prevalence. Except for the Hisayama study, they 
also reported on the ESA use.  
 
There were 2,694 subjects in the Gonryo study; the mean eGFR was 69.9 ml/min/1.73m2 with 
15.7% having anaemia and 6.5% were on ESA therapy. Nagoya study included 578 subjects 
with a mean eGFR of 42.1 ml/min/1.73m2. 10.2% subjects had anaemia and 4.5% used ESA 
therapy. There were 441 subjects in Hisayama study; the mean eGFR was 61.5 ml/min/1.73m2. 
Only 2.7% had anaemia but data on ESA therapy were unavailable. CKD-JAC 2 study was the 
largest of all having 2933 subjects with a mean eGFR of 28.9 ml/min/1.73m2.  19.7% had 
anaemia while 13.3% were on ESA therapy (Supplementary table 5, Figure 9). 
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Figure 9 shows prevalence rate of anaemia according to CKD stage considering CKD stages 1 
and 2 as reference group.  Each CKD stage included data from two population based studies 
and four CKD patient based studies. There were 3242 subjects in the reference group and 133 
(4.1%) had anaemia. There were 6,103 subjects in stage 3 CKD, of whom 195 (3.2%) had 
anaemia. Relative risk of anaemia in CKD 3 was not significantly increased when compared to 
CKD 1&2 (RR 1.33, 95% confidence interval 0.76-2.35). There was no evidence of 
heterogeneity in the magnitude of the effect across studies (I2= 42.5%, p = 0.122) based on P 
value for I2 statistic, however there might be a degree of heterogeneity as the individual 
estimates fall either side of unity. There were 1668 subjects in CKD 4 and 414 had anaemia 
(RR 8.24, 95% CI 4.78-14.18). There was no evidence of heterogeneity in the magnitude of 
the effect across the included studies (I2= 37.8%, p = 0.154).  742 subjects were identified with 
CKD 5 but 415 (55.9%) had anaemia (RR 17.46, 95% CI 9.54-31.96) with no heterogeneity 
(I2= 51.6%, p = 0.066). 
 
Anaemia trend in pre-dialysis CKD 
When compared with those with CKD stage 1-2, prevalence of anaemia was generally higher 
within CKD categories 3, 4, and 5; although statistical significance was not observed in CKD 
3. Overall, there was evidence of increased anaemia prevalence with worsening levels of CKD 
although there was evidence of moderate heterogeneity across the assessed CKD categories (P 
for trend =0.01). 
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Anaemia in patients receiving maintenance dialysis 
A total of 464,130 subjects receiving either haemodialysis or peritoneal dialysis were included 
in this analysis. We received national registry data from Malaysia (32,159 patients), Japan 
(301,538 patients), Thailand (52,641 patients) and South Korea (72,867 patients). In addition, 
we received two datasets from India (4925 participants) and two from Japan (5082 
participants), which were also included in Japanese Society of Dialysis and Transplant (JSDT) 
Registry. The vast majority of patients were on haemodialysis (94.7%). Only Malaysian, 
Japanese and Thailand national registries provided information on subjects receiving peritoneal 
dialysis (Table 11). 
 
Anaemia prevalence across 5 countries according to dialysis modality is shown in Table 11. 
Prevalence of anaemia, defined as haemoglobin <100 g/L or use of ESA, was numerically 
higher in haemodialysis (70.2%) than peritoneal dialysis (55.0%).  
 
In HD cohorts, the anaemia prevalence ranged from 61-96% with mean haemoglobin of 92-
110g/L.  Average ferritin levels were higher in Malaysia and Thailand compared to the 
Japanese cohorts. In PD, anaemia frequency was 58.5% in Japan and 67.2% in Thailand with 
average haemoglobin levels of 100-110 g/L.  Ferritin levels were high: 683 and 777 ng/ml in 
in Malaysia and Thailand respectively (Table 11). 
 
Table 11 also shows treatment patterns of anaemia by dialysis modality. Among haemodialysis 
patients, ESA use ranged from 48.9% in an Indian cohort to 91% in Malaysian registry. 
Intravenous iron use varied even within the country, and ranged from 16.9% in the AICOPP 
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Japanese cohort to 36.5% in Q Cohort, also from Japan. Among peritoneal dialysis patients, 
ESA use was 42.9% in Thailand to 80% in Malaysia. IV iron use varied from 4% in Thailand 
to 14% in Malaysia.   
Data on the type of ESA used to treat anaemia was available only for Thailand and one dataset 
in India with 1999 subjects. In India, Epoetin alpha (65%) was the most common type of ESA 
used to treat anaemia followed by Epoetin beta pegol (23%) and Darbepoetin alpha (12%). 
Almost all subjects were treated with Epoetin alpha (99%) in Thailand (Table 12). 
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Discussion 
This review presents evidence on anaemia prevalence and treatment patterns anaemia among 
subjects with CKD as well as ESKD who are on maintenance dialysis using the best available 
data across Asia. Our review shows marked variation in anaemia prevalence across the 
countries as well as between individual studies in the same country. Based on data provided by 
the individual collaborators we estimated the overall prevalence of anaemia in general 
population in South Korea and Taiwan was 1.26% and among CKD patients in Japan it varied 
from 2.7% - 19.7%. Similarly, the overall prevalence of anaemia in dialysis patients was 
estimated to be 79.5% in Thailand, 72.5% in Japan, 77.7% in South Korea and 61.1% – 87.2% 
in India. As expected, the risk of having anaemia and receiving iron or ESA increased 
progressively with progression of CKD and peaked with ESKD. 
 
A striking finding of this study was lack of systematic data collection and recording, especially 
for non-dialysis CKD patients, in most countries in Asia including well-developed, high-
income countries. Not only is anaemia a potentially modifiable risk factor that accelerates the 
progression of CKD and increases mortality and hospitalization in subjects on maintenance 
dialysis, it is also a major driver of cost of treatment of CKD patients 139-143. As there is much 
larger number of patients with non-dialysis CKD than that receiving maintenance dialysis, 
reliable prevalence and treatment data are crucial to develop health policies for appropriate 
management of anaemia in CKD. 
 
Several studies have reported CKD prevalence in Asian countries. One recent review estimated 
the overall CKD prevalence rate in Asia to be 13.2%. Almost 365 million people were 
estimated to be suffering from CKD in the continent, with about 116 million in advanced stages 
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of CKD (stages 3-5). As expected, China and India – the two countries with largest populations 
in the world carry the highest disease burden (ARC CKD study-unpublished data). Another 
systematic review estimated total number of people receiving RRT globally was 2.62 million 
with 0.97 million living in Asia in 2010. This number is predicted to increase to 5.44 million 
globally and to 2.16 in Asia by 2030 96. However, these studies did not provide insights into 
the epidemiology of CKD complications including anaemia. 
 
Similar variations in anaemia prevalence have been noted in previous studies. A multicentre, 
cross-sectional study in Shanghai, a highly developed region in China, reported a high 
prevalence of anaemia (51.5%) in patients with CKD, with a rate as high as 22.1% even in 
stage 1 disease 144.  The United States National Health and Nutrition Examination Survey 
(NHANES III - 1988–1994) that defined anaemia as Hb <120g/L in men and <110g/L in 
women, found the prevalence of anaemia to be less than 2% in patients with GFR >60mL/min, 
increasing to 9% as the GFR dropped to 30 mL/min/1.73m2 123. In 2004 another cross-sectional 
survey done in 5222 subjects in the United States showed much higher rates of anaemia 
(47.7%). The prevalence (defined as Hb <120g/L for men and women) increased from 26.7% 
to 75.5% as GFR decreased from ≥60 to <15 mL/min/1.73m2 145. The number of people with 
CKD and anaemia in Asia is likely to increase, driven especially by projected demographic 
changes, urbanisation, diet, and physical activity and population ageing 49 50.   
 
Our review also provides some insights into the current anaemia treatment practices in Asian 
countries.  The current global guidelines recommend maintaining Hb between 100 to 120 g/L 
in adult patients with CKD 130 133. ESA use is recommended in adult CKD patients with Hb 
levels <100g/L. However, a large proportion of dialysis subjects from Thailand and India were 
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not on ESA or intravenous iron. The reason for suboptimal treatment for anaemia in patients 
with CKD in Asia is likely related to reimbursement policies in these countries, but need 
systematic exploration. We also note variations in the type of ESA preparation used in these 
two countries. It is worth pointing out that the use of biosimilar ESA preparations is common 
in both these countries146. We, however, did not have data on the prevalence of biosimilar use 
in the cohorts included in the present review. 
 
Our estimates build on and extend on previous estimates of worldwide anaemia burden in 
kidney disease, with specific reference to Asia. We obtained unpublished contemporary data 
from several countries in Asia, representing large portion of the regional population, using a 
comprehensive and systematic approach. To our knowledge, this is the first comprehensive 
report on regional prevalence in anaemia among CKD patients.  
 
There were several limitations to our review, mainly due to limited data availability, variability 
in the datasets used and their quality and reliability. Nonetheless, we obtained data from the 
most reliable available sources and believe that any variability in reliability of estimates for 
these countries would have a small effect on the overall results at most. Another potential 
limitation is that there may be some variation in evaluating laboratory parameters in different 
countries as individual studies did not follow a standardized protocol. We defined anaemia in 
this review as Hb<100g/L or on ESA therapy of all participants according to ARC protocol, 
but Hb levels may differ by sex, age, pregnancy, altitude, and smoking status and we were not 
able to distinguish between anaemia levels with and without treatment. Although it is expected 
to have a higher prevalence of anaemia among women than men due to menstruation and blood 
loss during childbirth studies on general population from South Korea and Taiwan shows 
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otherwise. The underlying reasons for this unexpected finding are to be explored. Our ability 
to analyse treatment of anaemia was severely restricted by the fact that most studies, especially 
non-dialysis studies, did not provide adequate information on treatment. We were also unable 
to examine the impact of anaemia on clinical outcomes. 
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Conclusion 
Our review reveals high anaemia prevalence among Asian patients with pre-dialysis CKD and 
those receiving maintenance dialysis.  Although ESA and various other treatments are used, 
accurate information on anaemia burden or its treatment patterns is sparse in Asia. More data 
are required to understand the impact of anaemia on outcomes, and the patient-related as well 
as health systems factors that influence treatment practice so that appropriate cost-effective 
treatment strategies to manage common CKD complications could be developed. 
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Table 9: Data sources  
  Japan India Malaysia South Korea Taiwan Thailand 
CKD or general 
population             
Data type Summary level (4)  N/A N/A IPD IPD N/A 
Outcome data Cross-sectional and 
no outcomes 
N/A N/A Follow-up outcomes 
for death and ESKD 
Cross-sectional and 
no outcomes 
N/A 
Total number of cohorts 4 N/A N/A 1 1 N/A 
Total number of patients 6646 N/A N/A 28995 3203 N/A 
Available information 
      
eGFR Yes N/A N/A Yes Yes N/A 
Hb Yes (4) N/A N/A Yes Yes N/A 
ESA therapy  Yes (3) N/A N/A No No N/A 
Dialysis population             
Data type Summary level IPD Summary 
level 
IPD N/A IPD 
Outcome data Cross-sectional and 
no outcomes 
Cross-sectional and no 
outcomes 
N/A Follow-up outcome 
for death 
N/A Follow-up outcome 
for death 
Number of cohorts 3 2 1 1 N/A 1 
Total number of patients 301538 4925 32159 72867 N/A 52641 
Available information 
      
eGFR Yes (1) Yes N/A No N/A No 
Hb Yes (3) Yes Yes Yes N/A Yes 
ESA therapy  Yes (3) Yes N/A Yes N/A Yes 
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Table 10: Prevalence of anaemia in South Korea and Taiwan based on general population data 
 
Overall 
South 
Korea 
Taiwan 
No anaemia 
Hb>10g/L 
(%) 
Anaemia 
Hb<10g/L 
(%) 
No anaemia 
 
(%) 
Mild 
anaemia 
(%) 
Moderate 
anaemia 
(%) 
Severe 
anaemia 
(%) 
Missing 
data 
(%) 
Number of Subjects  32198 28995 3203 
31650 
(98.3) 
406 
(1.3) 
24025 
(74.6) 
7781 
(24.2) 
193 
(0.6) 
57 
(0.2) 
142 
(0.4) 
 
Demographic information        
          
Females (%) 14143 (43.9) 12495 (43.1) 1648 (51.4) 14037 (44.3) 67 (16.5) 13704 (57.0) 378 (4.9) 17 (8.8) 5 (8.8) 39 (27.5) 
Age (mean; SD) 48.7 (16.6) 48.8 (16.6) 47.5 (16.5) 48.7 (16.6) 47.3 (16.0) 48.6 (16.4) 49.0 (17.3) 46.1 (14.9) 50.1 (16.8) 54.9 (18.1) 
BMI (mean; SD) 23.7 (3.4) 23.6 (3.3) 24.2 (4.3) 23.7 (3.4) 22.5 (3.3) 23.9 (3.5) 22.9 (3.3) 22.5 (3.1) 22.3 (3.3) 22.8 (3.1) 
Waist circumference (cm) 81.3 (10.2) 81.3 (10.0) 81.3 (11.7) 81.4 (10.2) 76.3 (9.4) 82.5 (10.1) 77.9 (9.6) 76.7 (9.5) 76 (8.5) 80.0 (9.4) 
Comorbid conditions 
                 
Hypertension (%) 9533 (29.6) 9028 (31.1) 505 (15.8) 9408 (29.7) 75 (18.5) 7448 (31) 1991 (25.6) 34 (17.6) 10 (17.5) 50 (35.2) 
Systolic blood pressure (mean; SD) 119 (18.0) 119 (17.5) 126 (21.1) 119.5 (18.0) 115.6 (19.4) 121 (17.6) 115 (18.7) 114 (19.1) 119 (19.5) 122 (19.4) 
Diabetes (%) 3536 (11.0) 3060 (10.5) 476 (14.9) 3474 (10.9) 43 (10.6) 2780 (11.6) 715 (9.2) 14 (7.2) 8 (14.04) 19 (13.4) 
Cerebrovascular disease 1287 (4.0) 1244 (4.3) 43 (1.3) 1262 (3.9) 17 (4.2) 966 (4.0) 302 (3.9) 8 (4.1) 3 (5.3) 8 (5.6) 
CKD category (ml/min/1.73m2) 
                 
CKD 1 (>90) 16883 (52.4) 14979 (51.7) 1904 (59.4) 16565 (52.3) 246 (60.6) 12375 (51.5) 4278 (55.0) 121 (62.7) 37 (64.9) 72 (50.7) 
CKD 2 (60-80) 14116 (43.84) 13046 (45.0) 1070 (33.4) 13942 (44.0) 113 (27.8) 10921 (45.5) 3068 (39.4) 52 (26.9) 14 (24.6) 61 (43.0) 
CKD 3a (45-59) 937 (2.9) 786 (2.7) 151 (4.7) 916 (2.9) 13 (3.2) 626 (2.6) 296 (3.8) 6 (3.1) 1 (1.7) 8 (5.6) 
CKD 3b (30-44) 179 (0.6) 132 (0.5) 47 (1.5) 162 (0.5) 16 (3.9) 78 (0.3) 92 (1.2) 7 (3.6) 1 (1.7) 1 (0.7) 
CKD 4 (15-29) 52 (0.2) 35 (0.1) 17 (0.5) 44 (0.1) 8 (1.9) 19 (0.1) 28 (0.4) 4 (2.1) 1 (1.7) 0 (0) 
CKD 5 (<15) 31 (0.1) 17 (0.1) 14 (0.4) 21 (0.1) 10 (2.5) 6 (0.02) 19 (0.2) 3 (1.5) 3 (5.3) 0 (0) 
 
 
Laboratory measurements        
          
Total cholesterol (mg/dL) 188.7 (36.7) 187.9 (36.4) 196.1 (38.8) 188.9 (36.7) 168.9 (32.9) 190.5 (36.8) 183.8 (35.8) 170.8 (31.6) 150.8 (27.4) 191.3 (39.5) 
LDL cholesterol (mg/dL) 122.5 (34.6) N/A 122.5 (34.6) 122.8 (34.6) 102.1 (28.8) 123.8 (34.5) 112.1 (33.8) 110.6 (25.9) 82.7 (29.2) 123.7 (1.3) 
HDL cholesterol (mg/dL) 51.8 (13.6) 50.8 (12.8) 59.5 (16.1) 51.8 (13.6) 51.3 (13.7) 51.5 (13.6) 53.0 (13.3) 50.9 (13.1) 47.3 (13.5) 52.5 (12.6) 
Triglyceride (mg/dL) 132.1 (104.7) 132.9(106.3) 125.0 (88.5) 132.6(105.2) 94.8 (59.9) 140.5 (112.0) 107.4 (74.2) 94.2 (63.8) 85.6 (40.6) 129.1 (87.7) 
UACR (mg/g; median and IQR) 4.1 (1.7-9.3) 2.5 (0.8-6.7) 
6.3 (4.0-
13.5) 
4.1 (1.6-9.2) 
6.9 (2.4-
45.2) 
4.1 (1.7-9.2) 4.0 (1.4-9.7) 
2.6 (1.2-
16.7) 
11.0 (3.8-
152.2) 
3.9 (1.4-8.3) 
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Glucose (mg/dL) 96.6 (24.0) 97.5 (23.3) 87.8 (27.5) 96.6 (23.9) 95.7 (23.6) 97.4 (24.8) 94.1 (21.2) 95.8 (19.0) 96.4 (21.5) 98.2 (28.5) 
Haematocrit (%) 41 (4.2) 41 (4.2) 42 (4.4) 42 (4.0) 29 (2.9) 43 (3.2) 37 (2.0) 29 (1.8) 25 (2.9) N/A 
 
  
*Anaemia defined as Haemoglobin < 10g/dL for both sexes 
 
Mild = Hb 9.5-13 g/dL (male); Hb 8.5-12 g/dL (female)  
Moderate = Hb 8.0-9.5 g/dL (male); Hb 7.0-8.5 g/dL (female) 
Severe = HB <8.0 d/dL (male); HB <7/0 g/dL (female) 
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Table 11: Prevalence of anaemia, serum iron status and treatment patterns in dialysis patients in Asia 
Country Data source Number of 
patients (n) 
Anaemia 
(n) 
% with 
anaemia 
Mean Hb 
(g/L) 
Mean serum 
Fe (umol/L) 
Mean serum 
Ferritin (ng/mL) 
ESA(n) % on ESA IV Iron(n) % IV Iron 
Haemodialysis                       
Registry data            
Malaysia  MDTR 2013 28898 NA NA 10.4 NA 594 26297 91.0 9825 34.0 
Japan JSDT registry 292543 212057 72.5 11 61 144 197304 67.4 NA NA 
Thailand  Thai RRT registry  40492 32201 79.5 10.1 NA 585 22810 56.3 5,975a) 25a) 
South Korea KSN ESRD registry 72867 56647 77.7 10 NA NA 55492 76.2 NA NA 
  
           
Other data sets 
           
India Cohort 1 1999 1744 87.2 9.2 72.5 NA 1230 61.5 NA NA 
India Cohort 2 2926 1789 61.1 9.2 69.87 NA 1430 48.9 671 22.9 
Japan **Q Cohort 3567 2984 83.7 10.5 NA 250 2996 84.0 1303 36.5 
Japan **AICOPP 1515 1455 96.0 9.4 57.2 222 1301 85.9 256 16.9 
  
439725 308877 70.2 10.7 70.9 229 304563 69.3 
  
            
Peritoneal dialysis 
          
Registry data 
           
Malaysia  MDTR 2013 3261 NA NA 10.4 NA 683 2609 80.0 457 14.0 
Japan JSDT registry 8995 5266 58.5 11 80 157 4912 54.6 NA NA 
Thailand Thai RRT registry  12149 8165 67.2 10 NA 777 5216 42.9 214b) 4b) 
    24405 13431 55.0 10.4 80 536 12737 52.2 
  
 Abbreviations: Gonryo, The Gonryo Study; Nagoya, Nagoya CKD cohort; Hisayama, The Hisayama Study; NA, not available 
* Compared to CKD stage 1–2, adjusted for gender using binomial models 
Anaemia was defined as haemoglobin <10 g/dL or use of ESA. 
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Table 12: Type of ESA used to treat anaemia and level of haemoglobin in India and Thailand  
ESA type N (%) Mean Hb (g/dL) Mean Fe 
India     
Epoetin alpha 796 (65) 9.2 75.8 
Darbepoetin alpha 142 (12) 9.5 71.9 
Epoetin beta pegol 284 (23) 9.3 66.6 
Not using ESA 769  9.1 74.6 
Total 1999 (100.0) 9.2 72.5 
      
Thailand     
Epoetin alpha 27,559 (99) 10.1 NA 
Darbepoetin alpha 21 (<1) 10.2 NA 
Epoetin beta pegol 142 (1) 10.4 NA 
Not using ESA 24,931  10.2 NA 
Total 52,653 (100.0) 10.1 NA 
NA = not available 
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Supplementary table 5: Prevalence of anaemia in CKD population according to CKD stages in Japan   
 
CKD stage Dataset Country Subjects (n) Subjects with 
anemia (n) 
Prevalence of 
anemia 
Relative risk* 
(95% CI) 
ESA use Mean GFR  
(ml/min/1.73m2) 
Stage 1–5       
 
        
 
  Gonryo Japan 2694 423 15.70% NA 6.50% 69.9 
  Nagoya Japan 578 59 10.20% NA 4.50% 42.1 
  Hisayama Japan 441 12 2.70% NA NA 61.5 
  CKD-JAC II Japan 2933 577 19.7% NA 13.30% 28.9 
Stage 1-2       
 
        
 
  Gonryo Japan 1672 112 6.70% NA 0.20% 92.5 
  Nagoya Japan 64 0 0.00% NA 0.00% 78.4 
  Hisayama Japan 191 2 1.00% NA NA 78.5 
  CKD-JAC II Japan 14 0 0.00% NA 0.00% 63.9 
  Total 
 
1941 114 5.90% NA 0.20% 90.4 
Stage 3       
 
        
 
  Gonryo Japan 573 72 12.60% 1.95 (1.47–2.58) 3.10% 45.4 
 
  Nagoya Japan 349 13 3.70% 1.56 (0.36–6.72) 1.10% 45 
 
  Hisayama Japan 230 6 2.60% 2.41 (0.49–11.83) NA 51 
 
  CKD-JAC II Japan 1316 74 5.60% 0.6 (0.16–2.26) 2.50% 39.9 
 
  Total 
 
2468 165 6.70% 1.93 (1.47–2.53) 2.40% 42.9 
 
Stage 4       
 
        
 
  Gonryo Japan 267 96 36.00% 5.41 (4.25–6.88) 21.70% 22.2 
 
  Nagoya Japan 136 30 22.10% 8.43 (2.08–34.20) 8.10% 23.6 
 
  Hisayama Japan 14 3 21.40% 22.26 (4.18–118.41) NA 22.7 
 
  CKD-JAC II Japan 1137 269 23.70% 2.3 (0.62–8.57) 15.10% 22.5 
 
  Total 
 
1554 398 25.60% 5.59 (4.44–7.05) 16.00% 22.5 
 
Stage 5       
 
        
 
  Gonryo Japan 182 143 78.60% 11.89 (9.81–14.42) 53.30% 10.2 
 
  Nagoya Japan 29 16 55.20% 18.48 (4.55–75.02) 37.90% 11.4 
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  Hisayama Japan 6 1 16.70% 19.89 (2.46–160.86) NA 8.9 
 
  CKD-JAC II Japan 466 234 50.20% 4.74 (1.28–17.60) 38.80% 11.8 
 
  Total 
 
683 394 57.70% 11.95 (9.91–14.41) 42.60% 11.3 
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Figure 9: Relative risk of anaemia across CKD stages 3-5 compared to CKD 1-2 (Studies from Japan unless otherwise stated) 
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 CHAPTER 6: Effects of Mediterranean diet on kidney outcomes – a systematic review 
and meta-analysis 
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Rationale 
Following the attempts to quantify global end stage kidney disease burden, chronic kidney 
disease and its complications with special reference to Asia, we focused on potential novel 
strategies to reduce the burden of CKD. 
There is a longstanding recognition that diet plays a major role in the aetiology of many chronic 
diseases. Mediterranean style diet has been associated with favourable effects on 
cardiovascular disease (CVD) risk factors. Since CVD and CKD share similar risk factor 
profile, Mediterranean diet may have a protective effect on CKD. While these favourable 
effects have mostly been reported in studies conducted among European and North American 
communities, modified versions of the Mediterranean style diet (Indo-Mediterranean diet) has 
been used in Asian populations with reported beneficial outcomes. 
We undertook this systematic review and meta-analysis to explore the effects of the 
Mediterranean style diet on kidney outcomes. 
  
Author contribution 
Thaminda Liyanage conducted background research, concept design and protocol 
development, literature search and data collection. Rasiah Sureshkumar conducted literature 
search and data collection. Min Jun and Vlado Perkovic oversaw the concept design, literature, 
search data collection, and contributed to critical revision and editing the study protocol.    
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Study Protocol  
Background  
Chronic kidney disease (CKD) is one of the leading causes of death worldwide1. The burden 
of CKD also varies considerably between regions46 96. There is a longstanding recognition that 
diet plays a major role in the aetiology of many chronic diseases, thereby contributing to a 
significant geographical variability in morbidity and mortality rates from chronic disease across 
different countries and populations worldwide147 148. 
Populations in the Mediterranean region have been reported to experience lower mortality from 
CVD compared with northern European populations, possibly as a result of different dietary 
patterns148. Several observational studies have suggested reduced mortality and morbidity in 
regions consuming a Mediterranean diet147 149-152.  
Furthermore, the Mediterranean diet has been associated with favourable effects on CVD risk 
factors which are also risk factors for CKD. For example, recent studies have reported a 
decreased incidence of hypertension, diabetes mellitus, and metabolic syndrome with a greater 
adherence to a Mediterranean dietary pattern 151-153. These findings have been strengthened by 
recent systematic reviews supporting beneficial effects of the Mediterranean diet on metabolic 
syndrome and its individual components 154 155. A systematic review by Bloomfield et al156 
published in 2016, broadly examined multiple health outcomes of the Mediterranean style diet 
but failed to report on renal outcomes due to lack of suitable  evidence. Since CVD and CKD 
share similar risk factor profile, Mediterranean diet may have a protective effect on CKD.  
There is considerable variability in the definition of Mediterranean diet and duration of the 
interventions evaluated and uncertainty regarding the net effect on major outcomes as well as 
their consistencies. We therefore undertook this systematic review and Meta analysis. 
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Objectives 
To conduct a systematic review and a Meta-analysis of randomised control trials (RCT) and 
observational studies to evaluate the effects of Mediterranean diet on kidney outcomes. 
 
Methods 
Types of studies 
All randomized controlled trials and observational studies reporting the effects of 
Mediterranean diet with data available on kidney outcomes. 
 
Types of participants 
Adult participants with or without pre-existing kidney disease exposed to Mediterranean diet 
continuously for at least 6 months duration 
 
Types of interventions 
Providing specific dietary advice to follow a Mediterranean style diet or provision of dietary 
supplements relevant to the Mediterranean diet. 
A diet with non-restricted fat intake and with at least two of the following seven components 
will be required to meet our definition of a Mediterranean style diet 157. 
1) High monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient). 
2) Low to moderate red wine consumption. 
3) High consumption of legumes. 
4) High consumption of grains and cereals. 
5) High consumption of fruits and vegetables. 
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6) Low consumption of meat and meat products and increased consumption of fish. 
7) Moderate consumption of milk and dairy products. 
 
Types of outcome measures 
1) Change in proteinuria or albuminuria 
2) New onset or progression of proteinuria or albuminuria 
3) Change in eGFR 
4) New onset eGFR < 60 and eGFR < 30 
5) End stage kidney disease 
6) Composite of doubling of creatinine (or similar), ESKD or renal death 
7) Composite of doubling of creatinine, ESKD or all cause death 
8) Components of each of the composite outcomes 
  
 
Search methods for identification of studies 
We will search relevant studies from the following sources.  
1. Cochrane Central Register of Controlled Trials CENTRAL (Inception - March 2017) 
2. MEDLINE OVID SP (Inception - March 2017) 
3. ClinicalTrials.gov 
4. Other resources 
 Experts in the field will be contacted for unpublished and ongoing trials 
 Authors will be contacted where necessary for additional information 
 Reference lists of review articles and relevant studies 
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Selection of studies 
Two authors (TL & RS) will independently review the abstracts of all studies from the initial 
search. Those that meet the inclusion criteria will be collated. Two authors will independently 
apply the inclusion criteria to each full text article. Any discrepant assessments will be resolved 
in discussion with a third author (VP) by consensus. 
Data extraction and management 
Two authors (TL & RS) will independently extract information using a standardized data 
collection form. These data will be extrapolated from tables and graphs in published papers. 
Extracted data will include type of intervention and their duration and outcomes measures. 
 
Assessment of risk of bias in included studies 
The following items will be independently assessed for RCTs by two authors using the risk of 
bias assessment tool158. 
• Was there adequate sequence generation (selection bias)? 
• Was allocation adequately concealed (selection bias)? 
• Was knowledge of the allocated interventions adequately prevented during the 
study (detection bias)? 
Participants and personnel 
Outcome assessors 
• Were incomplete outcome data adequately addressed (attrition bias)? 
• Are reports of the study free of suggestion of selective outcome reporting 
(reporting bias)? 
• Was the study apparently free of other problems that could put it at a risk of 
bias? 
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Measures of treatment effect 
We will collect data on all-cause mortality, composite renal outcomes (50% reduction in 
glomerular filtration rate or doubling of serum creatinine), end stage kidney disease (ESKD), 
incidence of type 2 diabetes, quality of life and adverse effects (all AE, serious AE).  
 
Dealing with missing data 
If information is missing from a study, we will contact the authors to obtain the necessary 
information. 
 
Data synthesis and analysis 
For observational studies prevalence rates will be calculated from raw proportions and 95% 
CIs with the Wilson method159.  For RCTs individual study relative risks (RRs) and 95% 
confidence intervals (CIs) will be calculated from event numbers extracted from each trial 
before data pooling.  In calculating risk ratios, the total number of patients randomized in each 
group will be used as the denominator. Summary estimates of relative risk ratios will be 
obtained using a random effects model. The percentage of variability across studies attributable 
to heterogeneity beyond chance will be estimated using the I2 statistic160. Potential publication 
bias is assessed using the Egger test and represented graphically using Begg’s funnel plots of 
the natural log of the RR versus its standard error 161. Potential heterogeneity in estimates of 
treatment effect will be explored using univariate meta-regression160 and by comparing 
summary results obtained from subsets of studies grouped by number of participants, number 
of mortality events, publication year, intervention used, diabetic status, baseline morbidity and 
study quality. A cumulative meta-analysis will be performed to identify any trends in the effect 
of Mediterranean diet over time. A two-sided p-value less than 0.05 is considered statistically 
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significant for all analyses. All statistical analyses will be performed with STATA, version 9.2 
(Stata, College Station, Texas). 
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Sensitivity analysis 
If a sufficient number of studies (more than 10) are included, we will explore the robustness of 
the results by performing a sensitivity analysis by incrementally including studies with a high 
risk of bias. 
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Appendix 6.1 
Search strategy 
MEDLINE & CENTRAL  
1) exp Observational study/ 
2) exp Prospective study/ 
3) exp Cohort study/ 
4) (prospective adj7 study).tw 
5) exp Clinical Trial/ 
6) exp Random Allocation/ 
7) exp Single Blind Method/ 
8) exp Double Blind Method/ 
9) (random$ adj5 trial$).tw. 
10) (random$ adj5 allocation$).tw. 
11) (Blind$ adj5 method$).tw. 
12) or/1-11 
13) diet, mediterranean/ 
14) (mediterranean adj3 diet$).tw. 
15) (mediterranean adj3 food$).tw. 
16) exp wine/ 
17) red wine$.tw. 
18) exp seafood/ 
19) seafood$.tw. 
20) cheese$.tw. 
21) exp cheese/ 
22) exp fruit/ 
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23) or/13-22 
24) 12 and 23 
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Outcome  
Search results and characteristics of included studies 
Database search identified 7504 articles: 5807 were identified in MEDLINE and 1697 in 
Cochrane Central Registry. We removed 3165 duplicates electronically using Endnote 
reference management software and reviewed 4339 abstracts to identify 105 articles for full 
text review. Two more articles were identified through reviewing reference lists of review 
articles were also included for full text review. After reviewing all 107 articles we did not find 
any suitable study fulfilling the selection criteria for inclusion in this review (Figure 10). Most 
studies did not report relevant outcomes while others had cross sectional study design or limited 
follow up duration. 
In 2016, Bloomfield et al156 conducted a systematic review and meta-analysis of randomised 
control trials and observational studies and reported the effects on health outcomes, including 
renal outcomes, of a Mediterranean style diet without restriction on fat intake. Similar to our 
findings they were not able to identify any suitable study, hence did not report effects on renal 
outcomes.  
During this process we noted most studies focussed on the effects of the Mediterranean style 
diet on cardiovascular risk factors such as total cholesterol, LDL and HDL cholesterol, 
hypertension and diabetes mellitus while several randomised control trials examined the effect 
on cardiovascular endpoints. Therefore we proceeded to conduct a systematic review and meta-
analysis to examine the effects of the Mediterranean diet on cardiovascular outcomes.  
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Figure 10: Identification process for eligible studies  
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CHAPTER 7: Effects of the Mediterranean diet on cardiovascular outcomes - a 
systematic review and meta-analysis  
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Rationale 
Cardiovascular disease (CVD) is a leading cause of mortality worldwide.  The Mediterranean 
dietary pattern is widely recommended for the prevention of chronic disease, including CVD. 
Although the Mediterranean diet has been associated with modest beneficial effects on CVD 
risk factors,  real uncertainty remains about the data underpinning the value of the 
Mediterranean diet to human health. This review describes the available randomised control 
trial evidence on the clinically important effects of the Mediterranean diet on cardiovascular 
disease and mortality.  
 
Publication details 
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Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong M, Jardine M, Hillis GS, and 
Perkovic V. Effects of the Mediterranean diet on cardiovascular outcomes - a systematic review 
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Journal publication: 
Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong M, Jardine M, Hillis GS, and 
Perkovic V. (2016) Effects of the Mediterranean Diet on Cardiovascular Outcomes - A 
Systematic Review and Meta-Analysis. PLoS ONE 11(8): e0159252. 
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Abstract 
Background 
A Mediterranean dietary pattern is widely recommended for the prevention of chronic disease. 
We sought to define the most likely effects of the Mediterranean diet on vascular disease and 
mortality. 
 
Methods 
We searched MEDLINE, EMBASE and the Cochrane Central Register without language 
restriction for randomized controlled trials comparing Mediterranean to control diets.  Data on 
study design, patient characteristics, interventions, follow-up duration, outcomes and adverse 
events were sought. Individual study relative risks (RR) were pooled to create summary 
estimates. 
 
Results 
Six studies with a total of 10950 participants were included.  Effects on major vascular events 
(n=477), death (n=693) and vascular deaths (n=315) were reported for 3, 5 and 4 studies 
respectively.  For one large study (n=1000) there were serious concerns about the integrity of 
the data.  When data for all studies were combined there was evidence of protection against 
major vascular events (RR 0.63, 95% confidence interval 0.53-0.75), coronary events (0.65, 
0.50-0.85), stroke (0.65, 0.48-0.88) and heart failure (0.30, 0.17-0.56) but not for all-cause 
mortality (1.00, 0.86-1.15) or cardiovascular mortality (0.90, 0.72-1.11).   
After the study of concern was excluded the benefit for vascular events (0.69, 0.55-0.86) and 
stroke (0.66, 0.48-0.92) persisted but apparently positive findings for coronary events (0.73, 
0.51-1.05) and heart failure (0.25, 0.05-1.17) disappeared.  
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Conclusion 
The Mediterranean diet may protect against vascular disease. However, both the quantity and 
quality of the available evidence is limited and highly variable. Results must be interpreted 
with caution.  
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Introduction 
Cardiovascular disease (CVD) is a leading cause of mortality worldwide accounting for one 
quarter of the estimated 52 million deaths in 20101 162. The burden of CVD varies between 
regions and a proportion of this variability may be due to different dietary patterns1 163.  
 
Populations in the Mediterranean region have been reported to experience lower morbidity and 
mortality rates from CVD compared with northern European populations148, which has been 
attributed to their consumption of a Mediterranean diet high in fruits and vegetables, nuts and 
cereals, fish, olive oil, with moderate red wine consumption and minimal amounts of red meat 
and dairy products147 149 150. In addition, the Mediterranean diet has been associated with 
beneficial effects on CVD risk factors such as glycaemia, blood pressure and lipid levels151-153. 
Two recent systematic reviews have showed some beneficial effects of the Mediterranean diet 
on the metabolic syndrome and its constituents but neither have explored the effects on vascular 
events or mortality154 155. 
 
Although there are randomized controlled trials (RCTs) assessing the effect of the 
Mediterranean diet on the primary or secondary prevention of CVD164 165 the largest of these 
trials recorded just a few hundred events. There is also concern that one of the key trials 
supporting the beneficial effects of the Mediterranean diet was seriously methodologically 
compromised166. There is, therefore, real uncertainty about the data underpinning the value of 
the Mediterranean diet to human health. We undertook this systematic review and meta-
analysis to better define the effects of the Mediterranean diet on cardiovascular events and 
mortality.  
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Subjects and methods 
Data sources and searches 
We performed a systematic review of the literature according to the PRISMA statement for the 
conduct of meta-analyses of intervention studies (www.prisma-statement.org). Relevant 
studies were identified by searching the following data sources: MEDLINE via Ovid (from 
inception through February 2014), EMBASE (from inception through February 2014) and the 
Cochrane Library database (Cochrane Central Register of Controlled Trials; no date 
restriction), using relevant text words and medical subject headings (Appendix 7.1). The search 
was limited to randomised controlled trials (RCTs) without language restriction. Reference lists 
from identified trials and review articles were manually scanned to identify any other relevant 
studies. The clinicaltrials.gov website was also searched for RCTs that were registered as 
completed but not yet published.  
 
Study selection 
The literature search, data extraction and quality assessment were conducted independently by 
two authors using a standardised approach (TL and AW). All completed RCTs assessing the 
effects of a Mediterranean diet compared to any control diet involving adults, with follow up 
period longer than three months, that reported one or more of the relevant outcomes were 
eligible for inclusion. Although there is considerable variability, a diet with non-restricted fat 
intake and with at least two of the following seven components was defined as a Mediterranean 
style diet for the purposes of this review; 1) use of olive oil as the main cooking oil, 2) moderate 
red wine consumption, 3) high consumption of nuts and/or legumes, 4) high consumption of 
grains and cereals, 5) high consumption of fruits and vegetables, 6) high consumption of fish 
with low consumption of meat and meat products and 7) low to moderate consumption of milk 
and dairy products157. 
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Data extraction and quality assessment 
Published reports were obtained for each trial and standard information about each trial was 
extracted into a spreadsheet. The data sought included summary metrics for each trial about 
baseline patient characteristics (age, gender, history of diabetes, history of hypertension, mean 
systolic and diastolic blood pressure levels, lipid levels, smoking status, body mass index and 
history of cardiovascular disease), details of the dietary intervention, follow-up duration, 
outcome events and adverse events. Study quality was judged according to the Cochrane risk 
of bias assessment tool158. Any disagreement in extracted data was adjudicated by a third 
reviewer (VP). 
 
Outcomes 
We sought data on total cardiovascular events (stroke, myocardial infarction, cardiovascular 
mortality or a broadly comparable definition reported by the study), coronary events (fatal or 
non-fatal myocardial infarction, coronary revascularization), cerebrovascular events (fatal or 
non-fatal stroke), heart failure, total mortality, incidence of type 2 diabetes mellitus, end-stage 
kidney disease, adverse effects (all adverse effects and serious adverse effects) and quality of 
life. 
 
Data synthesis and analysis 
Individual study relative risks (RRs) and 95% confidence intervals (CIs) were calculated from 
event numbers extracted from each trial. In calculating RRs, the total number of patients 
randomized in each group was used as the denominator. If no events were reported in either 
treatment or control group of any trial, 0.5 was used as the numerator. For the three arm 
PREDIMED study165, the olive oil supplement arm and the nuts supplement arm were jointly 
considered as the treatment group whereas in the four arm study by Burr et al167 only the “fish 
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and fruit” arm fulfilled the defined criteria for the Mediterranean diet and this was compared 
to the “sensible eating” arm. Primary summary estimates of RRs were obtained using a fixed 
effects model. Given the small number of included trials, publication bias and percentage of 
variability across studies attributable to heterogeneity beyond chance were not assessed as 
these may be unreliable. A two-sided p-value less than 0.05 was considered statistically 
significant. All analyses were performed with STATA, version 9.2 (Stata, College Station, 
Texas). 
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Results 
Search results and characteristics of included studies 
The literature search yielded 4637 articles, of which 51 were reviewed in full text (Figure 11). 
Of these, six RCTs, involving a total of 10950 participants, met the inclusion criteria. Among 
these, 477 major cardiovascular events were reported from three trials164 165 168 and 693 deaths 
from five trials164 165 167-169. The remaining study assessed the effect on quality of life170. The 
majority of the excluded trials did not study the Mediterranean diet as defined in the protocol, 
studied only individual components of the Mediterranean diet, did not report relevant 
outcomes, were not original investigations or were duplicate reports.  
 
The trials had a sample size that ranged from 48 to 7447 participants (Table 13). Two studies 
were single-centre164 169 and four were multi-centre165 167 168 170. All studies provided dietary 
advice to participants and two studies provided food supplements in addition to dietary 
advice164 165. The studies were conducted between March 1988 and December 2010. The mean 
age of the study participants ranged between 41 and 67 years. One study only enrolled men167, 
one study only enrolled women170 and four studies enrolled both men and women164 165 168 169. 
Primary prevention was the objective of three studies165 169 170, secondary prevention was the 
goal of two studies164 167 and the remaining study included patients with and without a prior 
history of cardiovascular disease168. 
 
In regard to study quality (Table 14), four of the six studies concealed the randomized 
allocation sequence164 165 168 169, no studies were double-blinded and blinded assessments of 
outcomes were made in only 3 studies164 165 168.  For one study subsequent publications raised 
serious concerns about the integrity such that the veracity of results was significantly in 
doubt166 168. 
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Effects of Mediterranean diet on vascular outcomes and death 
Major cardiovascular events - Effects of the Mediterranean diet were reported for this outcome 
by three trials164 165 168 including 9052 participants and 477 events. The Mediterranean diet was 
associated with a 37% relative reduction in the risk of major cardiovascular events (RR 0·63, 
95% CI: 0·53-0·75, p< 0·001) compared to control diet. Exclusion of the study with serious 
concerns about its integrity (n=1000, 145 events) did not result in a change of overall direction 
of the effect (RR 0.69, 95% CI 0.55-0.86, p< 0.001) (Figure 12). 
 
Fatal outcomes - Data on all-cause mortality were available from 5 trials164 165 167-169 including 
10671 participants and 693 deaths, four of which also separately reported data for 
cardiovascular mortality (10623 participants and 315 deaths)164 165 167 168. The Mediterranean 
diet had no clear effect on all-cause mortality (RR 1·00, 95% CI: 0·86-1·15, p=0·97) or 
cardiovascular mortality (RR: 0·90, 95% CI: 0·72-1·11, p=0·32) compared to control. 
Excluding the trial by Singh et al. further widened the confidence intervals (Figure 12). Across 
the various subgroups of studies examined, greater benefits were suggested in small, single 
centre studies with incomplete follow-up (Suplementary figures 4 and 5). 
 
Cause-specific cardiovascular outcomes - Three trials164 165 168 reported 221 coronary events 
and 167 cerebrovascular events. Use of the Mediterranean diet was associated with a relative 
risk of 0·65 (95% CI 0.50-0·85) for coronary events and 0·65 (95% CI 0·48-0·88) for 
cerebrovascular events. Only two studies164 168 involving 1605 participants and reporting 56 
events were available to provide an effect estimate for heart failure, showing a relative risk of 
0·30 (95% CI: 0·17-0·56). Exclusion of the data from the trial by Singh et al resulted in null 
findings for all of the cause specific outcomes except cerebrovascular events which continued 
to remain significant (RR: 0·66, 95% CI: 0·48-0·92, p=0·01) (Figure 12).  
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Effects on other outcomes and adverse events 
One study that enrolled 279 participants reported data on quality of life170. There was a 
significant improvement with Mediterranean diet as measured by the Problem Areas in 
Diabetes (PAID)171 self-care summary score (p=0·005) but no effect on any other domain of 
that score or the Medical Outcome Study (MOS -12) short form general health survey172 (all 
p>0.05). No data were available on new onset type 2 diabetes mellitus, end-stage kidney 
disease or adverse events for any of the included studies. 
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Discussion 
This systematic review and meta-analysis supports the beneficial effects of the Mediterranean 
diet on cardiovascular outcomes, although the quantity and quality of the available evidence is 
relatively limited and there is much greater uncertainty about the effects of the Mediterranean 
diet than is widely understood as a result. There are also no data about adverse outcomes 
reported by any study, creating difficulties in the understanding of the overall balance between 
the risks and benefits of the Mediterranean diet. While the completed trials suggest it is likely 
that the Mediterranean diet protects against certain types of vascular diseases the evidence base 
falls short of that required to make definitive conclusions or firm recommendations. 
 
Underpinning the rationale for the large-scale outcome trials were the findings of a series of 
prospective cohort studies147 149 150 and recent reviews of those studies that reported moderately 
decreased risks of all-cause mortality, cardiovascular mortality and the incidence of 
cardiovascular disease associated with a Mediterranean diet173 174. However, observational 
studies of the effects of diet on cardiovascular disease are highly prone to confounding and it 
is hard to infer causation from these types of studies. Also in support of protective effects are 
the data from smaller RCTs examining the effects of Mediterranean diet on intermediate 
metabolic outcomes. These trials show small to moderate beneficial effects for multiple 
determinants of vascular risk175-177. A recent overview of these RCTs trials identified blood 
pressure falls of 2.4mmHg (1.2 to 3.5) systolic and 1.6mmHg (1.1 to 2.0) diastolic, an LDL 
reduction of 2.71 mg/dl (5.03 to 0.39), a reduction in serum triglycerides of 6.14mg/dl (1.93 to 
10.35) and an elevation in HDL cholesterol of 1.17mg/dl (0.38 to 1.96)155. Another recent 
review of observational studies and RCTs by Bloomfield et al broadly examining multiple 
health outcomes of the Mediterranean style diet identified one RCT reporting moderate 
beneficial effects on cardiovascular endpoints156. After an average follow-up of 4.8 years, this 
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RCT reported 29% reduction in major cardiovascular events compared with the control group 
but all-cause mortality remained unchanged178. 
 
Despite these encouraging findings, neither the cohort studies nor the RCTs of intermediate 
outcomes show benefits of a magnitude congruent with the very large point estimates of effect 
on cardiovascular outcomes proposed by some of the individual trials included in our review. 
Furthermore, while several other potential mechanisms of benefit such as antioxidant or anti-
inflammatory effects have been postulated for the Mediterranean diet179 180, large trials of 
intervention strategies specially targeting these pathways have been universally negative181. 
This raises an important question about the plausibility of large beneficial effects of the 
Mediterranean diet and raises concern about the possible effects of random or systematic errors. 
In regard to the former, the total volume of data available is small and much less than might 
typically be available for comparable investigations of the effects of drugs on the same 
outcomes. In terms of possible systematic errors, the un-masked design of the studies is a 
substantial weakness inherent in the nature of the intervention and may have led to differential 
ascertainment and assignment of outcomes across randomised groups. The much greater 
estimated treatment effects on more subjective outcomes like coronary events, strokes and heart 
failure compared to the non-significant estimates of effect for the objective outcome of 
mortality reinforces this possibility.  
 
This review benefits from its comprehensive, systematic approach and the broad range of 
clinically important endpoints considered. It does, however, suffer from a number of 
limitations. We could not explore heterogeneity across the individual study results for key 
outcomes in detail and our analyses based upon limited published summary data are restricted 
in their capacity to investigate this. Heterogeneity seems a possibility not only due to the 
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different nature of the interventions used across the trials but also due to a combination of 
factors such as differing outcome definitions and varied durations of follow-up. In addition, 
the fact that larger benefits were seen in smaller, single-centre studies with incomplete follow 
up raises the possibility of overestimation of benefits by these studies. The absence of any data 
about the risks of adverse events is also a significant short-coming.  Another issue affecting the 
evidence base supporting the use of the Mediterranean diet is the concern about the integrity 
of the trial by Singh et al.168. Following a site visit organized by the Lancet to Dr. Singh’s 
research facility due to concerns raised by multiple parties, including then the editor of BMJ, 
it was concluded that it was not possible to be sure of the rigor for recording data and its 
handling. While unable to point to specific evidence to refute the study's results, they raised 
concerns about the quality of the data likely to be generated from a research facility that lacked 
access to the kind of highly qualified support staff necessary to conduct a clinical trial to 
sufficiently high international standards. These concerns have been extensively reported and it 
is clear that the conduct and reporting of the trial are so weak as to raise serious concerns about 
the trial results166.  If the Mediterranean diet was seeking registration or reimbursement under 
any regulatory assessment scheme it seems very unlikely that the data provided by the Singh 
trial would be eligible to contribute. Accordingly the best current estimates of the effect of the 
Mediterranean diet on cardiovascular outcomes are those that exclude the data from that study.   
 
  
  
193 
 
Conclusion 
The American Heart Association/American College of Cardiology182, the European Society of 
Cardiology183 and the National Heart Foundation of Australia (www.heartfoundation.org.au) 
are three societies that all recommend the Mediterranean diet to reduce cardiovascular risk. All 
are careful to base this advice on the observed favourable although modest effects of the 
Mediterranean diet on intermediate cardiovascular risk factors. Clearly, recommendations 
based upon definitive clinical outcomes would be far preferable, and are supported by the 
findings of this review, however the strength of conclusions should remain circumspect 
because of the weakness of the evidence base. It seems unlikely that clinicians and patients 
fully appreciate the limitations of the data and the extent of the uncertainty. This is an area that 
warrants another well-conducted, adequately powered trial including Caucasian as well as 
diverse non Caucasian populations to precisely and reliably define the overall balance of 
benefits and risks associated with the Mediterranean diet compared to variety of regional diets. 
 
Prior presentations of the results 
This work has been presented at the American College of Cardiology Annual Scientific 
Sessions in 2015 in abstract form.  The abstract is available from the following link: 
http://content.onlinejacc.org/article.aspx?articleid=2198774 
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Appendix 7.1 
Search strategy 
MEDLINE & CENTRAL  
1. exp Clinical Trial/ 
2. exp Random Allocation/ 
3. exp Single Blind Method/ 
4. exp Double Blind Method/ 
5. (random$ adj5 trial$).tw. 
6. (random$ adj5 allocation$).tw. 
7. (Blind$ adj5 method$).tw. 
8. or/1-7 
9. diet, mediterranean/ 
10. (mediterranean adj3 diet$).tw. 
11. (mediterranean adj3 food$).tw. 
12. exp wine/ 
13. red wine$.tw. 
14. exp seafood/ 
15. seafood$.tw. 
16. cheese$.tw. 
17. exp cheese/ 
18. exp fruit/ 
19. or/9-18 
20. 8 and 19 
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EMBASE  
#1 'randomized controlled trial'/exp OR 'randomized controlled trial'  
#2 'clinical trial (topic)'/exp OR 'clinical trial (topic)'  
#3 'mediterranean diet'/exp OR 'mediterranean diet' 
#4 'red wine'/exp OR 'red wine'  
#5 'red wine'/exp OR 'red wine'  
#6 'seafood'/exp OR 'seafood'  
#7 'nut'/exp OR 'nut' 
#8 'cheese'/exp OR 'cheese'  
#9 1 or 2 
#10 or/4-8 
#11 9 and 10  
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Figure 11: Identification process for eligible studies 
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Figure 12: Forrest plot of the included studies showing relative risk of Mediterranean diet 
compared to control diet by various outcome measures (Fixed effects model analysis) 
 
Note: Best summary estimate was derived by excluding the study by Sing et al.  
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Supplementary figure 4: Subgroup analysis of five studies reporting all-cause mortality 
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Supplementary figure 5: Subgroup analysis of four studies reporting cardiovascular mortality 
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Table 13: Characteristics of the studies included in the systematic review and meta-analysis 
Author 
(Year) 
Inclusion 
criteria 
Treatment Group  Control Group Setting Duration of 
follow up  
(mean) 
Total 
participants 
(n) 
Mean 
age 
(yrs) 
Male, n 
(%) 
DM, n 
(%) 
Primary 
or 
secondary 
prevention 
Composite  
CV events 
(n) ** 
Coronary 
events 
(n) 
Cerebro-
vascular 
events 
(n) 
All-
cause 
deaths 
(n) 
de 
Lorgeril 
et 
al(1994) 
Age <70; first 
MI within 6 
mths  
Advice on high bread, 
vegetables, fish and 
less meat. Margarine 
supplements as it was 
considered patients 
would not accept olive 
oil as only fat. 
Prudent western 
diet advice by 
attending 
physician 
Single 
centre 
France 
27 months 605 53.5 549 
(90.7) 
NR Secondary  44 22 3 28 
Singh et 
al (2002) 
>25yrs with 
cardiac RF or 
angina, previous 
MI 
Indo-Mediterranean 
diet advice (high fruit, 
vegetables, nuts, 
whole grains, mustard 
seed or soy bean oil) 
Dietary advice 
according to 
NCEP 
guidelines 
Multi 
centre India 
2 years 1000 48.5 897 
(89.7) 
210 
(21) 
Primary 
and 
secondary 
145 93 25 62 
Toobert 
et al 
(2003) 
Post-
menopausal 
women with 
type 2 DM  
Mediterranean diet 
advice, physical 
activity, stress 
management, social 
support, smoking 
advice 
Usual post-
menopausal 
care 
Multi 
centre USA 
6 months 279 NR 0 (0) NR Primary NR NR NR NR 
Burr et al 
(2003) 
Males <70yrs 
with angina  
Oily fish, fruit, 
vegetables and oats 
diet advice 
Sensible eating Multi 
centre 
United 
Kingdom 
3-9 years 
(range) 
1571 61.15 1571 
(100) 
210 
(13.3) 
Secondary  NR NR NR 251 
Ng et al 
(2011) 
>18 yrs with 
HIV 
Advice on high fruit, 
vegetables, nuts, white 
meat, canola or olive 
oil as main cooking 
oil. 
Dietary advice 
according to 
NCEP 
guidelines 
Single 
centre 
Hong Kong 
1 year 48 41 37 (77) NR Primary NR NR NR 4 
Estruch 
et al 
(2013) 
Male (55-80 
yrs) and female 
(60-80 yrs) with 
type 2 DM or 
≥3 major 
cardiac risk 
factors  
Mediterranean diet 
+extra virgin  olive 
oil; Mediterranean 
diet + nuts; both 
intervention groups 
received supplements 
Low fat control 
diet 
Multi 
centre 
Spain 
4.8 years 
(median) 
7447 67 3165 
(42.5) 
3614 
(48.5) 
Primary 288 106 139 348 
**defined as per authors or combined cardiac and cerebrovascular endpoints; MI=myocardial infarction; DM=diabetes mellitus; CV=cardiovascular; RF=risk factors; HIV=human immunodeficiency virus; 
NECP=national cholesterol education programme; USA=United States of America 
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Table 14: Quality assessment of included studies  
Study/author (year) Random 
sequence 
generation 
Allocation 
concealment  
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment  
Completion rate (%) 
(Treatment/Placebo) 
Intention-to-
treat 
described 
Incomplete 
outcome data 
adequately 
addressed 
Selective 
outcome 
reporting 
Lyon Diet Heart 
Study, de Lorgeril et 
al 1994 
Yes Yes No Yes 90.1/87.4 Yes Yes No  
Indo-Mediterranean  
Diet Study, Singh et al 
(2002) 
Yes Yes No Yes 98.2/97.8 Yes Yes No 
Toobert et al (2003) Yes No No No 84/93.1 Yes Yes No 
Burr et al (2003) Yes No No No 100/100 Yes Yes No 
Ng et al (2011) Yes Yes No No 68/82.6 Yes Yes No 
PREDIMED study, 
Estruch et al (2013) 
Yes Yes No Yes 95.1/88.7 Yes Yes No 
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CHAPTER 8:  Conclusion   
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Global health systems are struggling to cope with the burden of chronic kidney disease 
today184 .  The kidney disease burden continues to grow rapidly across the world, both in 
developed as well as in developing countries3 64 184. The impact of kidney disease has 
widespread consequences which extend much further than the affected individual; the family, 
the community in which they live and finally the country will have to bear the substantial 
burden of managing resource intensive kidney disease.  
 
In 2015 in the United States, overall prevalence of chronic kidney disease (stages 1-5) in adult 
general population was 14.8 % and an estimated 30 million American adults had CKD. 124,111 
new cases of end stage kidney disease were reported with a total of nearly 500,000 patients 
receiving dialysis treatment and well over 200,000 living with a kidney transplant. The cost of 
care for kidney disease patients was nearly US$100 billion, including US$64 billion for CKD 
and another US$34 billion for patients with ESKD185. Approximately 1.7 million Australian 
adults had chronic kidney disease (stages 1-5) in 2012, costing estimated AUD 4.1 billion2. By 
2020, the number of patients requiring renal replacement therapy in Australia is projected to 
increase by 54-72%, costing between AUD 11.3-12.3 billion3. 
 
People with CKD have 2-3 fold greater risk of cardiac death than people without CKD186  and 
the risk of dying from cardiovascular events is 20 times greater than the risk of requiring renal 
replacement therapy187. Nonetheless, if kidney disease is detected early and managed 
optimally, then the otherwise inevitable deterioration of kidney function can be reduced as 
much as 50% or may even be reversed and lead to cost savings73-76 188. Kidney disease is 
common; it is detrimental but preventable as well as treatable. Delivering coordinated 
multifaceted renal care requires estimating the magnitude of the disease burden and addressing 
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the poor outcomes of these patients through appropriate, timely and cost effective 
interventions.  
 
This thesis has estimated, based on the best available evidence, the burden of kidney disease 
around the world, with special reference to Asia, where there is a large population and an 
extensive knowledge deficit. It has also investigated the effects of a regional diet as an 
intervention, in an attempt to explore novel methods to improve renal outcomes. These results 
are likely to make important contributions to the existing knowledge base as they describe the 
epidemiology of kidney disease around the world and in Asia and test the effects of lesser 
known interventions such as regional diets on clinically important “hard” outcomes such as 
kidney failure, cardiovascular disease, and death in people with kidney disease. Through a 
systematic approach, I aimed to address well known current gaps in knowledge and assess the 
effects of potentially beneficial interventions across a range of kidney diseases to improve 
clinical outcomes.  
 
In this thesis, I have shown that:  
1. The number of people receiving RRT is projected to grow from 2.62 million in 2010, 
to 5.4 million by 2030.  Between 2.3 and 7.1 million people who could have been kept 
alive with RRT in 2010 died prematurely due to a lack of access to RRT. Most of these 
deaths occurred in Asia, Africa and Latin America.  
 
2. The protocol for establishing a large collaboration of the leaders in kidney research 
across Asia as a platform for future research - The Asian Renal Collaboration 
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3. In Asia, an estimated 365 million people had CKD with an overall prevalence rate of 
13.2%. Additionally, 116 million of those people have more advanced forms of CKD 
(stages 3-5). The highest burden of CKD as well as advanced CKD was observed in 
China and India; the two countries with largest populations in the region. There is a 
considerable variation in CKD prevalence across Asia. 
 
4. There is marked variation in the prevalence of renal anaemia in CKD patients as well 
as ESKD patients, across Asian countries and between individual studies in the same 
country. The risk of having anaemia and receiving iron or erythropoietin stimulating 
agents (ESA) increased progressively with progression of CKD and peaked with 
ESKD. 
 
5. There are no RCTs or observational studies examining the effects of the Mediterranean 
diet on kidney outcomes.  
 
6. The Mediterranean diet may have beneficial effects on cardiovascular “hard” clinical 
outcomes, in addition to known beneficial effects on biochemical cardiovascular risk 
factors, but the quantity and quality of the available evidence is relatively limited. 
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Defining the CKD burden 
CKD is now widely recognised as an important public health issue in most countries 
worldwide. There have been various attempts by health care systems to quantify kidney disease 
burden, either in isolation or as wider international collaborations, with variable success27 28 82 
84 189. National kidney disease registries such as the United States Renal Data Systems 
(USRDS) and Japanese Society of Dialysis and Transplant (JSDT) as well as regional registries 
such as European Renal Association-European Dialysis and Transplant Association (ERA-
EDTA) and Latin American Society of Nephrology and Hypertension (Sociedad 
Latinoamericana de Nefrología e Hipertensión - SLNH) have been at the forefront. In addition, 
various institutions and individuals have attempted to describe epidemiology of kidney disease. 
These were relatively small studies, limited to different geographical areas and reported highly 
heterogeneous statistics with varying quality and reliability102 107 111.  However, most 
epidemiological data have come from studies conducted in European and North American 
populations and comparatively little has come from studies of Asian populations. A systematic 
approach to quantify kidney disease burden does not exist in many Asian countries, except in 
several high income countries such as Japan, South Korea and Singapore where renal registries 
are maintained, predominately to capture RRT statistics. 
 
To this end, the work presented in this thesis is of great clinical importance as it summarises 
all available data on renal replacement therapy worldwide, and estimates current global, 
regional and national RRT delivery, highlighting the number of premature deaths without 
access to RRT. Moreover, this provides estimates to the year 2030, empowering policy makers 
to plan appropriate response. The work in this thesis highlights the urgent need for a 
confidential, standardised, systematic data collection, recording and retrieval system on kidney 
disease for each country, with appropriate access to interested working groups. A mechanism 
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to facilitate low and middle income countries technically as well as financially, especially in 
Asia and Africa, may enhance the utility of the system.  If implemented, these standardised 
national registries will minimise heterogeneity, thus improve validity and reliability of captured 
data and facilitate longitudinal assessments to understand changes over time. Professional 
bodies such as the International Society of Nephrology, World Congress of Nephrology and 
political organisations such as United Nations Organisation, World Health Organisation have 
a key role to play in this effort.                
 
Reducing the CKD burden  
The ideal approach to reduce the kidney disease burden would be through primary prevention, 
by appropriately managing kidney disease risk factors including blood pressure69, diabetes and 
obesity70, as well as acute kidney injury (AKI)71 through effective population-based 
interventions. While being ideal, it is difficult achieve in clinical practice mainly due to late 
diagnosis of these conditions, and the fact that  less than 10% of people with CKD are aware 
that they have the condition190. With progression of kidney disease, patients with CKD undergo 
extensive physiological changes rather distinct to that of general population.  Dysfunction of 
numerous physiological mechanisms in more advance stages of CKD requires multiple 
interventions to restore normal physiology. However, the effects of therapeutic interventions 
aimed at restoring normal physiology, specially reducing the cardiovascular risk associated 
with altered physiology, have not been clearly defined to date.  
Nonetheless, a number of specific interventions potentially beneficial to certain patients’ 
populations with specific characteristics has been identified. Intensive glycaemic control in 
CKD patients with diabetes mellitus70 191, fibrate therapy for CKD patients with 
dyslipidaemia192, antioxidant therapy for dialysis dependent patients193 194, extended hours 
haemodialysis for dialysis dependent patients195, blood pressure control and renin angiotensin 
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system blockade, especially in proteinuric patients34 196-199 have been some potentially 
beneficial therapeutic interventions. Most interventions considered reported only modest 
benefits in reducing cardiovascular disease in individuals with CKD. Possibly because these 
therapeutic interventions targeted a single risk factor while people with kidney disease, 
particularly in more advanced stages, have a multitude of complex physiological dysfunctions 
including oxidative stress, hypertension, dyslipidaemia and body fluid disequilibrium.  Based 
on the available literature, it is apparent that meaningful risk reduction is difficult to achieve, 
particularly in those with advanced disease who have the highest risk of developing adverse 
events. What is more certain is that the progressive decline in kidney function is strongly 
associated with a graded elevation in the rates of cardiovascular disease and death200. Despite 
these well recognised realities, the prominence given to nephrology research has been generally 
low over the past few decades. In 2004, Strippoli et al reported that the number of randomised 
control trials, published in the area of nephrology from 1996-2002, designed to assess efficacy 
of clinical interventions was fewer than any other specialties in internal medicine201. This is a 
critical issue that requires urgent attention. It would therefore be important to direct future 
research and resources to the development of methods to improve early diagnosis of kidney 
disease to address modifiable renal and cardiovascular risk factors and to develop novel 
therapeutic interventions targeting possibly multiple risk factors.  
 
Diet has been considered a potential intervention, as diet is recognised to play a major role in 
the aetiology of many chronic diseases, thereby contributing to a significant geographical 
variability in morbidity and mortality rates from chronic disease across different countries and 
populations worldwide147 148. Based on the work presented in this thesis, a systematic review 
and meta-analysis found beneficial effects of the Mediterranean diet on cardiovascular 
outcomes, although the quantity and quality of the available evidence is relatively limited 
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(Chapter 7). Another systematic review and meta-analysis on the effects of the Mediterranean 
diet on kidney outcomes revealed a critical shortage of clinical trials or observational studies 
addressing the issue (Chapter 6). Smaller randomised control trials examining the effects of the 
Mediterranean diet on intermediate metabolic outcomes have shown small to moderate 
beneficial effects for multiple determinants of vascular risk175-177. Exploring the role of the 
Mediterranean diet, and other dietary approaches, on the onset and progression of CKD would 
thus be an important area of future research. 
 
 
 
  
  
210 
 
APPENDIX 1: Physical component Quality of life (QOL) reflects the impact of time and 
moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 
QOL: an AUSDiab analysis 
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Rationale 
Mild to moderate levels of kidney dysfunction are common among community dwelling adults. 
However, measures of quality of life (QOL) are lower in this population. The Australian 
Diabetes, Obesity and Lifestyle (AusDiab) study is a representative, longitudinal population-
based study of Australian adults aged ≥25 years which included the administration of SF-36 
questionnaire, a generic QOL assessment tool. This chapter evaluates the stability of repeated 
measures of the SF-36 derived SF-6D utility score, and the physical and mental component 
scores over time in the presence of markers of CKD in a community-dwelling adult Australian 
population through reanalysis of AusDiab database. 
 
Author contributions 
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and the editing the manuscript. Meg Jardine oversaw the concept design, analysis and 
manuscript preparation. 
  
  
212 
 
Abstract 
Aim: We aimed to evaluate the association of chronic kidney disease (CKD) markers and the 
passage of time on measures of QOL over five years in a community cohort. 
Methods: Included were 6400 participants in the AusDiab surveys with baseline creatinine, 
and/or albuminuria, and baseline and 5-year SF-36 QOL measures. Five-year changes in SF-
6D utility, and the Physical (PCS) and Mental (MCS) Component Summary scores, were 
evaluated using regression analyses according to the baseline presence of reduced eGFR 
(CKD-Epi eGFR ≤60m/min/1.73m2) or albuminuria (urine albumin:creatinine ratio ≥3.4 
mg/mmol). Multivariable analyses were adjusted for potential confounders including 
demographic, comorbidities and socioeconomic factors.  
Results: At baseline, 151 (2.4%) and 301 (5.1%) had reduced eGFR and albuminuria 
respectively. Baseline SF-6D utility was lower in those with reduced eGFR, and PCS was lower 
in those with reduced eGFR or albuminuria, compared with those without (unadjusted), but not 
after accounting for known confounders. Baseline MCS scores were not affected by the 
presence of reduced eGFR or albuminuria. Over 5 years all participant groups exhibited stable 
SF-6D and MCS scores but declining PCS scores. The decline in PCS was greater for those 
with reduced eGFR, which remained significant after adjustment -2.7 (-4.1 to -1.3) vs. -0.8 (-
1.1 to -0.6, p<0.01). Analyses according to CKD stages were essentially the same.  
Conclusions: The SF-6D utility and mental QOL domains appear stable over 5 years, and were 
not unaffected by time or markers of CKD health. Physical QOL appeared to deteriorate over 
time, especially for those with CKD, making it a more likely candidate assessment measure for 
intervention and health service evaluations.  
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Introduction  
Mild to moderate levels of kidney dysfunction are common among community dwelling adults. 
An estimated 12% of the total US population and more than 40% of those over 70 years have 
chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) 
<60ml/min/1.73m2, or the presence of albumin in the urine202. Prevalence may be increasing 
with time28 97 203. In a vast majority of these people, CKD is detected through the presence of 
abnormalities in biochemical markers rather than through symptomatic presentations.  
However, the presence of CKD is not benign, with morbidity, mortality and health resource 
utilisation begin to rise above background community rates at eGFR levels of 60-
70ml/min/1.73m2.14  
 
Measures of quality of life (QOL) are lower in people with relatively mild CKD in cross-
sectional studies17 although the association sometimes disappears in studies that adjust for 
known confounders such as age and comorbidities204 205 . The importance of evaluating patient 
experience outcomes in clinical trials of pharmaceuticals and medical devices is being 
increasingly emphasized206 207. Evaluations of the impact on the patient experience will require 
tools that are responsive to change and thus may plausibly reflect changes induced by health 
service delivery and interventions208 209. Established QOL tools are candidate measures for the 
assessment of the impact of disease and treatment on physical, psychological, and social 
functioning and well-being. Within health research, QOL is variously assessed with utility tools 
that can measure quality-adjusted life-year (QALYs), generic QOL that can compare across 
disease states, and disease-specific tools. The Medical Outcomes Study 36-Item Short Form 
(SF-36) is a widely-used generic QOL tool that incorporates eight health domains, two 
component summary  scores (the physical [PCS] and mental [MCS] scores)210  and can be used 
to derive the SF-6D utility score211 .  
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The Australian Diabetes, Obesity and Lifestyle (AusDiab) study is a representative, 
longitudinal population-based study of Australian adults aged ≥25 years which included the 
administration of SF-36 questionnaires212. We aimed to evaluate the stability of repeated 
measures of the SF-36 derived SF-6D utility score and the physical and mental component 
scores over time in the presence of markers of CKD in a community-dwelling adult Australian 
population.  
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Materials and methods  
Survey population and methods 
Included in the current analysis were participants in the Australian Diabetes, Obesity and 
Lifestyle (AusDiab) surveys who had available baseline measures of kidney disease (serum 
creatinine and or albuminuria), and baseline and 5-year SF-36 QOL measures. The AusDiab 
study is a longitudinal population-based study of Australian adults aged ≥25 years, established 
to examine the prevalence and incidence of diabetes and its complications, as well as high 
blood pressure, heart disease and kidney disease. The methods have been described previously 
212. In short, the AusDiab study survey design was based on a stratified cluster method and 
included seven strata (six states and the Northern Territory of Australia), each with six clusters 
that were randomly selected with probability proportional to size. This resulted in 42 primary 
sampling units.  Australian adults aged 25 years or older were invited to participate and the 
survey activities occurred over a 21-month period between May 1999 and December 2001.  
 
The study was approved by the International Diabetes Institute Ethics Committee (Melbourne, 
Australia). Written informed consent was obtained from all participants. The survey involved 
an initial household interview with questionnaire relating to medical history, smoking status, 
higher education, household income, medications, followed by physical examination that 
included measurement of blood pressure and standard anthropometry. Participants were asked 
to self-administer the SF-36 General Health and Well-Being questionnaire, and to bring this 
along to the biochemical examination visit. The biomedical examination visits were conducted 
within 8-days from the initial household interview, during which an oral glucose tolerance test, 
blood for renal function tests and spot urine specimens were collected.  All blood and urine 
tests were performed at a central laboratory (Hitech Laboratories, Melbourne, Australia). 
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Between June 2004 and December 2005, all participants were then invited to attend the second 
phase AusDiab study.  
 
A) Demographic and clinical characteristics  
Body mass index was calculated from weight and height measurements. Current smoking was 
defined as smoking at least daily, and non-smoking was defined as smoked less than 100 
cigarettes over a lifetime or being an ex-smoker. Use of blood pressure and lipid-lowering 
medications were captured during the household interview. Cardiovascular disease was defined 
by the self-report of physician-diagnosed angina, myocardial infarction, or stroke. 
Hypertension was defined as systolic blood pressure of 140 mm Hg or greater, diastolic blood 
pressure of 90 mm Hg or greater, or use of blood pressure–lowering medication irrespective of 
blood pressure levels. Hyperlipidemia was defined as total cholesterol level greater than 232 
mg/dL (6.0 mmol/L), low-density lipoprotein cholesterol level greater than 154 mg/dL (4.0 
mmol/L), or use of lipid-lowering drugs irrespective of total or low-density lipoprotein 
cholesterol levels. Individuals were defined as having diabetes mellitus if they reported an 
existing diagnosis of diabetes mellitus, were taking oral glucose lowering agents or insulin 
therapy, or met World Health Organisation–defined diagnostic blood glucose criteria on 
challenge with a standard 75-g oral glucose tolerance test after an overnight fast of at least 10 
hours138.  
 
B) Kidney function and albuminuria. 
Serum creatinine collected during both phases of the study was used for Glomerular Filtration 
Rate (eGFR) estimation using the CKD Epidemiology Collaboration (CKD-EPI) equation24. 
Early morning spot urinary albumin and creatinine were analysed by Olympus AU600 
Analyser. Immunoturbidimetric method was used to determine urinary albumin. For the 
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purpose of this study, markers of CKD were categorized as A) reduced eGFR: eGFR 
<60ml/min/1.73m2 or eGFR ≥60ml/min/1.73m2 , B) albuminuria: UACR ≥3.4 mg/mmol or 
UACR< 3.4mg/mmol, or C) CKD staging by KDIGO CKD risk categories213 : no/low risk 
CKD, defined as eGFR ≥60 ml/min/1.73m2 and urine albumin/creatinine ratio (UACR) 
<3.4mg/mmol; CKD stage 1-2, defined as eGFR ≥60 ml/min/1.73m2 and UACR ≥3.4 
mg/mmol and at least KDIGO-defined moderately increased risk; CKD Stage ≥ 3, defined as 
eGFR <60 ml/min/1.73m2 with or without albuminuria.  
  
C) Health-related quality of life (QOL) 
QOL was assessed using the Medical Outcomes Study’s Health Status Survey short form (SF-
36)214. The Medical Outcomes Study 36-Item Short Form (SF-36) is a generic QOL tool first 
developed in 1988 that has been translated in more than 170 languages, and used in a wide 
range of patient groups from various socio-economic situations and diagnosis210. The SF-36 
measures eight health subdomains scored from 0 (worst possible health status) to 100 (best 
possible health status): Physical Functioning, Role–Physical, Bodily Pain, General Health, 
Vitality, Social Functioning, Role–Emotional, and Mental Health. Scores were converted to a 
mean of 50 with a standard deviation of 10 (T-score), then standardized to the Australian 
population using a Z-score transformation. The two summary scores, the physical health 
component summary (PCS) and mental health component summary (MCS) scores, were 
derived from the eight subdomains according to the SF-36 methodology215. The SF-6D is a 
utility score provides a means of SF-36 items in economic evaluationby applying a set of 
preference weights obtained from a sample of the general population in Australia to specified 
SF-36 items216 . The SF-6D allows the analyst to obtain quality adjusted life years (QALYs) 
from the SF-36, commonly used in cost utility analysis. 
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Statistical analysis 
SF-36, SF-6D and component summary scores were reported as mean (95% confidence 
interval) or percent prevalence (95% confidence interval). Differences in continuous variables 
were analyzed with a two-tailed unpaired t-test, and categorical variables with a chi-square test. 
Multivariate regression analyses were adjusted according to age, sex, income, education, 
language, hypertension, diabetes, serum total cholesterol, HDL-cholesterol, triglycerides, lipid-
modifying agents, body mass index, current smoking and history of cardiovascular disease. All 
analyses were conducted using SAS (SAS Institute Inc., Cary, NC) survey commands 
(Procedure surveyreg or surveyfreq) for analyzing complex survey data. Two-sided values of 
p <0.05 were considered statistically significant in all analyses. 
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Results 
Of the 11247 and 6400 participants of the baseline and 5-year follow up phase of the AusDiab 
study, 6,262 participants had baseline eGFR and baseline and 5-year SF-36 information, 
including 151 (2.4%) participants with eGFR <60ml/min/1.73m2 at baseline. There were 5912 
participants with baseline UACR measures and baseline and 5-year SF-36 information, 
including 301 (5.1%) with albuminuria. There were 5888 participants with both baseline eGFR 
and UACR measures of whom 5,473 had no/low risk CKD, 264 participants had CKD stage 1-
2 and 151 participants had CKD stage ≥3.   In comparison with participants with normal kidney 
function, participants with baseline eGFR <60ml/min/1.73m2 were more likely to be older, 
have not completed secondary schooling and have a lower household income (Table 15). Those 
with eGFR <60ml/min/1.73m2 had a greater prevalence of hypertension, cardiovascular disease 
and use of lipid lowering medications, had higher serum triglyceride levels and lower 
prevalence of current smoking but there were no differences in sex, body mass index, total or 
HDL cholesterol, diastolic blood pressure or prevalence of diabetes (Table 15). 
 
Effects of kidney function on Quality of Life measures at baseline 
At baseline, unadjusted SF-6D utility scores and mean physical component summary (PCS) 
scores were lower in participants with eGFR <60ml/min/1.73m2 than those with eGFR 
≥60ml/min/1.73m2 but in both cases the difference disappeared after adjustment for known 
confounders (Table 16). Both unadjusted and adjusted mean mental component summary 
(MCS) scores were similar in participants with eGFR <60 or ≥60 ml/min/1.73m2. Of the eight 
subdomains, unadjusted Physical Functioning, Role Physical, Bodily Pain, General Health, and 
Vitality were lower in those with eGFR <60ml/min/1.73m2 but only General Health and 
Vitality remained significantly lower after adjustment for known confounders (Table 16).  
  
220 
 
Effects of kidney function on stability of Quality of Life measures 
SF-6D utility scores and MCS scores did not change significantly over 5 years in participants 
with either eGFR <60 or with ≥60 ml/min/1.73m2 (Table 19).  PCS scores, already lower at 
baseline for those with an eGFR<60 ml/min/1.73m2, declined faster than in those with an eGFR 
≥60ml/min/1.73m2 (Table 19) in both unadjusted (-3.7 vs. -0.6, p=0.002) and adjusted analyses 
(-2.7 vs. -0.8, p<0.01) (Figure 13).  
Of the individual subdomains, Physical Functioning and Role Physical subdomain scores fell 
faster in participants with eGFR <60ml/min/1.73m2 in unadjusted analyses but only Physical 
Functioning fell significantly after adjustment for known confounders (-4.0 vs. -0.9, p<0.001, 
eGFR <60 and ≥60 ml/min/1.73m2, respectively) (Table 16).  
 
Effects of albuminuria on Quality of Life measures at baseline 
At baseline, both unadjusted and adjusted SF-6D utility scores were similar in those with and 
without albuminuria (Table 17). Participants with albuminuria had a lower unadjusted PCS 
score and higher MCS score, compared to those without, but the differences disappeared after 
adjustment for known confounders (Table 17). Of the eight subdomains, unadjusted Physical 
Functioning, General Health and Role Emotional were different in those with albuminuria but 
only Role Emotional remained significantly different (and higher) after adjustment for known 
confounders (Table 17).  
 
Effects of albuminuria on stability of Quality of Life measures 
SF-6D utility scores and MCS scores did not change significantly over 5 years in participants 
either with or without albuminuria in neither unadjusted or adjusted analyses (Figure 13). 
Unadjusted PCS scores declined in participants both with and without albuminuria at similar 
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rates (-1.3 vs. -0.7, p=0.20) although the decline in both groups was not significant after 
adjustment for known confounders (Figure 13). 
 
Effect of CKD stage on Quality of Life measures at baseline  
At baseline, unadjusted SF-6D utility scores were lower in participants with CKD≥3 than in 
those with no/low risk CKD or CKD1-2 although the differences disappeared after adjustment 
for known confounders. Baseline MCS scores were paradoxically higher in participants with 
CKD1-2 compared with those no/low risk CKD or CKD≥3 in both unadjusted and adjusted 
analyses.  PCS scores were progressively lower in no/low risk CKD, CKD1-2 and CKD≥3 
although the differences disappeared after adjustment for known confounders (Figure 13). 
There were some differences in individual subdomain scores between participants with 
different stages of CKD, but none remained significant after adjustment for known confounders 
(Supplementary table 6).  
 
Effects of CKD stage on stability of Quality of Life measures 
SF-6D utility scores and MCS scores did not change significantly over 5 years in participants 
with no/low risk CKD, CKD1-2 or CKD≥3 in unadjusted or adjusted analyses (Supplementary 
table 6). PCS scores declined in all groups over 5 years with the fastest decline in those with 
CKD stage ≥3.  
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Discussion  
The impact of markers of kidney disease and the passage of five years on commonly used 
measures of QOL was assessed in a large, stable cohort of Australian community-dwelling 
adults. SF-6D utility scores and MCS scores were similar in participants with and without 
baseline eGFR <60ml/min/1.73m2 and/or albuminuria after adjustment for known 
confounders, and the scores remained unchanged over 5 years. PCS scores were relatively 
lower in participants with baseline eGFR <60ml/min/1.73m2 but not in those with albuminuria. 
PCS scores declined over 5 years in all participants with a greater decline in those with baseline 
eGFR <60ml/min/1.73m2. The findings demonstrate that PCS, but not SF-6D or MCS, is 
responsive to the presence of kidney disease and the passage of time, at least in stable, 
community-dwelling populations with relatively mild disease. 
 
There were additional differences in some QOL measures in participants with baseline eGFR 
<60ml/min/1.73m2 or albuminuria compared with those without, that were explained by known 
confounders. This finding indicates the importance of considering the impact of other factors, 
particular clinical disease and age, before attributing QOL scores purely to the presence of 
CKD.  
 
In cross-sectional surveys, various individual SF-36 subdomains have been reported to be 
lower in those with reduced compared with normal kidney function18. Additionally, SF-36 PCS 
scores, but not MCS scores, have been found to be lower in association with kidney disease in 
cross-sectional studies of US nephrology outpatients17 and participants of the Chronic Renal 
Insufficiency Cohort (CRIC) Study and the Hispanic Chronic Renal Insufficiency (H-CRIC) 
Study217. EQ-5D utility scores were inversely associated with KDIGO CKD stage in the large, 
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community-based,  cross-sectional Korean KNHANES) Survey218. Some studies have even 
reported higher MCS scores in people with CKD although these studies may be subjected to 
selection bias and did not always control for confounders18 217.  
 
The relationship of albuminuria or proteinuria with QOL is less well defined given the paucity 
of available data until recently. One cross-sectional study found the presence of proteinuria 
was not associated with low baseline QOL scores217 while others found EQ-5D utility scores 
were related to the presence of proteinuria at baseline218-220 .  
 
The impact of non-dialysis-dependent chronic kidney disease on QOL over time is poorly 
defined. A study of Japanese pre-dialysis patients found greater declines in QOL were 
associated with reduced kidney function or lower haematocrit19. Another study failed to detect 
an association of QOL trajectory and kidney disease although may have been underpowered221. 
We are not aware of previous reports of the relationship between albuminuria or proteinuria 
and the longitudinal trajectory of QOL. 
 
Recently, welcome emphasis has been placed on the primacy of the patient experience in the 
evaluation of health outcomes for people with kidney disease206 207. However, the patient 
experience will only have a meaningful impact on evidence generation, and hence practice, if 
assessment measures have the capacity to discriminate changes in modifiable health states. 
QOL measures will be most useful in assessment when they are known to reflect meaningful 
alterations in a patients’ experience of illness or in response to a therapy, rather than reflect 
non-modifiable or extraneous factors such as demography or personality. As a starting point, 
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QOL measures that are responsive to differences in kidney disease status are candidate 
measures for the assessment of interventions. 
 
A related area of uncertainty is the determination of the minimally important difference (as 
opposed to statistically significant difference) in QOL scores. The estimation of minimally 
important differences in QOL tools is complex, with no clear consensus on the minimal 
important difference for PCS and MCS scores in the CKD context222 223, or utility scores. Some 
literature in CKD224  and chronic diseases225 , has suggested a difference in scores of 3–5 may 
be the minimally important difference in PCS. We detected a mean fall in PCS scores of 2.7 
(4.1 to 1.3) in participants with eGFR <60ml/min/1.73m2 when compared to those with eGFR 
≥60 ml/min/1.73m2 after adjusting for known confounders. The clinical meaning of this 
difference remains unclear. 
 
The AusDiab Study has many strengths, including the large and representative population-
based nature of the cohort, the assessment of albuminuria, and its ability to assess changes in 
patient-reported QOL measures over a five-year period giving results applicable to community-
dwelling populations with stable, normal to mildly impaired kidney function. The results may 
not be generalizable to a sicker population with advanced CKD. Markers of kidney disease 
(eGFR and UACR) were measured only once at each encounter which may have an impact on 
the precision of UACR in particular, given its physiological variation219 226 227. Inherent in its 
design, the study has selected those who volunteered to attend the first assessment and then 
were alive and willing to attend the second assessment and so the findings are not generalizable 
to a sicker or more unstable population. Finally, despite robust risk adjustment, our study is 
subject to residual bias and confounding. 
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In conclusion, this longitudinal study of a large, stable Australian population found that a SF-
6D utility and SF-36 MCS QOL were stable over time in people with and without markers of 
kidney disease. In contrast, SF-36 PCS QOL fell overall with time, and this loss was 
exaggerated in those with relatively mild markers of kidney disease suggesting that measures 
of physical QOL, rather than mental QOL, are responsive to time and kidney disease. Physical 
QOL may be a more appropriate candidate measure than utility-based or mental measures of 
QOL for studies assessing the impact of interventions in patients with CKD.  
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Figure 13: Adjusted change in SF-36 mean physical and mental component summary score by kidney function and presence or absence of albuminuria over 5-years
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 Table 15: Baseline characteristics  
eGFR levels 
(estimated by CKD-EPI formula) 
≥60  
ml/min/1.73 m2 
<60  
ml/min/1.73 m2 
p 
N of sample 6,111 151  
Median of eGFR (range), ml/min/1.73m2 101.1 (60.0-149.1) 54.9 (14.7-59.9)  
 
Demographic and socioeconomic factors 
   
Age, years 48.2 71.7 <0.001 
Female, % 50.8 50.2 0.92 
Total household income ≥$800, % 52.9 11.7 <0.001 
High education level (completed secondary schooling), 
% 
65.5 41.8 <0.001 
English language, % 96.4 97.9 0.33 
 
History and comorbidities 
   
History of cardiovascular disease, % 5.7 32.4 <0.001 
Current smoking, % 12.5 1.9 <0.001 
Hypertension, % 26.4 83.4 <0.001 
Diabetes, % 6.0 5.1 0.72 
 
Physical examination and biochemistry 
   
Systolic blood pressure, mmHg 126.9 143.7 <0.001 
Diastolic blood pressure, mmHg 70.6 71.8 0.34 
Body mass index, Kg/m2 26.6 28.1 0.12 
Serum total cholesterol, mmol/L 5.6 5.6 0.76 
Serum HDL-cholesterol, mmol/L 1.4 1.4 0.37 
Serum triglycerides, mmol/L 1.4 1.8 <0.001 
Treated with lipid-modifying agents, % 6.9 42.6 <0.001 
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Table 16: Overall mean health related quality of life, SF-36 physical and mental component summery scores, individual scale scores and their change by eGFR <60 
or ≥60 ml/min/1.73m2  
Endpoints 
eGFR levels 
(ml/mim/1.73m2) 
N of 
sample 
Weighted 
 number of 
participants 
Unadjusted   Multivariable-adjusted a)  
In 1999-2000  In 2004-2005  Change over time  In 1999-2000  In 2004-2005  Change over time 
mean (95% CI) p  mean (95% CI) p  mean (95% CI) p  mean (95% CI) p   mean (95% CI) p   mean (95% CI) p 
SF6D score 
 
SF-6D 
≥60 6,111 6,179,375 0.774 (0.766 to 0.782) 
0.02 
 0.772 (0.764 to 0.780) 
<0.001 
 -0.003 (-0.008 to 0.003) 
0.15 
  0.771 (0.765 to 0.777) 
0.51 
  0.765 (0.760 to 0.771) 
0.35 
  -0.006 (-0.011 to 0.000) 
0.92 
 <60 151 145,991 0.729 (0.692 to 0.766)  0.707 (0.685 to 0.729)  -0.022 (-0.045 to 0.002)   0.759 (0.724 to 0.794)   0.754 (0.731 to 0.776)   -0.004 (-0.03 to 0.022) 
SF36 scores 
 
PCS 
≥60 6,111 6,179,375 51.8 (51.1 to 52.6) 
<0.001 
 51.2 (50.5 to 52.0) 
<0.001 
 -0.6 (-0.8 to -0.4) 
0.002 
 51.0 (50.6 to 51.4) 
0.15 
 50.2 (49.8 to 50.6) 
0.001 
 -0.8 (-1.1 to -0.6) 
0.009 
 <60 151 145,991 42.7 (40.0 to 45.4)  39.1 (37.2 to 40.9)  -3.7 (-5.5 to -1.8)  49.3 (47.0 to 51.6)  46.6 (44.6 to 48.5)  -2.7 (-4.1 to -1.3) 
 
MCS 
≥60 6,111 6,179,375 49.9 (49.3 to 50.5) 
0.75 
 49.5 (49.1 to 50.0) 
0.27 
 -0.4 (-0.9 to 0.1) 
0.52 
  50.3 (49.8 to 50.9) 
0.27 
  49.8 (49.3 to 50.2) 
0.63 
  -0.6 (-1.0 to -0.1) 
0.06 
 <60 151 145,991 50.6 (46.5 to 54.7)  51.1 (48.5 to 53.6)  0.5 (-2.0 to 3.0)   48.2 (44.5 to 51.9)   50.3 (48.1 to 52.5)   2.1 (-0.6 to 4.8) 
SF36 subdomains 
 Physical 
functioning 
≥60 6,111 6,179,375 51.9 (51.0 to 52.7) 
<0.001 
 51.2 (50.4 to 52.1) 
<0.001 
 -0.7 (-0.9 to -0.4) 
0.005 
 51.0 (50.5 to 51.4) 
0.12 
 50.1 (49.7 to 50.5) 
<0.001 
 -0.9 (-1.2 to -0.5) 
<0.001 
 <60 151 145,991 41.7 (38.9 to 44.5)  37.8 (34.6 to 41.0)  -3.9 (-6.1 to -1.8)  48.5 (45.4 to 51.5)  44.5 (41.8 to 47.1)  -4.0 (-5.4 to -2.6) 
 
Role Physical 
≥60 6,111 6,179,375 51.2 (50.7 to 51.7) 
<0.001 
 50.6 (50.0 to 51.2) 
<0.001 
 -0.6 (-0.9 to -0.3) 
0.03 
  50.8 (50.5 to 51.2) 
0.10 
  49.9 (49.6 to 50.3) 
0.01 
  -0.9 (-1.2 to -0.6) 
0.79 
 <60 151 145,991 44.7 (41.3 to 48.1)  41.5 (39.2 to 43.8)  -3.2 (-5.5 to -0.9)   48.1 (44.9 to 51.3)   46.9 (44.6 to 49.1)   -1.2 (-3.7 to 1.3) 
 
Bodily pain 
≥60 6,111 6,179,375 51.0 (50.4 to 51.6) 
0.00 
 50.7 (50.2 to 51.3) 
<0.001 
 -0.3 (-0.6 to 0.0) 
0.52 
 50.6 (50.1 to 51.0) 
0.98 
 50.1 (49.7 to 50.5) 
0.38 
 -0.5 (-0.8 to -0.2) 
0.39 
 <60 151 145,991 47.1 (44.3 to 49.8)  46.0 (44.4 to 47.7)  -1.1 (-3.4 to 1.3)  50.5 (48.0 to 53.1)  51.1 (48.8 to 53.3)  0.5 (-1.7 to 2.7) 
 
Genral health 
≥60 6,111 6,179,375 51.2 (50.5 to 51.9) 
0.00 
 50.5 (49.9 to 51.2) 
<0.001 
 -0.7 (-1.0 to -0.3) 
0.46 
  51.1 (50.7 to 51.5) 
0.03 
  50.2 (49.9 to 50.6) 
0.21 
  -0.8 (-1.2 to -0.5) 
0.45 
 <60 151 145,991 46.1 (43.3 to 48.9)  44.6 (42.1 to 47.0)  -1.5 (-3.6 to 0.6)   49.0 (47.3 to 50.7)   49.0 (47.0 to 50.9)   0.0 (-2.0 to 1.9) 
 
Vitality 
≥60 6,111 6,179,375 50.3 (49.9 to 50.8) 
0.04 
 49.9 (49.4 to 50.4) 
0.03 
 -0.4 (-0.8 to -0.1) 
0.44 
 50.5 (50.1 to 50.8) 
0.00 
 49.8 (49.5 to 50.1) 
0.28 
 -0.7 (-1 to -0.4) 
0.01 
 <60 151 145,991 47.1 (44.2 to 49.9)  47.5 (45.6 to 49.5)  0.5 (-1.6 to 2.6)  46.9 (44.8 to 49.0)  48.9 (47.3 to 50.5)  2.0 (0.2 to 3.7) 
 
Role emotional 
≥60 6,111 6,179,375 50.6 (49.9 to 51.2) 
0.21 
 50.1 (49.5 to 50.7) 
0.00 
 -0.5 (-0.9 to 0.0) 
0.18 
  50.5 (49.9 to 51.0) 
0.41 
  49.7 (49.2 to 50.2) 
0.41 
  -0.8 (-1.2 to -0.4) 
0.85 
 <60 151 145,991 47.8 (43.3 to 52.2)  44.8 (41.4 to 48.3)  -2.9 (-6.7 to 0.8)   48.7 (44.2 to 53.1)   48.3 (44.9 to 51.6)   -0.4 (-4.6 to 3.8) 
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Mental health 
≥60 6,111 6,179,375 50.1 (49.5 to 50.7) 
0.83 
 49.8 (49.3 to 50.3) 
0.43 
 -0.3 (-0.7 to 0.2) 
0.39 
 50.3 (49.7 to 50.8) 
0.32 
 49.9 (49.4 to 50.4) 
0.63 
 -0.4 (-0.8 to 0.0) 
0.17 
 <60 151 145,991 49.6 (45.5 to 53.8)  50.9 (48.2 to 53.6)  1.3 (-2.1 to 4.7)  48.4 (44.6 to 52.1)  50.5 (48.1 to 52.9)  2.2 (-1.4 to 5.7) 
 Social 
functioning 
≥60 6,111 6,179,375 51.0 (50.5 to 51.6) 
0.06 
 50.3 (49.8 to 50.7) 
<0.001 
 -0.8 (-1.3 to -0.2) 
0.14 
  51.0 (50.5 to 51.4) 
0.34 
  50.0 (49.7 to 50.4) 
0.13 
  -0.9 (-1.5 to -0.3) 
0.64 
 <60 151 145,991 48.0 (45.0 to 51.0)  45.4 (43.1 to 47.8)  -2.6 (-4.8 to -0.3)   49.4 (46.2 to 52.5)   47.8 (44.7 to 50.8)   -1.6 (-4.3 to 1.1) 
Abbreviations: PCS, Physical health component score; MCS, Mental health component score; eGFR, estimated glomelar filtration rate; CI, confidence interval, p value, comparison group eGFR≥60 ml/min/1.73m2.. 
a) Adjusted for age, sex, income, education, language, hypertension, diabetes, serum total cholesterol, HDL-cholesterol, triglycerides, lipid-modifying agents, body mass index, current smoking, history of cardiovascular disease. 
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Table 17: Overall mean health related quality of life, SF-36 physical and mental component summery scores, individual scale scores and their change by presence 
or absence of albuminuria. 
Endpoints 
UACR 
(mg/mmol) 
N of sample 
Weighted number of 
participants 
Unadjusted   Multivariable-adjusted a)  
In 1999-2000  In 2004-2005  Change over time  In 1999-2000  In 2004-2005  Change over time 
mean (95% CI) p   mean (95% CI) p   mean (95% CI) p   mean (95% CI) p   mean (95% CI) p   mean (95% CI) p 
SF6D score 
  
SF-6D 
<3.4  5,611 5,741,389 0.772 (0.764 to 0.781) 
0.91 
  0.770 (0.761 to 0.778) 
0.40 
  
-0.003 
(-0.008 to 0.002) 
0.14 
  
0.769 
(0.762 to 0.776) 
0.06 
  
0.763 
(0.757 to 0.768) 
0.12 
  -0.006 (-0.012 to -0.001) 
0.84 
  
≥3.4 301 281,431 0.774 (0.755 to 0.793)   0.759 (0.737 to 0.781)   -0.015 
(-0.030 to 0.000) 
  0.792 
(0.771 to 0.813) 
  0.784 
(0.758 to 0.809) 
  -0.008 (-0.025 to 0.009) 
SF36 scores 
 PCS 
<3.4  5,611 5,741,389 51.7 (50.9 to 52.4) 
<0.001 
 51.0 (50.2 to 51.8) 
<0.001 
 -0.7 (-0.9 to -0.5) 
0.20 
 50.9 (50.4 to 51.3) 
0.99 
 49.9 (49.5 to 50.3) 
0.90 
 -0.9 (-1.2 to -0.7) 
0.86 
 
≥3.4 301 281,431 48.2 (46.6 to 49.9)  47.0 (45.2 to 48.7)  -1.3 (-2.2 to -0.4)  50.9 (49.3 to 52.4)  50.0 (48.7 to 51.4)  -0.9 (-1.7 to 0.0) 
  
MCS  
<3.4  5,611 5,741,389 49.8 (49.1 to 50.5) 
0.01 
  49.5 (49.0 to 50.0) 
0.06 
  -0.3 (-0.8 to 0.2) 
0.24 
  50.1 (49.6 to 50.7) 
0.06 
  49.7 (49.3 to 50.1) 
0.06 
  -0.5 (-1.0 to 0.0) 
0.74 
  ≥3.4 301 281,431 52.0 (50.7 to 53.3)   50.7 (49.6 to 51.8)   -1.3 (-2.7 to 0.1)   51.8 (50.2 to 53.4)   51.1 (49.7 to 52.5)   -0.7 (-2.1 to 0.6) 
SF36 subdomains 
 Physical functioning 
<3.4  5,611 5,741,389 51.7 (50.8 to 52.6) 
<0.001 
 51.0 (50.1 to 51.9) 
<0.001 
 -0.7 (-1.0 to -0.4) 
0.11 
 50.8 (50.3 to 51.3) 
0.97 
 49.8 (49.4 to 50.3) 
0.75 
 -1.0 (-1.3 to -0.6) 
0.71 
 
≥3.4 301 281,431 48.2 (46.4 to 49.9)  46.5 (44.5 to 48.4)  -1.7 (-2.9 to -0.4)  50.8 (49.4 to 52.3)  49.7 (48.3 to 51.0)  -1.2 (-2.4 to 0.1) 
  
Role Physical 
<3.4  5,611 5,741,389 51.1 (50.5 to 51.6) 
0.11 
  50.4 (49.8 to 51.0) 
0.003 
  -0.7 (-1.0 to -0.3) 
0.08 
  50.6 (50.2 to 51.0) 
0.21 
  49.7 (49.3 to 50.1) 
0.49 
  -0.9 (-1.3 to -0.6) 
0.47 
  ≥3.4 301 281,431 49.8 (48.4 to 51.3)   48.0 (46.6 to 49.4)   -1.9 (-3.2 to -0.6)   51.6 (50.1 to 53.1)   50.2 (48.8 to 51.6)   -1.4 (-2.7 to -0.1) 
 Bodily pain 
<3.4  5,611 5,741,389 50.9 (50.3 to 51.5) 
0.42 
 50.6 (50.0 to 51.2) 
0.23 
 -0.3 (-0.6 to 0.0) 
0.66 
 50.4 (49.9 to 51.0) 
0.15 
 50.0 (49.6 to 50.4) 
0.03 
 -0.5 (-0.8 to -0.1) 
0.59 
 
≥3.4 301 281,431 50.2 (48.6 to 51.8)  49.6 (48.2 to 51.0)  -0.6 (-2.1 to 0.9)  51.7 (50.0 to 53.4)  51.5 (50.2 to 52.9)  -0.1 (-1.3 to 1.1) 
  
Genral health 
<3.4  5,611 5,741,389 51.1 (50.4 to 51.8) 
0.007 
  50.4 (49.6 to 51.1) 
0.012 
  -0.7 (-1.1 to -0.4) 
0.38 
  50.9 (50.5 to 51.3) 
0.71 
  50.0 (49.6 to 50.4) 
0.89 
  -0.9 (-1.2 to -0.6) 
0.80 
  ≥3.4 301 281,431 48.6 (47.1 to 50.2)   47.4 (45.4 to 49.3)   -1.2 (-2.4 to -0.1)   50.6 (49.0 to 52.2)   49.9 (47.8 to 51.9)   -0.7 (-2.0 to 0.6) 
 Vitality 
<3.4  5,611 5,741,389 50.2 (49.8 to 50.7) 
0.60 
 49.8 (49.3 to 50.3) 
0.41 
 -0.4 (-0.8 to 0.0) 
0.70 
 50.3 (49.9 to 50.7) 
0.98 
 49.6 (49.4 to 49.9) 
0.58 
 -0.7 (-1.0 to -0.3) 
0.48 
 
≥3.4 301 281,431 49.8 (48.3 to 51.3)  49.0 (47.3 to 50.7)  -0.7 (-2.2 to 0.8)  50.3 (48.3 to 52.4)  50.2 (48.2 to 52.1)  -0.2 (-1.5 to 1.1) 
  
Role emotional 
<3.4  5,611 5,741,389 50.3 (49.6 to 51.0) 
0.008 
  49.9 (49.2 to 50.7) 
0.527 
  -0.4 (-0.9 to 0.1) 
0.04 
  50.2 (49.6 to 50.8) 
<0.001 
  49.5 (49.0 to 50.1) 
0.35 
  -0.7 (-1.2 to -0.2) 
0.16 
  ≥3.4 301 281,431 51.9 (51.0 to 52.8)   49.1 (46.8 to 51.4)   -2.8 (-4.8 to -0.7)   52.6 (51.6 to 53.6)   50.5 (48.6 to 52.4)   -2.1 (-3.9 to -0.2) 
 Mental health 
<3.4  5,611 5,741,389 50.0 (49.4 to 50.7) 
0.23 
 49.8 (49.3 to 50.3) 
0.51 
 -0.2 (-0.6 to 0.2) 
0.35 
 50.1 (49.5 to 50.7) 
0.15 
 49.8 (49.4 to 50.2) 
0.13 
 -0.3 (-0.8 to 0.1) 
0.97 
 
≥3.4 301 281,431 51.3 (49.5 to 53.1)  50.4 (48.7 to 52.0)  -0.9 (-2.3 to 0.5)  51.6 (49.8 to 53.5)  51.3 (49.3 to 53.3)  -0.3 (-1.9 to 1.2) 
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Social functioning 
<3.4  5,611 5,741,389 50.9 (50.3 to 51.5) 
0.53 
  50.0 (49.5 to 50.5) 
0.84 
  -0.8 (-1.4 to -0.3) 
0.69 
  50.8 (50.2 to 51.3) 
0.09 
  49.8 (49.3 to 50.2) 
0.08 
  -1.0 (-1.6 to -0.4) 
0.89 
  ≥3.4 301 281,431 51.4 (50.0 to 52.8)   50.2 (48.8 to 51.5)   -1.2 (-3.0 to 0.6)   52.3 (50.7 to 53.8)   51.4 (49.7 to 53.1)   -0.9 (-2.6 to 0.9) 
Abbreviations: PCS, Physical health component score; MCS, Mental health component score; UACR,urinary albumin-to-creatinine ratio; CI, confidence interval; p value comparison group <3.4 mg/mmol. 
a) Adjusted for age, sex, income, education, language, hypertension, diabetes, serum total cholesterol, HDL-cholesterol, triglycerides, lipid-modifying agents, body mass index, current smoking, history of cardiovascular disease. 
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Supplementary table 6: Overall mean health related quality of life, SF-36 physical and mental component summery scores, individual scale scores and their change 
by CKD stages (KDIGO CKD classification). (4 -5) 
Endpoints CKD stage 
N of 
sampl
e 
Weighted 
number of 
participant
s 
Unadjsuted    Multivariable-adjsuted a)  
In 1999-2000  In 2004-2005  Change over time  In 1999-2000  In 2004-2005  Change over time 
mean (95% CI) p 
p 
trend 
  mean (95% CI) p 
p 
trend 
  mean (95% CI) p 
p 
trend 
  mean (95% CI) p 
p 
trend 
  mean (95% CI) p 
p 
trend 
  mean (95% CI) p 
p 
trend 
SF6D score 
 
SF-6D 
No/low risk 
CKD 
5,473 5,603,215 
0.774 (0.765 to 
0.783) 
ref 
0.08 
  0.771 (0.763 to 
0.779) 
ref 
<0.00
1 
  -0.003 (-0.008 to 
0.003) 
ref 
0.08 
  0.769 (0.762 to 
0.777) 
ref 
0.57 
  0.763 (0.757 to 
0.769) 
ref 
0.47 
  -0.006 (-0.012 to 
0.000) 
ref 
0.89 
 CKD stage 1-2  
264 254,480 
0.778 (0.758 to 
0.799) 
0.71   
0.766 (0.744 to 
0.787) 
0.65   
-0.013 (-0.029 to 
0.003) 
0.22   
0.794 (0.771 to 
0.818) 
0.06   
0.788 (0.761 to 
0.814) 
0.07   
-0.006 (-0.025 to 
0.012) 
1.00 
 CKD stage ≥3 
151 145,991 
0.729 (0.692 to 
0.766) 
0.02   0.707 (0.685 to 
0.729) 
<0.00
1 
  -0.022 (-0.045 to 
0.002) 
0.16   0.758 (0.724 to 
0.792) 
0.54   0.753 (0.731 to 
0.776) 
0.44   -0.004 (-0.030 to 
0.023) 
0.86 
SF36 scores 
 
PCS 
No/low risk 
CKD 
5,473 5,603,215 51.9 (51.2 to 52.7) ref 
<0.00
1 
 51.3 (50.5 to 52.0) ref 
<0.00
1 
 -0.6 (-0.8 to -0.4) ref 
0.003 
 51.0 (50.6 to 51.4) ref 
0.18 
 50.1 (49.7 to 50.5) ref 
0.01 
 -0.9 (-1.1 to -0.7) ref 
0.07 
 CKD stage 1-2  
264 254,480 48.9 (47.2 to 50.6) 0.001  47.8 (45.8 to 49.8) 0.002  -1.1 (-2.0 to -0.1) 0.38  51.0 (49.4 to 52.5) 0.99  50.3 (48.7 to 51.9) 0.78  -0.7 (-1.5 to 0.2) 0.61 
 CKD stage ≥3 
151 145,991 42.7 (40.0 to 45.4) 
<0.00
1 
 39.1 (37.2 to 40.9) 
<0.00
1 
 -3.7 (-5.5 to -1.8) 
0.00
3 
 49.0 (46.8 to 51.3) 0.11  46.4 (44.5 to 48.2) 
<0.00
1 
 -2.7 (-4.0 to -1.3) 0.01 
 
MCS 
No/low risk 
CKD 
5,473 5,603,215 49.8 (49.1 to 50.5) ref 
0.28 
  49.4 (48.9 to 49.9) ref 
0.09 
  -0.3 (-0.9 to 0.2) ref 
1.00 
  50.2 (49.6 to 50.8) ref 
0.90 
  49.6 (49.1 to 50.1) ref 
0.09 
  -0.6 (-1.1 to -0.1) ref 
0.15 
 CKD stage 1-2  
264 254,480 52.0 (50.6 to 53.5) 0.01   50.7 (49.7 to 51.7) 0.04   -1.4 (-2.8 to 0.0) 0.18   52.0 (50.4 to 53.7) 0.04   51.2 (49.9 to 52.6) 0.03   -0.8 (-2.2 to 0.6) 0.74 
 CKD stage ≥3 
151 145,991 50.6 (46.5 to 54.7) 0.70   51.1 (48.5 to 53.6) 0.24   0.5 (-2.0 to 3.0) 0.54   48.3 (44.6 to 51.9) 0.32   50.4 (48.3 to 52.6) 0.49   2.1 (-0.6 to 4.8) 0.06 
SF36 subdomains 
 Physical 
functionin
g 
No/low risk 
CKD 
5,473 5,603,215 51.9 (51.1 to 52.8) ref 
<0.00
1 
 51.3 (50.5 to 52.2) ref 
<0.00
1 
 -0.6 (-0.9 to -0.3) ref 
0.007 
 50.9 (50.4 to 51.4) ref 
0.11 
 50.0 (49.6 to 50.5) ref 
<0.00
1 
 -0.9 (-1.2 to -0.5) ref 
0.007 
 CKD stage 1-2  
264 254,480 48.6 (46.7 to 50.4) 0.003  47.3 (45.2 to 49.4) 
<0.00
1 
 -1.3 (-2.8 to 0.3) 0.40  50.7 (49.1 to 52.3) 0.81  49.9 (48.4 to 51.4) 0.80  -0.8 (-2.3 to 0.6) 0.94 
 CKD stage ≥3 
151 145,991 41.7 (38.9 to 44.5) 
<0.00
1 
 37.8 (34.6 to 41.0) 
<0.00
1 
 -3.9 (-6.1 to -1.8) 
0.00
5 
 48.3 (45.3 to 51.2) 0.09  44.3 (41.8 to 46.9) 
<0.00
1 
 -3.9 (-5.4 to -2.5) 
<0.00
1 
 
Role 
Physical 
No/low risk 
CKD 
5,473 5,603,215 51.2 (50.7 to 51.8) ref 
<0.00
1 
  50.6 (50.0 to 51.2) ref 
<0.00
1 
  -0.6 (-1.0 to -0.3) ref 
0.02 
  50.8 (50.4 to 51.2) ref 
0.17 
  49.8 (49.4 to 50.2) ref 
0.05 
  -1.0 (-1.3 to -0.6) ref 
0.81 
 CKD stage 1-2  
264 254,480 50.4 (49.0 to 51.9) 0.27   48.8 (47.1 to 50.5) 0.05   -1.6 (-2.9 to -0.3) 0.15   51.8 (50.3 to 53.4) 0.18   50.6 (48.9 to 52.4) 0.36   -1.2 (-2.4 to 0.0) 0.72 
 CKD stage ≥3 
151 145,991 44.7 (41.3 to 48.1) 
<0.00
1 
  41.5 (39.2 to 43.8) <0.00
1 
  -3.2 (-5.5 to -0.9) 0.03   48.0 (44.8 to 51.2) 0.09   46.8 (44.7 to 49.0) 0.009   -1.1 (-3.7 to 1.4) 0.89 
 
Bodily 
pain 
No/ low risk 
CKD 
5,473 5,603,215 51.0 (50.4 to 51.6) ref 0.02  50.7 (50.1 to 51.3) ref 
<0.00
1 
 -0.3 (-0.6 to 0.0) ref 0.44  50.5 (50.0 to 51.0) ref 0.44  49.9 (49.5 to 50.3) ref 0.07  -0.5 (-0.9 to -0.2) ref 0.31 
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 CKD stage 1-2  
264 254,480 50.6 (49.0 to 52.3) 0.68  49.9 (48.3 to 51.6) 0.42  -0.7 (-2.2 to 0.8) 0.60  51.9 (50.1 to 53.7) 0.12  51.7 (50.3 to 53.1) 0.02  -0.2 (-1.3 to 1.0) 0.53 
 CKD stage ≥3 
151 145,991 47.1 (44.3 to 49.8) 0.006  46.0 (44.4 to 47.7) 
<0.00
1 
 -1.1 (-3.4 to 1.3) 0.53  50.5 (47.9 to 53.1) 0.99  51.0 (48.8 to 53.2) 0.32  0.6 (-1.7 to 2.8) 0.36 
 
General 
health 
No/ low risk 
CKD 
5,473 5,603,215 51.2 (50.5 to 51.9) ref 
<0.00
1 
  50.5 (49.8 to 51.2) ref 
<0.00
1 
  -0.7 (-1.0 to -0.3) ref 
0.21 
  51.0 (50.6 to 51.4) ref 
0.07 
  50.1 (49.7 to 50.5) ref 
0.17 
  -0.9 (-1.2 to -0.6) ref 
0.37 
 CKD stage 1-2  
264 254,480 49.1 (47.3 to 50.9) 0.04   47.8 (45.6 to 49.9) 0.04   -1.3 (-2.5 to -0.2) 0.25   50.9 (49.2 to 52.5) 0.89   50.0 (47.8 to 52.3) 0.95   -0.8 (-2.3 to 0.6) 0.94 
 CKD stage ≥3 
151 145,991 46.1 (43.3 to 48.9) 0.001   44.6 (42.1 to 47.0) 
<0.00
1 
  -1.5 (-3.6 to 0.6) 0.47   48.8 (47.1 to 50.6) 0.03   48.7 (46.8 to 50.6) 0.16   -0.1 (-2.1 to 1.9) 0.46 
 
Vitality 
No/ low risk 
CKD 
5,473 5,603,215 50.3 (49.8 to 50.8) ref 
0.08 
 49.9 (49.4 to 50.4) ref 
0.05 
 -0.4 (-0.8 to 0.0) ref 
0.71 
 50.4 (50.0 to 50.8) ref 
0.05 
 49.7 (49.4 to 50.0) ref 
0.85 
 -0.7 (-1.1 to -0.4) ref 
0.01 
 CKD stage 1-2  
264 254,480 50.2 (48.6 to 51.8) 0.93  49.3 (47.6 to 51.0) 0.56  -0.9 (-2.1 to 0.3) 0.45  50.8 (48.7 to 52.8) 0.72  50.4 (48.5 to 52.3) 0.43  -0.4 (-1.5 to 0.7) 0.55 
 CKD stage ≥3 
151 145,991 47.1 (44.2 to 49.9) 0.04  47.5 (45.6 to 49.5) 0.03  0.5 (-1.6 to 2.6) 0.45  46.8 (44.8 to 48.9) 0.003  48.8 (47.3 to 50.3) 0.29  2.0 (0.2 to 3.7) 0.008 
 
Role 
emotional 
No/ low risk 
CKD 
5,473 5,603,215 50.4 (49.7 to 51.1) ref 
0.55 
  50.0 (49.3 to 50.7) ref 
0.005 
  -0.4 (-0.9 to 0.1) ref 
0.02 
  50.3 (49.7 to 50.9) ref 
0.87 
  49.5 (48.9 to 50.1) ref 
0.98 
  -0.8 (-1.2 to -0.4) ref 
0.83 
 CKD stage 1-2  
264 254,480 51.9 (51.0 to 52.9) 0.02   49.6 (47.0 to 52.2) 0.76   -2.3 (-4.7 to 0.0) 0.11   52.5 (51.4 to 53.6) 
<0.00
1 
  50.8 (48.8 to 52.9) 0.25   -1.7 (-3.7 to 0.3) 0.36 
 CKD stage ≥3 
151 145,991 47.8 (43.3 to 52.2) 0.24   44.8 (41.4 to 48.3) 0.005   -2.9 (-6.7 to 0.8) 0.16   48.7 (44.3 to 53.1) 0.47   48.3 (45.1 to 51.5) 0.47   -0.4 (-4.6 to 3.8) 0.84 
 
Mental 
health 
No/ low risk 
CKD 
5,473 5,603,215 50.0 (49.3 to 50.7) ref 
0.76 
 49.8 (49.2 to 50.3) ref 
0.31 
 -0.2 (-0.7 to 0.2) ref 
0.64 
 50.2 (49.5 to 50.8) ref 
0.89 
 49.8 (49.3 to 50.2) ref 
0.07 
 -0.4 (-0.9 to 0.1) ref 
0.19 
 CKD stage 1-2  
264 254,480 51.4 (49.4 to 53.3) 0.22  50.3 (48.7 to 52.0) 0.50  -1.0 (-2.5 to 0.5) 0.30  51.8 (49.8 to 53.8) 0.13  51.4 (49.3 to 53.4) 0.10  -0.4 (-2.0 to 1.1) 0.96 
 CKD stage ≥3 
151 145,991 49.6 (45.5 to 53.8) 0.86  50.9 (48.2 to 53.6) 0.42  1.3 (-2.1 to 4.7) 0.40  48.4 (44.8 to 52.1) 0.36  50.6 (48.3 to 53.0) 0.50  2.2 (-1.2 to 5.7) 0.16 
 Social 
functionin
g 
No/ low risk 
CKD 
5,473 5,603,215 51.0 (50.3 to 51.6) ref 
0.18 
  50.1 (49.7 to 50.6) ref 
<0.00
1 
  -0.8 (-1.4 to -0.2) ref 
0.21 
  50.8 (50.3 to 51.4) ref 
0.91 
  49.9 (49.5 to 50.3) ref 
0.72 
  -1.0 (-1.6 to -0.4) ref 
0.85 
 CKD stage 1-2  
264 254,480 51.8 (50.4 to 53.1) 0.35   50.5 (49.1 to 52.0) 0.58   -1.2 (-3.0 to 0.6) 0.68   52.4 (50.9 to 54.0) 0.08   51.6 (49.7 to 53.5) 0.08   -0.8 (-2.6 to 0.9) 0.87 
  CKD stage ≥3 
151 145,991 48.0 (45.0 to 51.0) 0.06   45.4 (43.1 to 47.8) 
<0.00
1 
  -2.6 (-4.8 to -0.3) 0.16   49.3 (46.1 to 52.4) 0.34   47.8 (44.8 to 50.8) 0.16   -1.5 (-4.3 to 1.3) 0.74 
Abbreviations: PCS, Physical health component score; MCS, Mental health component score;  CKD, chronic kidney disease; CI, confidence interval; ref, reference 
CKD stages were defined as UACR<3.4 mg/mmol and eGFR ≥60 ml/min/1.73 m2 for no CKD,  UACR≥3.4 mg/mmol and eGFR ≥60 ml/min/1.73 m2 for CKD stage 1-2, and UACR≥3.4 mg/mmol and eGFR <60 ml/min/1.73 m2 for CKD stage ≥3 
a) Adjusted for age, sex, income, education, language, hypertension, diabetes, serum total cholesterol, HDL-cholesterol, triglycerides, lipid-modifying agents, body mass index, current smoking, history of cardiovascular disease. 
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Worldwide access to treatment for end-stage kidney disease: 
a systematic review
Thaminda Liyanage*, Toshiharu Ninomiya*, Vivekanand Jha, Bruce Neal, Halle Marie Patrice, Ikechi Okpechi, Ming-hui Zhao, Jicheng Lv, 
Amit X Garg, John Knight, Anthony Rodgers, Martin Gallagher, Sradha Kotwal, Alan Cass, Vlado Perkovic
Summary
Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the 
disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We 
aimed to quantify estimates of this burden.
Methods We systematically searched Medline for observational studies and renal registries, and contacted national 
experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries 
without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030.
Findings In 2010, 2·618 million people received RRT worldwide. We estimated the number of patients needing RRT 
to be between 4·902 million (95% CI 4·438–5·431 million) in our conservative model and 9·701 million 
(8·544–11·021 million) in our high-estimate model, suggesting that at least 2·284 million people might have died 
prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, 
particularly Asia (1·907 million people needing but not receiving RRT; conservative model) and Africa 
(432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5·439 million 
(3·899–7·640 million) people by 2030, with the most growth in Asia (0·968 million to a projected 2·162 million 
[1·571–3·014 million]).
Interpretation The large number of people receiving RRT and the substantial number without access to it show the 
need to both develop low-cost treatments and implement eﬀ ective population-based prevention strategies.
Funding Australian National Health and Medical Research Council. 
Introduction
Renal replacement therapy (RRT), through either dialysis 
or renal transplantation, is a lifesaving yet high-cost 
treatment for people with end-stage kidney disease. It 
has been available in high-income countries for more 
than 50 years, with rapid growth in the number of people 
treated during this period. The use of dialysis to treat 
end-stage kidney disease varies substantially between 
regions, probably because of diﬀ erences in population 
demographics, prevalence of end-stage kidney disease, 
and factors aﬀ ecting access to and provision of RRT.1,2
The prevalence of end-stage kidney disease could rise 
sharply over the next few decades, driven by population 
ageing and an increasing prevalence of diabetes and 
hypertension.1,3,4 The demographic transition driving 
this rise is expected to occur predominantly in 
developing rather than developed countries, challenging 
the economic capacity of many countries to provide 
RRT to an increasing number of people with end-stage 
kidney disease.5–7
To develop service provision strategies for people with 
end-stage kidney disease, the burden of the disorder 
and availability of RRT need to be known, and 
projections of future demand for RRT made. In this 
systematic review, we quantiﬁ ed the worldwide burden 
of end-stage kidney disease and use of RRT, and 
estimated future trends.
Methods
Data sources
We systematically searched the literature describing the 
prevalence of end-stage kidney disease in countries around 
the world according to the Meta-analysis of Observational 
Studies in Epidemiology group consensus statement8 for 
conduct of such studies. We deﬁ ned end-stage kidney 
disease as kidney failure needing continuing maintenance 
dialysis or a kidney transplant for survival. We deﬁ ned 
RRT as any form of maintenance dialysis (either 
haemodialysis or peritoneal dialysis, excluding short-term 
dialysis methods for acute kidney injury, such as 
continuous venovenous haemoﬁ ltration, haemo dialysis, 
and haemodiaﬁ ltration, or acute peritoneal dialysis) or 
kidney transplantation. We obtained separate data on 
dialysis prevalence. All completed studies, reviews, and 
registries reporting the epidemiology of end-stage kidney 
disease or RRT, or both, after the year 2000 were eligible for 
inclusion. Two authors (TL and TN) independently did the 
literature search using a standardised approach. Because 
of the scarcity of data on incidence of end-stage kidney 
disease, we restricted this analysis to prevalence data.
We identiﬁ ed relevant studies by searching Medline via 
Ovid from Jan 1, 1950, to Aug 31, 2013, using relevant text 
words and medical subject headings that included all 
spellings of “renal replacement therapy”, “renal dialysis”, 
“kidney transplantation”, “haemodialysis”, “peritoneal 
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dialysis”, “renal transplant”, “incidence”, “prevalence”, 
and “epidemiology”, without any language restrictions 
(appendix). We manually scanned reference lists from 
identiﬁ ed reports and reviews to identify any other 
relevant studies. We also did Google and Google Scholar 
searches using individual country names for relevant 
information such as conference proceedings and 
individual country or regional registries. Additionally, we 
contacted experts for unpublished data from regions 
where reliable data were unavailable or available data 
were out of date. We assessed Taiwan, Hong Kong, and 
Macao separately from China because they use diﬀ erent 
renal registry systems from those used on the mainland.
We obtained  life expectancy at birth, median age of the 
population, and population size by 5 year age groups for 
the year 2010 from the UN Department of Economic and 
Social Aﬀ airs website,9 along with future projections for 
each country. We obtained information on gross national 
income (GNI) from the World Bank website10 and the 
forecast annual change in gross domestic product (GDP) 
for each country (up to 2018) from the International 
Monetary Fund website.11 Finally, we obtained relevant 
data for Taiwan from the Frederick S Pardee Center for 
International Futures website,12 and data about prevalence 
of diabetes and hypertension from the Global Health 
Observatory Data website.13
Data extraction
We obtained published reports for each renal registry, 
review article, and individual study (appendix), and 
extracted standard information. For the prevalence of 
dialysis and renal transplantation, when available, we 
regarded end-stage kidney disease registries as the 
primary information source for data extraction, otherwise 
we used individual articles. We used the most recent 
available data. We classiﬁ ed data sources as high, good, 
or moderate quality. We deemed formalised national 
registries to be high quality, published national and 
regional surveys to be good quality, and all other sources 
to be moderate quality (appendix).
Statistical analysis
We obtained actual numbers of patients receiving RRT in 
each country where available, or estimated them by 
multiplying the prevalence of RRT by the total population 
in each country. For 71 countries and Hong Kong, we based 
the prevalence of RRT on combined data for renal 
transplantation and dialysis, and for 52 countries and 
Taiwan, we based it on dialysis only. For the 76 countries 
and Macao without reported prevalence data, we made a 
national estimate by use of a multivariable Poisson 
regression and generalised estimating equation (appendix). 
This model used the information available from the 
123 countries (and Taiwan and Hong Kong) with prevalence 
data in conjunction with life expectancy at birth and GNI to 
derive a national estimate.14 We made worldwide estimates 
by summing numbers across the countries.
Access to RRT is widely recognised to be restricted in 
many countries, and reported numbers using RRT are 
likely to underestimate needs. To estimate the total 
number of people needing RRT, we used age-speciﬁ c 
prevalence data for RRT from 20 high-income countries 
(table 1). For four of these countries (Japan, Singapore, 
Taiwan, and the USA), RRT is known to be provided to 
See Online for appendix
High-estimated model 
(USA, Japan, Taiwan, and 
Singapore)
Conservatively estimated 
model (other 
16 countries)*
0–19 years 309·5 (285·3–335·7) 214·1 (177·8–257·7)
20–24 years 561·3 (512·1–615·1) 352·8 (311·5–399·6)
25–29 years 705·7 (640·9–777·1) 427·6 (386·3–473·3)
30–34 years 887·2 (801·8–981·9) 518·2 (478·6–561·1)
35–39 years 1115·6 (1002·8–1241·2) 628·0 (592·1–666·1)
40–44 years 1402·6 (1253·8–1569·2) 761·1 (729·7–793·8)
45–49 years 1763·6 (1567·3–1984·5) 922·3 (890·3–955·5)
50–54 years 2217·4 (1958·8–2509·9) 1117·8 (1070·3–1167·3)
55–59 years 2788·1 (2448·0–3175·2) 1354·7 (1275·0–1439·3)
60–64 years 3505·2 (3058·6–4017·1) 1641·7 (1513·4–1780·8)
65–69 years 4407·3 (3821·5–5083·3) 1989·4 (1793·7–2206·8)
70–74 years 5541·4 (4773·9–6432·4) 2411·0 (2124·5–2736·4)
75–79 years 6967·5 (5962·9–8141·3) 2922·0 (2515·5–3394·2)
≥80 years 10 050·8 (8510·1–11 869·3) 3973·9 (3294·5–4793·5)
Data are prevalence per million people (95% CI). *Australia, Austria, Belgium, 
Canada, Denmark, Finland, France, Greece, Iceland, Netherlands, New Zealand, 
Norway, Saudi Arabia, Spain, Sweden, and the UK.
Table 1: Estimated age-speciﬁ c prevalence of patients with end-stage 
kidney disease based on data from 20 high-income countries Figure 1: Search strategy
CKD=Chronic kidney disease. RRT=renal replacement therapy. 
3611 titles identiﬁed by Medline database search
2934 titles excluded—not epidemiology 
of CKD or RRT 
677 abstracts reviewed
609 abstracts excluded
136 not CKD or RRT
441 no relevant data reported
13 trial of paediatric population
19 other publication from same trial
3 articles identiﬁed by 
Google and Google 
Scholar searches
6 countries identiﬁed 
by expert input 
(summary data)
77 articles critically reviewed
18 articles included 
(prevalence data for 123 countries)
59 excluded—no relevant or timely 
data reported
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almost all individuals needing it. For at least some of the 
remaining 16 countries, about half of people needing 
RRT receive it.15,16 We developed high and low estimates of 
the total national need for RRT in every country by 
applying estimated age-speciﬁ c prevalence data for RRT 
to the population of every country in the world. We again 
made this estimation by use of Poisson regression models 
with generalised estimating equations (appendix). We 
used the model developed using the data drawn from the 
four countries where RRT uptake is high to provide an 
upper estimate of the likely need for RRT in each country, 
and the one for the other 16 countries where uptake is 
known to be incomplete to provide a lower estimate. 
Once again, we made worldwide estimates by summing 
numbers across the countries.
We calculated future projections of national prevalence 
of RRT for each country by applying an estimate of the 
annual percentage change in GNI—extrapolated from the 
annual percentage change of GDP from 2010 to each 
year—to the baseline ﬁ gures obtained. Beyond 2018, the 
annual percentage change of GNI up to 2018 was projected 
to continue. We calibrated the national projections from 
the baseline prevalence of RRT in a similar way to that 
done for risk equations (appendix).17 We calculated the 
number of patients receiving RRT for each year by 
multiplying the estimated prevalence of RRT for each year 
by the total population projected for that year on the basis 
of data obtained from the UN Department of Economic 
and Social Aﬀ airs website.9 We made worldwide estimates 
by summing data across countries. We did all statistical 
analyses with SAS (version 9.3) and regarded two-sided 
values of p<0·05 to be signiﬁ cant in all analyses.
Role of the funding source
The funding bodies had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. TL, TN, VJ, JK, and VP had full access to all 
the data in the study. VP had ﬁ nal responsibility for the 
decision to submit for publication.
Results
With our search strategy, we identiﬁ ed 3611 articles, of 
which 68 were selected for full text review. We also 
identiﬁ ed nine potential articles from other sources, such 
Total 
population 
(×1000)
Receiving dialysis Receiving RRT* Needing RRT (conservatively estimated model) Needing RRT (high-estimated model)
Estimated 
number 
(×1000)
Prevalence 
(pmp)
Estimated 
number 
(×1000)
Prevalence 
(pmp)
Estimated 
number 
(×1000)
Prevalence 
(pmp)
Diﬀ erence between 
needing and 
receiving RRT (%)
Estimated 
number 
(×1000)
Prevalence 
(pmp)
Diﬀ erence between 
needing and 
receiving RRT (%)
Region
World 6 915 149 2050 296 2618 379 4902 
(4438–5431)
709 
(642–785)
–47% (–52 to –41) 9701 
(8544–11021)
1403 
(1235–1594)
–73% (–76 to –69)
Africa 1 031 079 81 79 83 80 515 
(463–574)
499 
(449–556)
–84% (–86 to –82) 949 
(845–1067)
920 
(820–1035)
–91% (–92 to –90)
Asia 4 165 440 909 218 968 232 2875 
(2610–3174)
690 
(627–762)
–66% (–70 to –63) 5632 
(4969–6387)
1352 
(1193–1533)
–83% (–85 to –81)
Europe 739 963 327 442 532 719 759 
(683–846)
1026 
(923–1143)
–30% (–37 to –22) 1600 
(1396–1836)
2162 
(1886–2481)
–67% (–71 to –62)
Latin America and the 
Caribbean
595 872 276 463 373 626 401 
(363–444)
673 
(609–745)
–7% (–16 to 3) 785 
(693–891)
1317 
(1163–1496)
–52% (–58 to –46)
North America 346 373 441 1273 637 1839 323 
(292–360)
933 
(842–1038)
97%† (77–118) 673 
(588–770)
1943 
(1697–2223)
–5% (–17 to 8)
Oceania 36 420 15 412 25 686 30
(27–33)
824 
(743–916)
–17% (–24 to –7) 61
(54–70)
1675 
(1474–1920)
–59% (–64 to –54)
Income level‡
Low income 793 525 16 20 16 20 408 
(367–454)
514 
(462–572)
–96% (–96 to –96) 757
(673–853)
954 
(849–1074)
–98% (–98 to –98)
Lower-middle income 2 496 046 170 68 172 69 1486 
(1347–1645)
595 
(540–659)
–88% (–90 to –87) 2833 
(2510–3200)
1135 
(1006–1282)
–94% (–95 to –93)
Upper-middle income 2 520 598 688 273 803 319 1903 
(1729–2099)
755 
(686–833)
–58% (–62 to –54) 3783 
(3330–4299)
1501 
(1321–1706)
–79% (–81 to –76)
High income 1 104 980 1176 1064 1628 1473 1106 
(995–1233)
1001 
(900–1116)
47% (32–64) 2327 
(2030–2669)
2106 
(1837–2416)
–30% (–39 to –20)
Ranges in brackets are 95% CIs. pmp=per million people. RRT=renal replacement therapy. *In countries without available information about renal transplantation, the number of patients receiving RRT was 
estimated to be the same as the number receiving dialysis. †In the conservatively estimated model, the estimated prevalence of patients receiving RRT was lower than the actual prevalence in four countries with 
high prevalence—namely Japan, Singapore, Taiwan, and the USA. ‡Income levels were categorised according to the World Bank income groups in 2010: low-income GNI per capita ≤US $1005; lower-middle 
income $1006–3975; upper-middle income $3976–12 275; high income ≥$12 276.
Table 2: Estimated number of patients receiving renal replacement therapy worldwide and by region or income level in 2010
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as conference proceedings, input from the experts in the 
discipline, and Google and Google Scholar searches that 
used individual country names. We included 18 articles in 
this systematic review after full text review of these 
77 reports (ﬁ gure 1). These included 13 renal registries, 
of which four reported regional data for 42 countries 
and six reported individual country data (appendix). 
Additionally, experts in the region provided unpublished 
data of the number of people undergoing RRT for some 
countries—namely India, Pakistan, Bangladesh, and 
Thailand (JV), China (M-hZ and LJ), and African 
countries (HMP). In total, we obtained prevalence data on 
dialysis for 123 countries (and Taiwan and Hong Kong), 
representing 93% of the world population.
When classiﬁ ed geographically, data were available for 
countries in all six major regions, but covered a variable 
proportion of the included countries for each region. We 
obtained dialysis prevalence data for 31 African countries 
(81% of African population), 28 Asian countries (94%), 35 
European countries (98%), 25 Latin American and 
Caribbean countries (98%), two North American countries 
(100%), and two countries in Oceania (74%). Additionally, 
we obtained age-speciﬁ c dialysis prevalence rates from 20 
high-income countries in Europe, North America, and 
Oceania, and from Japan, Taiwan, and Singapore (12% of 
global population; appendix).
The completeness and robustness of the data capture 
and reporting used for data extraction varied 
considerably. High-quality reports were available for 
57 countries (including Hong Kong and Taiwan), 
good-quality reports for 62, and moderate-quality 
reports for six. Even within the high-quality reports, 
noticeable diﬀ erences existed in catchment area 
(national vs regional), data collection and reporting 
methods (mandatory vs voluntary), and level of internal 
and external validation. We derived age-speciﬁ c RRT 
prevalence data of 20 countries from high-quality 
reports.
In total, 2·618 million people received RRT in 2010 
(table 2). 2·050 million (78%) received dialysis, and the 
remainder received a transplant. Actual data were 
available for 99% of these people across the countries 
with available data, whereas we estimated the prevalence 
in the countries without available data using a 
multivariable Poisson regression and generalised 
estimating equation (ﬁ gure 2, appendix). To develop this 
model, predictors of RRT prevalence were found to be 
GNI and life expectancy (both p<0·0001), but not the 
prevalence of diabetes or hypertension (both p>0·2). The 
validity of this model, developed on the basis of data 
from 20 high-income countries, was assessed by 
establishing the consistency of actual and estimated 
number of patients receiving dialysis in the countries for 
which data were available (R²=0·80, interclass correlation 
coeﬃ  cient (1,1)=0·86; appendix).
The prevalence of RRT varied widely both within and 
across geographical regions, ranging from 80 per 
million people in Africa to 1840 per million people in 
North America (ﬁ gures 2, 3). The absolute number 
of people receiving RRT was highest in Asia 
(0·968 million) and North America (0·637 million). 
With regard to income levels, the prevalence of 
RRT increased steeply with income levels (ﬁ gure 4). 
Most RRT recipients (92·8%) were in high-income 
(1·628 million) and upper-middle-income (0·803 million) 
countries, with only 7·2% of RRT recipients living in 
lower-middle income (0·172 million) and low-income 
(0·016 million) countries. 
We calculated the number of patients needing RRT 
using age-standardised data from the 20 high-income 
countries for which age-speciﬁ c prevalence estimates 
were available. The prevalence of patients undergoing 
Figure 2: Patients receiving renal replacement therapy in 2010
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500·0–999·9
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RRT steadily increased with age, but two groups of 
countries had manifestly diﬀ erent patterns in old ages: 
four countries (Japan, Taiwan, Singapore, and the USA) 
had a very high prevalence of RRT, particularly in old 
people, whereas the remaining 16 countries had a lower 
prevalence (appendix).
In total, the number of patients needing RRT in 
2010 was estimated to be 4·902 million (95% CI 
4·438–5·431 million) when using the model derived 
from the data in 16 countries (conservatively estimated 
model), in which RRT is likely to be only partly 
implemented (table 2). The estimate was 9·701 million 
(8·544–11·021 million) when we used the model derived 
from data in the four countries (high-estimate model), 
with near-complete levels of RRT use. This analysis 
suggests that between 2·284 million (47%) and 
7·083 million (73%) individuals needing RRT worldwide 
did not receive it. By region, Asia was estimated to 
have the highest number of people needing RRT 
(2·875 million; conservative model), but the proportion 
actually receiving this treatment ranged from 17% to 34% 
across the two models. Africa had the lowest access to 
RRT, ranging from 9% to 16%. Middle and eastern Africa 
had remarkably lower access than the rest of the 
continent, with only 1–3% in need of treatment receiving 
RRT (appendix).
On the basis of data describing demographic 
projections and the forecast rate of economic growth, 
we estimated that the projected number of people 
receiving RRT will more than double from 2·618 million 
people worldwide in 2010 to 5·439 million (95% CI 
3·899–7·640 million) in 2030 (ﬁ gure 5). The largest 
absolute growth in the number of people receiving RRT 
is projected for Asia, rising from 0·968 million people 
in 2010 to 2·162 million (1·571–3·014 million) by 2030. 
The number of people receiving RRT is also forecast to 
increase rapidly in Africa, from 0·083 million in 2010 to 
Figure 3: Prevalence (A) and number of patients (B) receiving RRT according 
to region
RRT=renal replacement therapy.
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0·236 million (0·167–0·347 million) by 2030, and Latin 
America and the Caribbean, increasing almost 2·5 times 
from 0·373 million in 2010 to 0·903 million 
(0·663–1·234 million) by 2030.
Discussion
In this systematic review, we used the best available data 
to calculate the number of people receiving RRT in 2010, 
noting that about 2·618 million people received this 
life-sustaining treatment worldwide. Additionally, our 
ﬁ ndings suggest that, at best, only half or less of all 
people needing RRT worldwide had access to it in 2010, 
meaning at least 2·284 million people might have died 
prematurely because they did not have access to the 
treatment in 2010. Most of this burden of preventable 
deaths fell on low-income and middle-income countries. 
Further modelling suggests that the number of people 
undergoing RRT will more than double to 5·439 million 
by 2030, mostly in developing regions such as Asia and 
Africa; however, the number of people without access to 
RRT will remain substantial. These data show a pressing 
need to develop low-cost RRT alternatives to reduce 
disparities in access to the treatment, and the importance 
of development, implementation, and assessment of cost 
eﬀ ective end-stage kidney disease prevention strategies.
These estimates build on and extend previous estimates 
of worldwide end-stage kidney disease burden—the 
number of people estimated to be receiving RRT has 
increased steadily from 1·1 million people during the 
1990s18 to 1·8 million in 2004,19 1·9 million in 2005,20 and 
now 2·618 million in 2010. Our data suggest that this 
trend is likely to continue, driven by demographic 
change—especially ageing of the global population—and 
improvements in access to dialysis in countries with 
growing economies. Importantly, these estimates do not 
take account of any future changes in prevalence of 
end-stage kidney disease potentially driven by projected 
increases in diabetes5 or hypertension,7 or by changes in 
urbanisation, diet, and physical activity,6 as relations 
between these variables and RRT prevalence were not 
apparent in our analysis. Nonetheless, these variables are 
very likely to be captured in the model because of the high 
degree of collinearity with life expectancy and economic 
development. The fact that an association was not noted 
could also be the result of the aggregate nature of the data 
obtained, which could obscure relations that would be 
apparent if more granular data were available. Any 
increases in the prevalence of diabetes and hypertension 
could therefore be additional to those estimated in this 
analysis and probably bring with them further preventable 
deaths and additional health-care costs.
The most important ﬁ nding of this analysis is that a 
large number of people in need of RRT worldwide do not 
presently receive it. One previous study20 used national 
rates of diabetes and hypertension to estimate incidence 
of end-stage kidney disease and access to RRT, and 
suggested that more than 1·2 million premature deaths 
occurred as a result of untreated end-stage kidney disease 
related to diabetes and hypertension in 2010. However, 
we did not ﬁ nd a strong relation between these risk 
factors and the prevalence of RRT at a national level, but 
instead noted that age, life expectancy, and economic 
development were the strongest drivers. Although 
economic factors have been previously reported to be 
predictors of RRT prevalence,3,21,22 the observation 
regarding the relation between average life expectancy 
and RRT prevalence is new. The strong predictive ability 
of our model for prevalence of RRT suggests that this 
approach is robust.
The large number of deaths occurring because of poor 
access to treatment sets a demanding task for the 
nephrology community and the health-care and research 
communities in general. Although documentation of the 
magnitude of the issue is a necessary ﬁ rst step, the size of 
the gap demands a combined advocacy, health-care 
Figure 5: Estimated number of patients undergoing RRT from 2010 to 2030 
worldwide (A) and by region (B)
95% CIs shown as error bars. RRT=renal replacement therapy. 
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delivery, and research approach.2 First, governments 
should be made aware of the number of preventable 
deaths in their jurisdictions and lobbied to increase 
access to dialysis for aﬀ ected individuals where it is 
aﬀ ordable in the context of the broad health needs of 
their populations. Second, eﬀ ective population-based 
approaches to prevention of end-stage kidney disease—
such as blood pressure control,23 renin–angiotensin 
system blockade, and management of key risk factors, 
including diabetes and obesity24—and acute kidney 
injury25 should be reﬁ ned and tested. Innovative models 
of preventive care should be piloted in low-income and 
middle-income countries, especially in areas where 
access to physicians is low.26 Evidence exists from places 
such as Chile, Taiwan, the UK, and Uruguay to suggest 
that multifaceted preventive strategies might stabilise or 
even reduce the incidence of people needing RRT, and 
lead to cost savings.1,27–30 These models should be 
implemented widely and rigorously assessed. Third, 
cost-eﬀ ective dialysis techniques should be developed and 
made available. For the foreseeable future, present 
dialysis techniques costing tens of thousands of US 
dollars per patient per year will remain unaﬀ ordable for 
many of the countries where access to RRT is lowest. In 
view of the increase in the expected number of patients 
needing treatment, dialysis provision will represent a 
substantial ﬁ nancial burden for even the most aﬄ  uent 
countries in the years ahead. Finally, barriers to patients 
receiving a kidney transplant should be identiﬁ ed and 
removed because these transplants are the most 
cost-eﬀ ective form of RRT and produce the best 
outcomes.3 Professional bodies such as the International 
Society of Nephrology have a key role to play in this eﬀ ort.
Our study has several strengths. We obtained 
contemporary data from 123 countries plus Taiwan and 
Hong Kong (almost double that of the most recent 
report),20 including 93% of the worldwide population, 
using a comprehensive and systematic approach, with 
conservative estimates used wherever possible. This 
study reports estimates of RRT use worldwide, and uses 
the most reliable methods available to develop estimates 
of premature deaths due to an absence of access to RRT. 
It also expands on previous studies by identifying a new 
association with life expectancy.
Some limitations should also be considered, mainly due 
to variability in the datasets used and their quality and 
reliability. The available data were not complete for some 
countries, and the two countries with the largest 
populations in the world, China and India, do not have 
comprehensive national registries. Nonetheless, we 
obtained data from the most reliable available sources and 
believe that any variability in reliability of estimates for 
these countries would have a small eﬀ ect on the results at 
most. We were unable to obtain suﬃ  cient RRT incidence 
data to allow meaningful analysis of incidence. Because we 
deemed national dialysis prevalence equal to total 
RRT prevalence where renal transplantation data were 
unavailable, the number of patients receiving RRT is 
probably slightly underestimated in this study. We also 
recognise that a much larger number of patients have 
kidney failure as deﬁ ned by the Kidney Disease: Improving 
Global Outcomes group31 (estimated glomerular ﬁ ltration 
rate <15 mL/min per 1·73 m²) than the number needing 
RRT because the indications for RRT are neither clear nor 
uniform. The models needed a series of assumptions, but 
each was well supported by the available data, and although 
strong predictive ability was achieved, substantial variation 
was still seen. We developed two diﬀ erent models of 
expected RRT need, and have focused on the more 
conservative one to minimise the risk of overestimation. 
Finally, our estimates do not take account of continuing 
changes such as urbanisation and westernisation and their 
association with rapidly increasing rates of diabetes and 
hypertension, so the estimates here might be conservative 
and underestimate the future burden of disease.
The number of people receiving RRT is projected to grow 
from 2·618 million in 2010 to 5·439 million by 2030. 
Between 2·284 and 7·083 million people who could have 
been kept alive with RRT in 2010 died prematurely because 
they did not have access to the treatment. Most of these 
deaths occurred in low-income and middle-income 
countries in Asia, Africa, and Latin America and the 
Caribbean. The predicted growth in the prevalence of 
end-stage kidney disease demands development of 
aﬀ ordable RRT techniques and implementation of eﬀ ective 
and aﬀ ordable early detection and prevention programs.
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SUMMARY AT A GLANCE
The authors describe the protocol for the
Asian Renal Collaborative, a project to syn-
thesise data from Asian observational studies
of chronic kidney disease. This project will
provide important information on the epide-
miology of chronic kidney disease in Asia.
ABSTRACT:
Aim: The burden of chronic kidney disease (CKD) is growing rapidly around
the world. However, there is limited information on the overall regional prev-
alenceofCKD, aswell as theprognostic implications and treatmentpatterns in
Asian region. We have established the Asian Renal Collaboration (ARC) with
the goal of consolidating region-wide data regarding CKD.
Methods: This collaborative project will synthesize data and perform meta-
analyses of observational studies conducted in Asia. Studies will be identiﬁed
through a systematic literature search including abstracts, proceedings of
meetings, electronic databases such as MEDLINE and EMBASE. Personal
enquiry among collaborators and experts in the regionwill identify additional
studies, or other data sources such as registries. Both cross-sectional and longi-
tudinal studies that describe the prevalence of CKD and its complications will
be included, as will longitudinal studies that describe important clinical
outcomes for people with CKD. Individual participant data will be sought,
where possible, from each of the studies included in the collaboration for
baselineparameters and subsequent outcomes, in order tomaximizeﬂexibility
and consistency of data analyses.
Conclusions: This study is an initiative offering a unique opportunity to obtain
information about theprevalence andmanifestations ofCKD inAsia, aswell as
its risk factors. The ARC will also provide insights into important outcomes
including progression of CKD, CKD complications, cardiovascular disease
and death. These ﬁndings will improve our understanding of kidney disease
in Asia, and thus help inform service provision, preventive care and further
research across the region.
Chronic kidney disease (CKD) is an important cause of
morbidity and mortality around the world. It has been
suggested that the incidence and prevalence of CKD and end
stage kidney disease (ESKD) will rise sharply in the coming
decades, predominately in Asia.1–4 Individuals with CKD have
a reduced life expectancy, and those who progress to end-stage
kidney disease (ESKD) have 20-fold higher mortality rates
compared with age- and sex-matched individuals with normal
kidney function.5 The rising number of patients initiating renal
replacement therapy in most Asian countries1,4,6 is placing a
substantial burden on healthcare systems.
During the past few decades, epidemiological studies
have provided much valuable information about CKD, its
progression to ESKD and its associations with complications
such as anaemia, cardiovascular disease and mortality. Cross-
sectional data indicate that the prevalence of CKD in the
general population varies between 6 and 20%.1,7–11 However,
most of the evidence has been generated from studies
conducted in European and North America and less evidence
has been derived from Asian populations. Disease patterns
and distribution of risk factors differ markedly in many Asian
compared to non-Asian populations, as well as varying
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substantially within the region itself (for example, regional
variations in the incidence of IgA nephropathy, CKD secondary
to herbal therapy and of undetermined aetiology, lower blood
cholesterol and body mass index, younger age of onset, among
others).12–16 Even less is known about the factors that
determine progression and development of complications
amongst subjects with CKD in the region. Therefore, it is
imperative that information speciﬁc to Asian populations is
collected and analyzed to improve our understanding of the
challenges, in order to more effectively manage this complex
condition in the region.
Collaborative overviews (with meta-analysis where appro-
priate), in which data from a number of observational studies
are combined,17–21 provide useful information additional to
that provided by the studies individually. The large number of
participants will also facilitate discernment of important differ-
ences in the magnitude of associations between disease stages,
geographical regions, and between patient subgroups.
The Asian Renal Collaboration (ARC) has been set up to
enable these analyses using (where possible) individual partic-
ipant data from observational studies or other sources, such as
registries, in Asia on a broad range of risk factors and clinical
outcomes. The main objectives of this project are to obtain
information from a large number of subjects about the
prevalence, manifestations and risk factors of CKD in Asia.
Additionally, this study aims to provide insight into impor-
tant clinical endpoints including progression of CKD, CKD
complications such as anaemia, cardiovascular disease,
mineral and bone disorder and mortality. It may be possible
to produce estimates of the likely eventual effects on CKD
of exposure levels of risk factors. Furthermore, we may
be able to estimate the impact of initiatives aiming to pre-
vent CKD progression and/or its complications including
cardiovascular disease.” This report describes the protocol
for the ARC project.
OBJECTIVES
We aim to understand the epidemiology and to estimate the
impact of CKD in Asia by pooling already existing individual
participant data (where available), or summary level data.
Therefore, this project has the following main aims: ﬁrstly, to
estimate the prevalence of CKD in Asian populations, both
overall and country-speciﬁc; secondly to evaluate the
prevalence of risk factors, complications and patterns of
treatment in CKD patients in Asia, and thirdly to investigate
clinical outcomes in CKD patients in Asia.
METHODS
Study eligibility
Studies are potentially eligible for inclusion in this project if
they include a population from the Asia-Paciﬁc region (deﬁned
as South Asia, Southeast Asia and East Asia according to the
United Nations), involve at least 500 adult (18years or older)
participants recorded or planned and have one of the following
study designs:
a Cross-sectional studies (or baseline data from longitudinal
studies) that describe the prevalence of CKD in a
community-based population and/or the prevalence of risk
factors, complications and the patterns of treatment in
people with CKD
b Longitudinal studies that describe clinical outcomes of
interest in people with CKD
Given the relative paucity of data, we will include all
available studies without a time limit. However, as a sensitivity
analysis, in addition to overall analysis, we are planning to
stratify studies by year of data collection. New studies will be
useful for contemporary estimates.
Identiﬁcation of studies
Studies have been identiﬁed through a systematic search of the
literature including abstracts and proceedings of meetings, as
well as electronic databases such as MEDLINE and EMBASE.
In addition, personal enquiry among collaborators and experts
in the region has identiﬁed studies that have not yet been
reported. Individual participant data will be sought from each
collaborating study (see Appendix 1). Eligible studies identiﬁed
subsequent to the preparation of this protocol will be invited to
participate in the collaboration and to contribute data to the
overviews.
Principal risk factors
The data requested for each participant include: date of baseline
survey, date of birth or age at baseline, gender, ethnicity,
occupation, education, history of stroke and coronary heart
disease. The principal risk factors about which data will be
sought are as follows: systolic and diastolic blood pressure,
diabetes, serum total cholesterol, HDL and LDL cholesterol,
triglycerides, obesity (assessed from height and weight),
electrocardiogram abnormality, smoking status, alcohol
consumption, exercise, serum creatinine, estimated glomerular
ﬁltration rate (eGFR), presence of albuminuria or proteinuria,
haemoglobin, iron status, calcium, phosphate, parathyroid
hormone and Vitamin D levels. For the risk factors measured
on multiple occasions, data on all recorded measurements will
be sought. Erythropoietin stimulating agent use, iron therapy,
anti-hypertensive medications, antithrombotic medications,
cholesterol lowering drugs, phosphate binders, calcium,
vitamin D, and calcimimetic use will be collected as the infor-
mation on treatment.
Principal outcomes
Data will be sought from each study on the date of occurrence
of each of the outcomes listed in Table 1. CKD stage will be
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deﬁned according to KDIGO guidelines. ESKD will be deﬁned
as receiving maintenance dialysis or having a functioning renal
transplant whereas anaemia will be deﬁned as haemoglobin
(Hb) <100g/L or on ESA therapy. Precise details of the
diagnostic criteria used for deﬁning the outcomes (e.g. major
cardiovascular events), and data on the completeness of
follow-upwill also be collected for individual studies. It is antic-
ipated that deﬁnitions for outcomes may vary across included
studies, but will be standardized whenever possible. All
analyses will be based on events classiﬁed according to the
tenth revision of the International Classiﬁcation of Diseases
(ICD-10) or similar. Quality assessment of outcome ascertain-
ment will be conducted and subgroup analyses will take place
in order to assess for potential bias. For any study that did not
use this classiﬁcation system, events are re-coded by the project
secretariat using all available information.
Data transfer and checking
A standardised central data request form has been developed
to collect the relevant data from each of the involved studies.
Data may be provided to the coordinating centre in any
format convenient to the collaborator. A unique, anonymous
identiﬁer will be sought for each individual in submitted
datasets, so as to allow further data linkage should this be
necessary in the future. All data provided to the coordinating
centre will be carefully checked for completeness and consis-
tency. Computer-generated reports from the data will be
referred back to the principal investigator of each study for
review and conﬁrmation in order to ensure that the individ-
ual study results are incorporated correctly into the overview.
All data queries will be discussed and resolved with the
responsible collaborating investigator. Where individual
participant data are not able to be shared, tabular data will
be sought using consistent deﬁnitions and statistical code
wherever possible.
The data provided for inclusion in the ARC will be held in
strict conﬁdence by the coordinating centre. The data manager
in the coordinating centre will store all data securely. The data
from each study will remain the sole property of the principal
investigators of that study and will not be used for any
presentation or publication without the consent of the collabo-
rating investigators from that study.
Statistical analysis
We use cross-sectional data. With IPD we obtain prevalence
as the relative frequency and compute at least nation speciﬁc
results. Relevant information will be extracted from published
data including by contacting authors if necessary. If we have
enough values from published data we will also compute
age and sex speciﬁc results from the IPD. Prevalence data will
be collected from nationally representative studies where
these are available, but non-representative national and
regional data will also be collected where these are not
Table 1 Principal outcomes of interest and their ICD-10 codes (where available)
Principal outcomes ICD – 10 codes
1. The prevalence of CKD in Asia
a) Reduced eGFR N18
b) Presence of albuminuria/proteinuria R80
c) CKD stages (deﬁned by KDIGO) N18
d) ESKD (deﬁned by treated ESKD – dialysis, HD
and PD and transplant)
N18.5
e) Renal transplant recipients Z94
2. Prevalence of risk factors, complications and
treatment patterns among CKD patients in Asia
a) Clinical characteristics – Age, gender, cause of
CKD, history of blood pressure, diabetes mellitus,
BMI, smoking status, other co-morbidities
b) Laboratory characteristics – Haemoglobin, iron
stores, albumin, calcium, phosphate, PTH, Vitamin D,
urine protein/creatinine ratio, urine albumin
c) Treatment pattern– Iron, ESA, antihypertensive
medication, Vitamin D, and other treatments
d) Prevalence of anaemia deﬁned by haemoglobin
(Hb) <100 or on ESA therapy
e) Quality of life
3. Clinical outcomes in CKD patients in Asia
a) Kidney outcomes
1) Increase in CKD stage
2) Progression to ESKD
3) Doubling of serum creatinine
b) Cardiovascular outcomes
1) Major cardiovascular events (Coronary heart
disease, stroke, or cardiovascular mortality)
2) Coronary heart disease (Myocardial infarction
or hospitalization from angina)
I20-25
3) Stroke I60-69
4) Cardiovascular mortality
5) Hospitalization from heart failure I50
6) Any other atherosclerotic disease (e.g. peripheral
arterial disease and aneurysm)
I70-73
7) Thromboembolic events (vascular access and
non-vascular access related)
I74
c) Mortality
1) All-cause mortality
2) Cause-speciﬁc mortality
All cardiovascular disease 100-178
Coronary heart disease 120-125
Pulmonary circulatory disease 126-128
Sudden cardiac death 149-149
Heart failure 150
Stroke 160-169
Subarachnoid haemorrhage 160
Haemorrhagic stroke 161-162
Ischaemic stroke 163-166
All neoplasms C00-C97
Oesophageal cancer C00-C14
Stomach cancer C10-C16
Colorectal cancer C18-C21
Liver cancer C22
Lung cancer C33-C34
Breast cancer C50
Liver disease K70-K77
Kidney disease N00-N19
Lung disease J00-J99
ICD-10, Tenth version of the International Classiﬁcation of Diseases.
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available. Summary pooled estimates will be calculated, and
associations with risk factors estimated. Models will be devel-
oped in an effort to estimate CKD prevalence where data are
not available. In the ﬁrst instance, the principal analyses of
the associations of risk factors with disease for each study will
be performed using Cox proportional hazards models (Cox
1972). We shall pool results using random effects meta-
analysis, weighting by inverse variance.22 If appropriate, we
will adjust for the effects of regression dilution bias using
repeat risk factor measurement data (ESCHDC group 1998).
Analyses will also be adjusted for potential confounding fac-
tors and stratiﬁed by potential effect modiﬁers. Analyses will
be conducted to assess the separate associations in men and
women, in different regions and ethnic groups, in different
age groups (at baseline and at death), and in different periods
of follow-up. Analyses will be conducted to determine
whether any subgroup differences are due to confounding
(e.g. different age distributions in the cohorts), effect modiﬁ-
cation (e.g. different predictor-risk relationship across regions)
or different diagnostic practices between countries, using
random effects meta-regression.22 In addition to exploring
heterogeneity of the associations between these subgroups,
we will explore heterogeneity between individual studies
(adjusting for major confounders) using i-squared statistics
and χ2 tests.22 Sensitivity analyses taking account of factors
including completeness of follow-up, methods of outcome
assessment, availability of repeat risk factor measurements
and imputation of missing values22 will be performed to
determine the robustness of the ﬁndings. This analysis plan
will be continuously evaluated and a more detailed analysis
plan will be developed, depending on available data.
Time frame and publication policy
Initial data collation is expected to be completed by the end of
December 2015. Statistical analysis will begin in 2015 with
reports prepared for publication from 2015 onwards. The
results of the study will be disseminated by manuscripts in
peer-reviewed publications and by presentations at interna-
tional meetings. All reports from this project will be sent to all
collaborating investigators for prior comments and approval.
All such reports will be published in the name of the Asian
Renal Collaboration.
Ethical approval and subject consent
Individual studies will have obtained ethical approval and
subject consent from their relevant institutions prior to partici-
pation in the collaboration. Thus, no further ethical approval or
subject consent will be sought from individual participants. All
data provided to the Collaboration by the principal investiga-
tors of individual studies will be provided in a de-identiﬁed
format ensure conﬁdentiality of subjects. For the process of
central data collection and analysis, a separate ethics approval
has been granted by the University of Sydney, Australia (ARC
project ID: 2015/217).
ORGANIZATION
The ARC is a collaborative project between the principal inves-
tigators of contributing observational studies. The project secre-
tariat is based at the George Institute for Global Health, Sydney,
Australia. The Executive Committee and the Secretariat, both
Fig. 1 Organizational Structure of the Asian Renal
Collaboration.
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of which are responsible to the collaborating individual study
investigators, manage the central coordination of the overall
project. External researchers will be able to propose research
projects to ARC, however each proposal will be reviewed by
the Steering Committee. The Steering Committee comprises
regional representatives (from China, Japan, South Korea,
India, Taiwan, Thailand and Malaysia) and representatives
from the project secretariat (Appendix 2, Fig. 1) and has overall
responsibility for the design, conduct, progress, data collection,
data analysis and publication of study results.
More than 20 studies from 7 countries are participating to
date, representing more than 2.1 million study participants.
This project has been funded by a grant from GlaxoSmithKline
limited (Table 2, Fig. 2).
CONCLUSION
The ARC will aim to deﬁne the burden of CKD in Asia, and
identify associated patters of risk factors and outcomes. It will
highlight differences and similarities between CKD in Asia
and other regions, and provide important information that will
inform future research directions in the region, as well as
health service planning.
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CKD epidemiology survey in southern Taiwan Taiwan 3352 IPD received
Multicenter prospective cohort study Thailand 3000 Awaited
Studies based on CKD Patients
Chinese Cohort Study of CKD in China China 3200 Awaited
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Other datasets
Indian Dialysis Cohort - 1 India 1653 IPD received
Indian Dialysis Cohort - 2 India 2926 IPD received
The Q-Cohort Study Japan 3567 Tabulated data received
The (AICOPP) Study Japan 1515 Tabulated data received
IPD, Individual patient level data.
Fig. 2 Studies included in the Asian Renal Collaboration (as at 31 November
2015).
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APPENDIX 1
DATA REQUEST FORMAT
1 Demographic factors
1.1 Date of birth or age at baseline
1.2 Gender
1.3 Ethnicity
1.4 Occupation (for whole cohort or individually, if available)
1.5 Education level
1.6 Some unique (but anonymous) identiﬁer in case queries arise
2 Baseline survey data (coded in whatever way the study has used)
Details of the coding conventions, preferably accompanied by a
copy of the questionnaire or data coding or data entry forms used
in the study.
2.1 Date or year of the baseline survey
2.2 History of stroke and coronary heart disease
2.3 Cause of kidney disease
2.4 Systolic and diastolic blood pressure
2.5 Diabetes
2.6 Lipid parameter (serum total, HDL- and LDL cholesterol and
triglycerides)
2.7 Body parameters (Height, weight, body mass index)
2.8 Electrocardiogram abnormality (Left ventricular hypertrophy and
atrial ﬁbrillation)
2.9 Smoking status
2.10 Alcohol consumption
2.11 Exercise
2.12 Serum creatinine, eGFR
2.13 Urinary albumin-to-creatinine ratio or daily albumin excretion
2.14 Presence of proteinuria, urinary protein-to-creatinine ratio, or
daily protein excretion
2.15 Haematology (Haemoglobin, white cell count and platelets)
2.16 Iron status (Serum iron, serum transferrin and serum ferritin)
2.17 Biochemistry (Urea, electrolytes, calcium and phosphate)
2.18 Parathyroid hormone and Vitamin D
3 Treatment
3.1 Erythropoietin stimulating agent (yes/no, type, dose, mode of
administration)
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3.2 Iron therapy (Use or not, type, dose, mode of administration)
3.3 Anti-hypertensive medications (y/n, type, dose)
3.4 Antithrombotic medications (y/n, type, dose)
3.5 Cholesterol lowering drugs (y/n, type, dose)
3.6 Phosphate binders (y/n, type, dose)
3.7 Calcium and Vitamin D therapy (y/n, type, dose)
3.8 Calcimimetics (y/n, type, dose)
4 Repeat survey(s) data
Please provide data from any repeat survey(s) in a format as similar as
conveniently possible to that for the baseline survey.
5 Events
5.1 Date last known to be alive (if not recorded as dead)
5.2 Date of event or, if date not available age at event, for all non-fatal
events of these types:
a Kidney outcomes
1 Increase in CKD stage
2 Progression to ESKD
3 Doubling serum creatinine
b Cardiovascular outcomes
1 Major cardiovascular events
2 (Coronary heart disease, stroke, or cardiovascular mortality)
3 Coronary heart disease (Myocardial infarction or hospitalization
from angina)
4 Stroke
5 Cardiovascular mortality
6 Hospitalization from Heart failure
7 Any other atherosclerotic disease (e.g. peripheral arterial disease
and aneurysm)
5.3 Date of death (or, age at death, if date not available)
5.4 Underlying cause of death [preferably coded according to
some speciﬁed version or other (e.g. 7th, 8th, 9th or 10th)
of the 4-digit International Classiﬁcation of Diseases, but if a
4-digit ICD code is not available then whatever code the
study already uses]
5.5 Stroke investigated by CT/MRI (y/n)
5.6 Autopsy (y/n)
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Abstract
Background
AMediterranean dietary pattern is widely recommended for the prevention of chronic dis-
ease. We sought to define the most likely effects of the Mediterranean diet on vascular dis-
ease and mortality.
Methods
We searched MEDLINE, EMBASE and the Cochrane Central Register without language
restriction for randomized controlled trials comparing Mediterranean to control diets. Data
on study design, patient characteristics, interventions, follow-up duration, outcomes and
adverse events were sought. Individual study relative risks (RR) were pooled to create sum-
mary estimates.
Results
Six studies with a total of 10950 participants were included. Effects on major vascular
events (n = 477), death (n = 693) and vascular deaths (n = 315) were reported for 3, 5 and 4
studies respectively. For one large study (n = 1000) there were serious concerns about the
integrity of the data. When data for all studies were combined there was evidence of protec-
tion against major vascular events (RR 0.63, 95% confidence interval 0.53–0.75), coronary
events (0.65, 0.50–0.85), stroke (0.65, 0.48–0.88) and heart failure (0.30, 0.17–0.56) but
not for all-cause mortality (1.00, 0.86–1.15) or cardiovascular mortality (0.90, 0.72–1.11).
After the study of concern was excluded the benefit for vascular events (0.69, 0.55–0.86)
and stroke (0.66, 0.48–0.92) persisted but apparently positive findings for coronary events
(0.73, 0.51–1.05) and heart failure (0.25, 0.05–1.17) disappeared.
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Conclusion
The Mediterranean diet may protect against vascular disease. However, both the quantity
and quality of the available evidence is limited and highly variable. Results must be inter-
preted with caution.
Introduction
Cardiovascular disease (CVD) is a leading cause of mortality worldwide accounting for one
quarter of the estimated 52 million deaths in 2010[1,2]. The burden of CVD varies between
regions and a proportion of this variability may be due to different dietary patterns[1,3].
Populations in the Mediterranean region have been reported to experience lower morbidity
and mortality rates from CVD compared with northern European populations[4], which has
been attributed to their consumption of a Mediterranean diet high in fruits and vegetables,
nuts and cereals, fish, olive oil, with moderate red wine consumption and minimal amounts of
red meat and dairy products[5–7]. In addition, the Mediterranean diet has been associated
with beneficial effects on CVD risk factors such as glycaemia, blood pressure and lipid levels
[8–10]. Two recent systematic reviews have showed some beneficial effects of the Mediterra-
nean diet on the metabolic syndrome and its constituents but neither have explored the effects
on vascular events or mortality[11,12].
Although there are randomized controlled trials (RCTs) assessing the effect of the Mediter-
ranean diet on the primary or secondary prevention of CVD[13,14] the largest of these trials
recorded just a few hundred events. There is also concern that one of the key trials supporting
the beneficial effects of the Mediterranean diet was seriously methodologically compromised
[15]. There is, therefore, real uncertainty about the data underpinning the value of the Mediter-
ranean diet to human health. We undertook this systematic review and meta-analysis to better
define the effects of the Mediterranean diet on cardiovascular events and mortality.
Materials and Methods
Data sources and searches
We performed a systematic review of the literature according to the PRISMA statement for the
conduct of meta-analyses of intervention studies (www.prisma-statement.org) (S1 File). Rele-
vant studies were identified by searching the following data sources: MEDLINE via Ovid (from
inception through February 2014), EMBASE (from inception through February 2014) and the
Cochrane Library database (Cochrane Central Register of Controlled Trials; no date restric-
tion), using relevant text words and medical subject headings (S2 File). The search was limited
to randomised controlled trials (RCTs) without language restriction. Reference lists from iden-
tified trials and review articles were manually scanned to identify any other relevant studies.
The clinicaltrials.gov website was also searched for RCTs that were registered as completed but
not yet published.
Study selection
The literature search, data extraction and quality assessment were conducted independently by
two authors using a standardised approach (TL and AW). All completed RCTs assessing the
effects of a Mediterranean diet compared to any control diet involving adults, with follow up
period longer than three months, that reported one or more of the relevant outcomes were
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eligible for inclusion. Although there is considerable variability, a diet with non-restricted fat
intake and with at least two of the following seven components was defined as a Mediterranean
style diet for the purposes of this review; 1) use of olive oil as the main cooking oil, 2) moderate
red wine consumption, 3) high consumption of nuts and/or legumes, 4) high consumption of
grains and cereals, 5) high consumption of fruits and vegetables, 6) high consumption of fish
with low consumption of meat and meat products and 7) low to moderate consumption of
milk and dairy products[16].
Data extraction and quality assessment
Published reports were obtained for each trial and standard information about each trial was
extracted into a spreadsheet. The data sought included summary metrics for each trial about
baseline patient characteristics (age, gender, history of diabetes, history of hypertension, mean
systolic and diastolic blood pressure levels, lipid levels, smoking status, body mass index and
history of cardiovascular disease), details of the dietary intervention, follow-up duration, out-
come events and adverse events. Study quality was judged according to the Cochrane risk of
bias assessment tool[17]. Any disagreement in extracted data was adjudicated by a third
reviewer (VP).
Outcomes
We sought data on total cardiovascular events (stroke, myocardial infarction, cardiovascular
mortality or a broadly comparable definition reported by the study), coronary events (fatal or
non-fatal myocardial infarction, coronary revascularization), cerebrovascular events (fatal or
non-fatal stroke), heart failure, total mortality, incidence of type 2 diabetes mellitus, end-stage
kidney disease, adverse effects (all adverse effects and serious adverse effects) and quality of
life.
Data synthesis and analysis
Individual study relative risks (RRs) and 95% confidence intervals (CIs) were calculated from
event numbers extracted from each trial. In calculating RRs, the total number of patients ran-
domized in each group was used as the denominator. If no events were reported in either treat-
ment or control group of any trial, 0.5 was used as the numerator. For the three arm
PREDIMED study[14], the olive oil supplement arm and the nuts supplement arm were jointly
considered as the treatment group whereas in the four arm study by Burr et al[18] only the
“fish and fruit” arm fulfilled the defined criteria for the Mediterranean diet and this was com-
pared to the “sensible eating” arm. Primary summary estimates of RRs were obtained using a
random fixed effects model. Given the small number of included trials, publication bias and
percentage of variability across studies attributable to heterogeneity beyond chance were not
assessed as these may be unreliable. A two-sided p-value less than 0.05 was considered statisti-
cally significant. All analyses were performed with STATA, version 9.2 (Stata, College Station,
Texas).
Results
Search results and characteristics of included studies
The literature search yielded 4637 articles, of which 51 were reviewed in full text (Fig 1). Of
these, six RCTs, involving a total of 10950 participants, met the inclusion criteria. Among
these, 477 major cardiovascular events were reported from three trials[13,14,19] and 693
deaths from five trials[13,14,18–20]. The remaining study assessed the effect on quality of life
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[21]. The majority of the excluded trials did not study the Mediterranean diet as defined in the
protocol, studied only individual components of the Mediterranean diet, did not report rele-
vant outcomes, were not original investigations or were duplicate reports (S3 File).
The trials had a sample size that ranged from 48 to 7447 participants (Table 1). Two studies
were single-centre[13,20] and four were multi-centre[14,18,19,21]. All studies provided dietary
advice to participants and two studies provided food supplements in addition to dietary advice
[13,14]. The studies were conducted between March 1988 and December 2010. The mean age
of the study participants ranged between 41 and 67 years. One study only enrolled men[18],
one study only enrolled women[21] and four studies enrolled both men and women
[13,14,19,20]. Primary prevention was the objective of three studies[14,20,21], secondary pre-
vention was the goal of two studies[13,18] and the remaining study included patients with and
without a prior history of cardiovascular disease[19].
In regard to study quality (Table 2), four of the six studies concealed the randomized alloca-
tion sequence[13,14,19,20], no studies were double-blinded and blinded assessments of out-
comes were made in only 3 studies[13,14,19]. For one study subsequent publications raised
Fig 1. Identification process for eligible studies.
doi:10.1371/journal.pone.0159252.g001
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serious concerns about the integrity such that the veracity of results was significantly in doubt
[15,19].
Effects of Mediterranean diet on vascular outcomes and death
Major cardiovascular events. Effects of the Mediterranean diet were reported for this out-
come by three trials[13,14,19] including 9052 participants and 477 events. The Mediterranean
diet was associated with a 37% relative reduction in the risk of major cardiovascular events (RR
063, 95% CI: 053–075, p< 0001) compared to control diet. Exclusion of the study with seri-
ous concerns about its integrity (n = 1000, 145 events) did not result in a change of overall
direction of the effect (RR 0.69, 95% CI 0.55–0.86, p< 0.001) (Fig 2).
Fatal outcomes. Data on all-cause mortality were available from 5 trials[13,14,18–20]
including 10671 participants and 693 deaths, four of which also separately reported data for
cardiovascular mortality (10623 participants and 315 deaths) [13,14,18,19]. The Mediterranean
diet had no clear effect on all-cause mortality (RR 100, 95% CI: 086–115, p = 097) or cardio-
vascular mortality (RR: 090, 95% CI: 072–111, p = 032) compared to control (Fig 2). Exclud-
ing the trial by Singh et al. further widened the confidence intervals (Fig 2). Across the various
subgroups of studies examined (S1 and S2 Figs), greater benefits were suggested in small, single
centre studies with incomplete follow-up.
Cause-specific cardiovascular outcomes. Three trials[13,14,19] reported 221 coronary
events and 167 cerebrovascular events. Use of the Mediterranean diet was associated with a rel-
ative risk of 065 (95% CI 0.50–085) (Fig 2) for coronary events and 065 (95% CI 048–088)
for cerebrovascular events. Only two studies[13,19] involving 1605 participants and reporting
56 events were available to provide an effect estimate for heart failure, showing a relative risk of
030 (95% CI: 017–056). Exclusion of the data from the trial by Singh et al resulted in null
findings for all of the cause specific outcomes except cerebrovascular events which continued
to remain significant (RR: 066, 95% CI: 048–092, p = 001) (Fig 2).
Effects on other outcomes and adverse events. One study that enrolled 279 participants
reported data on quality of life[21]. There was a significant improvement with Mediterranean
diet as measured by the Problem Areas in Diabetes (PAID) [22] self-care summary score
(p = 0005) but no effect on any other domain of that score or the Medical Outcome Study
Table 2. Quality assessment of included studies.
Study/author
(year)
Random
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Completion
rate (%)
(Treatment/
Placebo)
Intention-to-
treat
described
Incomplete
outcome data
adequately
addressed
Selective
outcome
reporting
Lyon Diet Heart
Study, de Lorgeril
et al (1994)
Yes Yes No Yes 90.1/87.4 Yes Yes No
Indo-
Mediterranean
Diet Study, Singh
et al (2002)
Yes Yes No Yes 98.2/97.8 Yes Yes No
Toobert et al
(2003)
Yes No No No 84/93.1 Yes Yes No
Burr et al (2003) Yes No No No 100/100 Yes Yes No
Ng et al (2011) Yes Yes No No 68/82.6 Yes Yes No
PREDIMED study,
Estruch et al
(2013)
Yes Yes No Yes 95.1/88.7 Yes Yes No
doi:10.1371/journal.pone.0159252.t002
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Fig 2. Forrest plot of the included studies showing relative risk of Mediterranean diet compared to control diet by
various outcomemeasures (Fixed effects model analysis).
doi:10.1371/journal.pone.0159252.g002
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(MOS -12) short form general health survey[23] (all p>0.05). No data were available on new
onset type 2 diabetes mellitus, end-stage kidney disease or adverse events for any of the
included studies.
Discussion
This systematic review and meta-analysis supports the beneficial effects of the Mediterranean
diet on cardiovascular outcomes, although the quantity and quality of the available evidence is
relatively limited and there is much greater uncertainty about the effects of the Mediterranean
diet than is widely understood as a result. There are also no data about adverse outcomes
reported by any study, creating difficulties in the understanding of the overall balance between
the risks and benefits of the Mediterranean diet. While the completed trials suggest it is likely
that the Mediterranean diet protects against certain types of vascular diseases the evidence base
falls short of that required to make definitive conclusions or firm recommendations.
Underpinning the rationale for the large-scale outcome trials were the findings of a series of
prospective cohort studies[5–7] and recent reviews of those studies that reported moderately
decreased risks of all-cause mortality, cardiovascular mortality and the incidence of cardiovas-
cular disease associated with a Mediterranean diet[24,25]. However, observational studies of
the effects of diet on cardiovascular disease are highly prone to confounding and it is hard to
infer causation from these types of studies. Also in support of protective effects are the data
from smaller RCTs examining the effects of Mediterranean diet on intermediate metabolic out-
comes. These trials show small to moderate beneficial effects for multiple determinants of vas-
cular risk[26–28]. A recent overview of these RCTs trials identified blood pressure falls of
2.4mmHg (1.2 to 3.5) systolic and 1.6mmHg (1.1 to 2.0) diastolic, an LDL reduction of 2.71
mg/dl (5.03 to 0.39), a reduction in serum triglycerides of 6.14mg/dl (1.93 to 10.35) and an ele-
vation in HDL cholesterol of 1.17mg/dl (0.38 to 1.96)[12].
Despite these encouraging findings, neither the cohort studies nor the RCTs of intermediate
outcomes show benefits of a magnitude congruent with the very large point estimates of effect
on cardiovascular outcomes proposed by some of the individual trials included in our review.
Furthermore, while several other potential mechanisms of benefit such as antioxidant or anti-
inflammatory effects have been postulated for the Mediterranean diet[29,30], large trials of
intervention strategies specially targeting these pathways have been universally negative[31].
This raises an important question about the plausibility of large beneficial effects of the Medi-
terranean diet and raises concern about the possible effects of random or systematic errors. In
regard to the former, the total volume of data available is small and much less than might typi-
cally be available for comparable investigations of the effects of drugs on the same outcomes.
In terms of possible systematic errors, the un-masked design of the studies is a substantial
weakness inherent in the nature of the intervention and may have led to differential ascertain-
ment and assignment of outcomes across randomised groups. The much greater estimated
treatment effects on more subjective outcomes like coronary events, strokes and heart failure
compared to the non-significant estimates of effect for the objective outcome of mortality rein-
forces this possibility.
This review benefits from its comprehensive, systematic approach and the broad range of
clinically important endpoints considered (S4 File). It does, however, suffer from a number of
limitations. We could not explore heterogeneity across the individual study results for key out-
comes in detail and our analyses based upon limited published summary data are restricted in
their capacity to investigate this. Heterogeneity seems a possibility not only due to the different
nature of the interventions used across the trials but also due to a combination of factors such
as differing outcome definitions and varied durations of follow-up. In addition, the fact that
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larger benefits were seen in smaller, single-centre studies with incomplete follow up raises the
possibility of overestimation of benefits by these studies. The absence of any data about the
risks of adverse events is also a significant short-coming. Another issue affecting the evidence
base supporting the use of the Mediterranean is the concern about the integrity of the trial by
Singh et al.[19]. Following a site visit organized by the Lancet to Dr. Singh’s research facility
due to concerns raised by multiple parties, including then the editor of BMJ, it was concluded
that it was not possible to be sure of the rigor for recording data and its handling. While unable
to point to specific evidence to refute the study's results, they raised concerns about the quality
of the data likely to be generated from a research facility that lacked access to the kind of highly
qualified support staff necessary to conduct a clinical trial to sufficiently high international
standards. These concerns have been extensively reported and it is clear that the conduct and
reporting of the trial are so weak as to raise serious concerns about the trial results[15]. If the
Mediterranean diet was seeking registration or reimbursement under any regulatory assess-
ment scheme it seems very unlikely that the data provided by the Singh trial would be eligible
to contribute. Accordingly the best current estimates of the effect of the Mediterranean diet on
cardiovascular outcomes are those that exclude the data from that study.
Conclusion
The American Heart Association/American College of Cardiology[32], the European Society
of Cardiology[33] and the National Heart Foundation of Australia (www.heartfoundation.org.
au) are three societies that all recommend the Mediterranean diet to reduce cardiovascular
risk. All are careful to base this advice on the observed favorable although modest effects of the
Mediterranean diet on intermediate cardiovascular risk factors. Clearly, recommendations
based upon definitive clinical outcomes would be far preferable, and are supported by the find-
ings of this review, however the strength of conclusions should remain circumspect because of
the weakness of the evidence base. It seems unlikely that clinicians and patients fully appreciate
the limitations of the data and the extent of the uncertainty. This is an area that warrants
another well-conducted, adequately powered trial able to precisely and reliably define the over-
all balance of benefits and risks associated with the Mediterranean diet.
Prior Presentations of Results
This work has been presented at the American College of Cardiology Annual Scientific Ses-
sions in 2015 in abstract form. The abstract is available from the following link: http://content.
onlinejacc.org/article.aspx?articleid=2198774
Supporting Information
S1 Fig. Subgroup analysis of five studies reporting all-cause mortality.
(TIFF)
S2 Fig. Subgroup analysis of four studies reporting cardiovascular mortality.
(TIFF)
S1 File. Study Protocol.
(DOCX)
S2 File. Search Strategy.
(DOCX)
S3 File. List of rejected articles after full text review.
(RTF)
Effects of the Mediterranean Diet
PLOS ONE | DOI:10.1371/journal.pone.0159252 August 10, 2016 9 / 11
S4 File. PRISMA check list.
(DOC)
Author Contributions
Conceived and designed the experiments: TL TN AWM. Jun VP. Analyzed the data: TL TN
AWM. Jun VP. Wrote the paper: TL TN BNM. Jun M. Jardine VP. Data interpretation and
critical revision of manuscript: TL TN AW BNM. Jun MWM. Jardine GH VP.
References
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (2012) Global and regional mor-
tality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet 380: 2095–2128. doi: 10.1016/S0140-6736(12)61728-0 PMID:
23245604
2. WHO (September, 2011) Cardiovascular Diseases, Fact Sheet Number 317.
3. Reddy KS, Yusuf S (1998) Emerging epidemic of cardiovascular disease in developing countries. Cir-
culation 97: 596–601. PMID: 9494031
4. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, et al. (1986) The diet and 15-year
death rate in the seven countries study. Am J Epidemiol 124: 903–915. PMID: 3776973
5. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D (2003) Adherence to a Mediterranean diet and
survival in a Greek population. N Engl J Med 348: 2599–2608. PMID: 12826634
6. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, et al. (2004) Mediterra-
nean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE proj-
ect. JAMA 292: 1433–1439. PMID: 15383513
7. Buckland G, Gonzalez CA, Agudo A, Vilardell M, Berenguer A, Amiano P, et al. (2009) Adherence to
the Mediterranean diet and risk of coronary heart disease in the Spanish EPIC Cohort Study. Am J Epi-
demiol 170: 1518–1529. doi: 10.1093/aje/kwp282 PMID: 19903723
8. Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A (2004) Olive
oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation
into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 80: 1012–1018. PMID: 15447913
9. Martinez-Gonzalez MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, Basterra-Gortari FJ, Beunza JJ,
Benito S, et al. (2008) Adherence to Mediterranean diet and risk of developing diabetes: prospective
cohort study. BMJ 336: 1348–1351. doi: 10.1136/bmj.39561.501007.BE PMID: 18511765
10. Rumawas ME, Meigs JB, Dwyer JT, McKeown NM, Jacques PF (2009) Mediterranean-style dietary
pattern, reduced risk of metabolic syndrome traits, and incidence in the FraminghamOffspring Cohort.
Am J Clin Nutr 90: 1608–1614. doi: 10.3945/ajcn.2009.27908 PMID: 19828705
11. Buckland G, Bach A, Serra-Majem L (2008) Obesity and the Mediterranean diet: a systematic review of
observational and intervention studies. Obes Rev 9: 582–593. doi: 10.1111/j.1467-789X.2008.00503.x
PMID: 18547378
12. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB (2011) The
effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies
and 534,906 individuals. J Am Coll Cardiol 57: 1299–1313. doi: 10.1016/j.jacc.2010.09.073 PMID:
21392646
13. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. (1994) Mediterranean alpha-
linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343: 1454–1459.
PMID: 7911176
14. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. (2013) Primary prevention of
cardiovascular disease with a Mediterranean diet. N Engl J Med 368: 1279–1290. doi: 10.1056/
NEJMoa1200303 PMID: 23432189
15. Horton R (2005) Expression of concern: Indo-Mediterranean Diet Heart Study. Lancet 366: 354–356.
PMID: 16054927
16. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, et al. (1995) Mediterranean
diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 61: 1402S–1406S. PMID: 7754995
17. Higgins J (2011) Cochrane Handbook for Systematic Reviews of Interventions.Version 5.1.0.
18. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. (2003) Lack of benefit of
dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 57: 193–200. PMID:
12571649
Effects of the Mediterranean Diet
PLOS ONE | DOI:10.1371/journal.pone.0159252 August 10, 2016 10 / 11
19. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, et al. (2002) Effect of an Indo-Mediterra-
nean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet
Heart Study): a randomised single-blind trial. Lancet 360: 1455–1461. PMID: 12433513
20. Ng GW, Chan UM, Li PC, WongWC (2011) Can a Mediterranean diet reduce the effects of lipodystro-
phy syndrome in people living with HIV? A pilot randomised controlled trial. Sex Health 8: 43–51. doi:
10.1071/SH09065 PMID: 21371381
21. Toobert DJ, Glasgow RE, Strycker LA, Barrera M Jr., Radcliffe JL, Wander RC, et al. (2003) Biologic
and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial. Dia-
betes Care 26: 2288–2293. PMID: 12882850
22. PolonskyWH (2000) Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum
13: 36–41.
23. Stewart AL, Hays RD, Ware JE Jr. (1988) The MOS short-form general health survey. Reliability and
validity in a patient population. Med Care 26: 724–735. PMID: 3393032
24. Sofi F, Abbate R, Gensini GF, Casini A (2010) Accruing evidence on benefits of adherence to the Medi-
terranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 92: 1189–
1196. doi: 10.3945/ajcn.2010.29673 PMID: 20810976
25. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N (2013) Medi-
terranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann Neurol 74: 580–
591. doi: 10.1002/ana.23944 PMID: 23720230
26. Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, et al. (2013) 'Mediterranean' dietary
pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 8:
CD009825. doi: 10.1002/14651858.CD009825.pub2 PMID: 23939686
27. Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, et al. (2011) Meta-analy-
sis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med
124: 841–851.e842. doi: 10.1016/j.amjmed.2011.04.024 PMID: 21854893
28. Grosso G, Mistretta A, Frigiola A, Gruttadauria S, Biondi A, Basile F, et al. (2014) Mediterranean diet
and cardiovascular risk factors: a systematic review. Crit Rev Food Sci Nutr 54: 593–610. doi: 10.1080/
10408398.2011.596955 PMID: 24261534
29. Detopoulou Paraskevi, Constantinos AD Smaragdi Antonopoulou (2013) Mediterranean diet in a new
perspective: A Systematic review for its benefits regarding mortality and cardiovascular disease and
potential protective mechanisms. Hellenic Journal of Nutrition & Dietetics Vol 4: 27–43.
30. Schwingshackl L, Hoffmann G (2014) Mediterranean dietary pattern, inflammation and endothelial
function: a systematic review and meta-analysis of intervention trials. Nutr Metab Cardiovasc Dis 24:
929–939. doi: 10.1016/j.numecd.2014.03.003 PMID: 24787907
31. Myung SK, JuW, Cho B, Oh SW, Park SM, Koo BK, et al. (2013) Efficacy of vitamin and antioxidant
supplements in prevention of cardiovascular disease: systematic review and meta-analysis of rando-
mised controlled trials. BMJ 346: f10. doi: 10.1136/bmj.f10 PMID: 23335472
32. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. (2014) 2013 AHA/
ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College
of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:
2960–2984. doi: 10.1016/j.jacc.2013.11.003 PMID: 24239922
33. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. (2012) European Guidelines
on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clini-
cal Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:
1635–1701. doi: 10.1093/eurheartj/ehs092 PMID: 22555213
Effects of the Mediterranean Diet
PLOS ONE | DOI:10.1371/journal.pone.0159252 August 10, 2016 11 / 11
 269 
 
REFERENCES 
 
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. 
doi: 10.1016/s0140-6736(12)61728-0 [published Online First: 2012/12/19] 
2. Wyld ML, Lee CM, Zhuo X, et al. Cost to government and society of chronic 
kidney disease stage 1-5: a national cohort study. Internal medicine journal 
2015;45(7):741-7. doi: 10.1111/imj.12797 [published Online First: 
2015/05/07] 
3. Cass A CS, Gallagher M et al. . The economic impact of end-stage kidney disease 
in Australia: Projections to 2020. Kidney Health Australia, Melbourne, 
Australia 2010 
4. Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal 
failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 
2006;1(1):43-51. doi: 10.2215/cjn.00220605 [published Online First: 
2007/08/21] 
5. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring 
renal replacement therapy on outcome in critically ill patients. Critical care 
medicine 2002;30(9):2051-8. doi: 10.1097/01.ccm.0000026732.62103.df 
[published Online First: 2002/09/28] 
6. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: 
a multinational, multicenter study. Jama 2005;294(7):813-8. doi: 
10.1001/jama.294.7.813 [published Online First: 2005/08/18] 
7. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a 
prospective study. The American journal of medicine 1983;74(2):243-8. 
[published Online First: 1983/02/01] 
8. Shusterman N, Strom BL, Murray TG, et al. Risk factors and outcome of hospital-
acquired acute renal failure. Clinical epidemiologic study. The American 
journal of medicine 1987;83(1):65-71. [published Online First: 1987/07/01] 
9. Novis BK RM, Aronson S, et al. Association of preoperative risk factors with post 
operative acute renal failure Anesth analg 1994;78:143-9. 
10. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an 
initiative to improve outcomes in acute kidney injury. Critical care (London, 
England) 2007;11(2):R31. doi: 10.1186/cc5713 [published Online First: 
2007/03/03] 
11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 2002;39(2 Suppl 1):S1-
266. [published Online First: 2002/03/21] 
12. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk 
factors in dialysis patients compared with the general population: the CHOICE 
Study. J Am Soc Nephrol 2002;13(7):1918-27. [published Online First: 
2002/06/29] 
13. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for 
development of cardiovascular disease: a statement from the American Heart 
Association Councils on Kidney in Cardiovascular Disease, High Blood 
Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. 
 270 
 
Hypertension 2003;42(5):1050-65. doi: 
10.1161/01.HYP.0000102971.85504.7c [published Online First: 2003/11/08] 
14. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: 
a systematic review. J Am Soc Nephrol 2006;17(7):2034-47. doi: 
10.1681/ASN.2005101085 
15. Parker TF, 3rd, Blantz R, Hostetter T, et al. The chronic kidney disease initiative. 
J Am Soc Nephrol 2004;15(3):708-16. [published Online First: 2004/02/24] 
16. United States Renal Data System - 2012 Atlas of CKD & ESRD. 2012.  
17. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease 
(CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. 
American journal of kidney diseases : the official journal of the National 
Kidney Foundation 2005;45(4):658-66. 
18. Chow FY, Briganti EM, Kerr PG, et al. Health-related quality of life in Australian 
adults with renal insufficiency: a population-based study. American journal of 
kidney diseases : the official journal of the National Kidney Foundation 
2003;41(3):596-604. doi: 10.1053/ajkd.2003.50121 
19. Fukuhara S, Yamazaki S, Marumo F, et al. Health-related quality of life of 
predialysis patients with chronic renal failure. Nephron Clinical practice 
2007;105(1):c1-8. doi: 10.1159/000096802 
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16(1):31-41. [published Online First: 1976/01/01] 
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Annals of internal 
medicine 1999;130(6):461-70. [published Online First: 1999/03/13] 
22. Hebert PL, Nori US, Bhatt UY, et al. A modest proposal for improving the 
accuracy of creatinine-based GFR-estimating equations. Nephrol Dial 
Transplant 2011;26(8):2426-8. doi: 10.1093/ndt/gfr151 [published Online 
First: 2011/03/31] 
23. Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in 
renal disease study equation in a large diverse population. J Am Soc Nephrol 
2007;18(10):2749-57. doi: 10.1681/asn.2007020199 [published Online First: 
2007/09/15] 
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Annals of internal medicine 2009;150(9):604-12. [published 
Online First: 2009/05/06] 
25. Pugliese G, Solini A, Bonora E, et al. The Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation provides a better definition of 
cardiovascular burden associated with CKD than the Modification of Diet in 
Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. 
Atherosclerosis 2011;218(1):194-9. doi: 10.1016/j.atherosclerosis.2011.04.035 
[published Online First: 2011/05/27] 
26. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a 
cross-sectional survey. Lancet 2012;379(9818):815-22. doi: 10.1016/s0140-
6736(12)60033-6 [published Online First: 2012/03/06] 
27. Perkovic V, Cass A, Patel AA, et al. High prevalence of chronic kidney disease in 
Thailand. Kidney Int 2008;73(4):473-9. doi: 10.1038/sj.ki.5002701 [published 
Online First: 2007/12/07] 
 271 
 
28. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in 
Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003;14(7 
Suppl 2):S131-8. [published Online First: 2003/06/24] 
29. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the 
United States. Jama 2007;298(17):2038-47. doi: 10.1001/jama.298.17.2038 
[published Online First: 2007/11/08] 
30. USRDS: the United States Renal Data System. American journal of kidney 
diseases : the official journal of the National Kidney Foundation 2003;42(6 
Suppl 5):1-230. [published Online First: 2003/12/05] 
31. ANZDATA Registry. The 38th Annual ANZDATA Report. Australia and New 
Zealand Dialysis and Transplant Registry, Adelaide, Australia. Available at: 
http://www.anzdata.org.au;. 2016 
32. O'Seaghdha CM, Perkovic V, Lam TH, et al. Blood pressure is a major risk factor 
for renal death: an analysis of 560 352 participants from the Asia-Pacific 
region. Hypertension 2009;54(3):509-15. doi: 
10.1161/hypertensionaha.108.128413 [published Online First: 2009/07/15] 
33. White SL, McGeechan K, Jones M, et al. Socioeconomic disadvantage and kidney 
disease in the United States, Australia, and Thailand. American journal of 
public health 2008;98(7):1306-13. doi: 10.2105/ajph.2007.116020 [published 
Online First: 2008/05/31] 
34. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the 
angiotensin-receptor antagonist irbesartan in patients with nephropathy due to 
type 2 diabetes. The New England journal of medicine 2001;345(12):851-60. 
doi: 10.1056/NEJMoa011303 [published Online First: 2001/09/22] 
35. Chan JC, Wat NM, So WY, et al. Renin angiotensin aldosterone system blockade 
and renal disease in patients with type 2 diabetes. An Asian perspective from 
the RENAAL Study. Diabetes Care 2004;27(4):874-9. [published Online 
First: 2004/03/30] 
36. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of 
perindopril and indapamide on macrovascular and microvascular outcomes in 
patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised 
controlled trial. Lancet 2007;370(9590):829-40. doi: 10.1016/s0140-
6736(07)61303-8 [published Online First: 2007/09/04] 
37. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering 
in type 2 diabetes. The New England journal of medicine 2008;358(24):2545-
59. doi: 10.1056/NEJMoa0802743 [published Online First: 2008/06/10] 
38. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and 
vascular outcomes in patients with type 2 diabetes. The New England journal 
of medicine 2008;358(24):2560-72. doi: 10.1056/NEJMoa0802987 [published 
Online First: 2008/06/10] 
39. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and 
macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52(11):2288-
98. doi: 10.1007/s00125-009-1470-0 [published Online First: 2009/08/06] 
40. Khatri M, Moon YP, Scarmeas N, et al. The association between a Mediterranean-
style diet and kidney function in the Northern Manhattan Study cohort. Clin J 
Am Soc Nephrol 2014;9(11):1868-75. doi: 10.2215/cjn.01080114 [published 
Online First: 2014/11/02] 
41. Jayasumana C, Orantes C, Herrera R, et al. Chronic interstitial nephritis in 
agricultural communities: a worldwide epidemic with social, occupational and 
 272 
 
environmental determinants. Nephrol Dial Transplant 2017;32(2):234-41. doi: 
10.1093/ndt/gfw346 [published Online First: 2017/02/12] 
42. Valcke M, Levasseur ME, Soares da Silva A, et al. Pesticide exposures and 
chronic kidney disease of unknown etiology: an epidemiologic review. 
Environmental health : a global access science source 2017;16(1):49. doi: 
10.1186/s12940-017-0254-0 [published Online First: 2017/05/26] 
43. Ekiti ME, Zambo JB, Assah FK, et al. Chronic kidney disease in sugarcane 
workers in Cameroon: a cross-sectional study. BMC nephrology 
2018;19(1):10. doi: 10.1186/s12882-017-0798-9 [published Online First: 
2018/01/18] 
44. Hsu LI, Hsieh FI, Wang YH, et al. Arsenic Exposure From Drinking Water and 
the Incidence of CKD in Low to Moderate Exposed Areas of Taiwan: A 14-
Year Prospective Study. American journal of kidney diseases : the official 
journal of the National Kidney Foundation 2017;70(6):787-97. doi: 
10.1053/j.ajkd.2017.06.012 [published Online First: 2017/08/29] 
45. Tsai CC, Wu CL, Kor CT, et al. Prospective associations between environmental 
heavy metal exposure and renal outcomes in adults with chronic kidney 
disease. Nephrology (Carlton, Vic) 2017 doi: 10.1111/nep.13089 [published 
Online First: 2017/06/21] 
46. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension 
and perspectives. Lancet 2013;382(9888):260-72. doi: 10.1016/s0140-
6736(13)60687-x [published Online First: 2013/06/04] 
47. White SL, Chadban SJ, Jan S, et al. How can we achieve global equity in 
provision of renal replacement therapy? Bull World Health Organ 
2008;86(3):229-37. [published Online First: 2008/03/28] 
48. International diabetes federation – Global Burden of Diabetes Atlas, 6th edition  
49. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the 
year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53. 
[published Online First: 2004/04/28] 
50. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: 
analysis of worldwide data. Lancet 2005;365(9455):217-23. doi: 
10.1016/s0140-6736(05)17741-1 [published Online First: 2005/01/18] 
51. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008-12. 
[published Online First: 2000/05/02] 
52. UN Department of Economic and Social Aff airs. Population Division, Population 
Estimates and Projections Section. World population prospects: the 2012 
revision. http://esa.un.org/wpp.  
53. World bank GNI/GNI growth data. http://www.worldbank.org.  
54. The International Monetary Fund website. http://www.imf.org.  
55. The Frederick S Pardee Centre for International Futures website. 
http://www.ifs.du.edu/ifs/frm_CountryProfile.aspx?Country=TW  
56. The Global Health Observatory Data Repository website.  
http://www.who.int/gho/ncd/risk_factors/en/.  
57. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional 
studies: an empirical comparison of models that directly estimate the 
prevalence ratio. BMC medical research methodology 2003;3:21. doi: 
10.1186/1471-2288-3-21 [published Online First: 2003/10/22] 
 273 
 
58. Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated 
kidney failure in older vs younger adults. Jama 2012;307(23):2507-15. doi: 
10.1001/jama.2012.6455 [published Online First: 2012/07/17] 
59. Sparke C, Moon L, Green F, et al. Estimating the total incidence of kidney failure 
in Australia including individuals who are not treated by dialysis or 
transplantation. American journal of kidney diseases : the official journal of 
the National Kidney Foundation 2013;61(3):413-9. doi: 
10.1053/j.ajkd.2012.10.012 [published Online First: 2012/11/28] 
60. Steyerberg EW, Borsboom GJ, van Houwelingen HC, et al. Validation and 
updating of predictive logistic regression models: a study on sample size and 
shrinkage. Statistics in medicine 2004;23(16):2567-86. doi: 10.1002/sim.1844 
[published Online First: 2004/08/03] 
61. Prof. Vivekanand Jha. Personal Communication. 
62. Zhao M,  Lv J. Personal Communication, Chinese Society of Nephrology Official 
Web Site  
63. Patrice HM. Personal Communication.  
64. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-
term implications. J Am Soc Nephrol 2002;13 Suppl 1:S37-40. [published 
Online First: 2002/01/17] 
65. Grassmann A, Gioberge S, Moeller S, et al. ESRD patients in 2004: global 
overview of patient numbers, treatment modalities and associated trends. 
Nephrol Dial Transplant 2005;20(12):2587-93. doi: 10.1093/ndt/gfi159 
[published Online First: 2005/10/06] 
66. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage 
renal disease and use of therapy. PLoS One 2013;8(8):e72860. doi: 
10.1371/journal.pone.0072860 [published Online First: 2013/09/12] 
67. Jha V. End-stage renal care in developing countries: the India experience. Ren 
Fail 2004;26(3):201-8. [published Online First: 2004/09/10] 
68. Ehrich JHH, El Gendi AA, Drukker A, et al. Demography of paediatric renal care 
in Europe: organization and delivery. Nephrology Dialysis Transplantation 
2005;20(2):297-305. doi: 10.1093/ndt/gfh299 
69. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering 
on the progression of chronic kidney disease: a systematic review and meta-
analysis. CMAJ : Canadian Medical Association journal = journal de 
l'Association medicale canadienne 2013;185(11):949-57. doi: 
10.1503/cmaj.121468 [published Online First: 2013/06/27] 
70. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves 
kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83(3):517-
23. doi: 10.1038/ki.2012.401 [published Online First: 2013/01/11] 
71. Bedford M, Farmer C, Levin A, et al. Acute kidney injury and CKD: chicken or 
egg? American journal of kidney diseases : the official journal of the National 
Kidney Foundation 2012;59(4):485-91. doi: 10.1053/j.ajkd.2011.09.010 
[published Online First: 2012/03/27] 
72. Joshi R, Jan S, Wu Y, et al. Global inequalities in access to cardiovascular health 
care: our greatest challenge. Journal of the American College of Cardiology 
2008;52(23):1817-25. doi: 10.1016/j.jacc.2008.08.049 [published Online First: 
2008/11/29] 
73. Mazzuchi N, Schwedt E, Sola L, et al. Risk factors and prevention of end stage 
renal disease in uruguay. Ren Fail 2006;28(8):617-25. doi: 
10.1080/08860220600925677 [published Online First: 2006/12/13] 
 274 
 
74. Wei SY, Chang YY, Mau LW, et al. Chronic kidney disease care program 
improves quality of pre-end-stage renal disease care and reduces medical 
costs. Nephrology (Carlton, Vic) 2010;15(1):108-15. doi: 10.1111/j.1440-
1797.2009.01154.x [published Online First: 2010/04/10] 
75. Lin CM, Yang MC, Hwang SJ, et al. Progression of stages 3b-5 chronic kidney 
disease--preliminary results of Taiwan national pre-ESRD disease 
management program in Southern Taiwan. J Formos Med Assoc 
2013;112(12):773-82. doi: 10.1016/j.jfma.2013.10.021 [published Online 
First: 2013/12/07] 
76. Rayner HC, Baharani J, Dasgupta I, et al. Does community-wide chronic kidney 
disease management improve patient outcomes? Nephrol Dial Transplant 
2014;29(3):644-9. doi: 10.1093/ndt/gft486 [published Online First: 
2013/12/18] 
77. Kidney Disease: Improving Global Outcomes (KDIGO)  2012 Clinical Practice 
Guideline for the Evaluation and Management of Chronic Kidney Disease.  
78. United States Renal Data System - 2011 Atlas of CKD & ESRD 
 
79. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of 
commonly measured variables and an evaluation of death rate differences 
between facilities. American journal of kidney diseases : the official journal of 
the National Kidney Foundation 1990;15(5):458-82. [published Online First: 
1990/05/01] 
80. Nakai S, Watanabe Y, Masakane I, et al. Overview of regular dialysis treatment in 
Japan (as of 31 December 2011). Therapeutic apheresis and dialysis : official 
peer-reviewed journal of the International Society for Apheresis, the Japanese 
Society for Apheresis, the Japanese Society for Dialysis Therapy 
2013;17(6):567-611. doi: 10.1111/1744-9987.12147 [published Online First: 
2013/12/18] 
81. United States Renal Data System - 2012 Atlas of CKD & ESRD. 2012 
82. Chen J, Wildman RP, Gu D, et al. Prevalence of decreased kidney function in 
Chinese adults aged 35 to 74 years. Kidney Int 2005;68(6):2837-45. doi: 
10.1111/j.1523-1755.2005.00757.x [published Online First: 2005/12/01] 
83. Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney 
disease in Okinawa, Japan. Kidney Int 2006;69(2):369-74. doi: 
10.1038/sj.ki.5000050 [published Online First: 2006/01/13] 
84. White SL, Cass A, Atkins RC, et al. Chronic kidney disease in the general 
population. Advances in chronic kidney disease 2005;12(1):5-13. [published 
Online First: 2005/02/19] 
85. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association 
between serum cholesterol concentration and ischaemic heart disease in 
observational studies: data from the BUPA study. BMJ (Clinical research ed) 
1994;308(6925):363-6. [published Online First: 1994/02/05] 
86. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart 
disease. Part 1, Prolonged differences in blood pressure: prospective 
observational studies corrected for the regression dilution bias. Lancet 
1990;335(8692):765-74. [published Online First: 1990/03/31] 
87. PSC. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 
people in 45 prospective cohorts. Prospective studies collaboration. Lancet 
1995;346(8991-8992):1647-53. [published Online First: 1995/12/23] 
 275 
 
88. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated 
glomerular filtration rate and albuminuria with all-cause and cardiovascular 
mortality in general population cohorts: a collaborative meta-analysis. Lancet 
2010;375(9731):2073-81. doi: 10.1016/s0140-6736(10)60674-5 [published 
Online First: 2010/05/21] 
89. Group IMC. Risk factors for cardiovascular disease in the developing world. A 
multicentre collaborative study in the International Clinical Epidemiology 
Network (INCLEN). . Journal of clinical epidemiology 1992;45(8):841-7. 
[published Online First: 1992/08/01] 
90. Kesteloot H, Huang DX, Yang XS, et al. Serum lipids in the People's Republic of 
China. Comparison of Western and Eastern populations. Arteriosclerosis 
(Dallas, Tex) 1985;5(5):427-33. [published Online First: 1985/09/01] 
91. Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: a collaborative study on 
trends and determinants in cardiovascular diseases in China, Part i: morbidity 
and mortality monitoring. Circulation 2001;103(3):462-8. [published Online 
First: 2001/02/07] 
92. Tsukamoto Y, Wang H, Becker G, et al. Report of the Asian Forum of Chronic 
Kidney Disease Initiative (AFCKDI) 2007. "Current status and perspective of 
CKD in Asia": diversity and specificity among Asian countries. Clinical and 
experimental nephrology 2009;13(3):249-56. doi: 10.1007/s10157-009-0156-8 
[published Online First: 2009/03/17] 
93. ESCHD. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke 
and Coronary Heart Disease Collaborative Research Group. Lancet 
1998;352(9143):1801-7. [published Online First: 1998/12/16] 
94. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: 
prevalence, numerical estimates, and projections. Diabetes Care 
1998;21(9):1414-31. [published Online First: 1998/09/04] 
95. D C. Regression Models and Life-Tables (with discussion). Journal of the Royal 
Statistical Society Series B (Methodological) 1972;34(2):187-220. 
96. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-
stage kidney disease: a systematic review. Lancet 2015;385(9981):1975-82. 
doi: 10.1016/s0140-6736(14)61601-9 [published Online First: 2015/03/18] 
97. Liyanage T, Ninomiya T, Perkovic V, et al. Chronic kidney disease in Asia: 
Protocol for a collaborative overview. Nephrology (Carlton, Vic) 
2017;22(6):456-62. doi: 10.1111/nep.12821 [published Online First: 
2016/05/18] 
98. UN Department of Economic and Social Aff airs. Population Division, Population 
Estimates and Projections Section. World population prospects: the 2017 
revision. http://esa.un.org/wpp.  
99. National Statistics Republic of China (Taiwan)  
http://eng.stat.gov.tw/lp.asp?ctNode=1628&CtUnit=778&BaseDSD=7&mp=5
.  
100. http://www.saedsayad.com/clustering_hierarchical.htm.  
101. Fatema K, Abedin Z, Mansur A, et al. Screening for chronic kidney diseases 
among an adult population. Saudi J Kidney Dis Transpl 2013;24(3):534-41. 
[published Online First: 2013/05/04] 
102. Hooi LS, Ong LM, Ahmad G, et al. A population-based study measuring the 
prevalence of chronic kidney disease among adults in West Malaysia. Kidney 
Int 2013;84(5):1034-40. doi: 10.1038/ki.2013.220 [published Online First: 
2013/06/14] 
 276 
 
103. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the 
Japanese general population. Clinical and experimental nephrology 
2009;13(6):621-30. doi: 10.1007/s10157-009-0199-x [published Online First: 
2009/06/11] 
104. Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of 
chronic kidney disease in the Thai adult population: Thai SEEK study. 
Nephrol Dial Transplant 2010;25(5):1567-75. doi: 10.1093/ndt/gfp669 
[published Online First: 2009/12/29] 
105. Ito J, Dung DT, Vuong MT, et al. Impact and perspective on chronic kidney 
disease in an Asian developing country: a large-scale survey in North 
Vietnam. Nephron Clinical practice 2008;109(1):c25-32. doi: 
10.1159/000134379 [published Online First: 2008/05/24] 
106. Jafar TH, Qadri Z, Hashmi S. Prevalence of microalbuminuria and associated 
electrocardiographic abnormalities in an Indo-Asian population. Nephrol Dial 
Transplant 2009;24(7):2111-6. doi: 10.1093/ndt/gfp042 [published Online 
First: 2009/02/20] 
107. Jayasekara KB, Dissanayake DM, Sivakanesan R, et al. Epidemiology of chronic 
kidney disease, with special emphasis on chronic kidney disease of uncertain 
etiology, in the north central region of Sri Lanka. Journal of epidemiology 
2015;25(4):275-80. doi: 10.2188/jea.JE20140074 [published Online First: 
2015/03/20] 
108. Khajehdehi P, Malekmakan L, Pakfetrat M, et al. Prevalence of chronic kidney 
disease and its contributing risk factors in southern Iran: a cross-sectional adult 
population-based study. Iranian journal of kidney diseases 2014;8(2):109-15. 
[published Online First: 2014/04/02] 
109. Prodjosudjadi W, Suhardjono, Suwitra K, et al. Detection and prevention of 
chronic kidney disease in Indonesia: initial community screening. Nephrology 
(Carlton, Vic) 2009;14(7):669-74. doi: 10.1111/j.1440-1797.2009.01137.x 
[published Online First: 2009/10/03] 
110. Sabanayagam C, Lim SC, Wong TY, et al. Ethnic disparities in prevalence and 
impact of risk factors of chronic kidney disease. Nephrol Dial Transplant 
2010;25(8):2564-70. doi: 10.1093/ndt/gfq084 [published Online First: 
2010/02/27] 
111. Sharma SK, Dhakal S, Thapa L, et al. Community-based screening for chronic 
kidney disease, hypertension and diabetes in Dharan. JNMA; journal of the 
Nepal Medical Association 2013;52(189):205-12. [published Online First: 
2013/04/18] 
112. Sharma SK, Zou H, Togtokh A, et al. Burden of CKD, proteinuria, and 
cardiovascular risk among Chinese, Mongolian, and Nepalese participants in 
the International Society of Nephrology screening programs. American journal 
of kidney diseases : the official journal of the National Kidney Foundation 
2010;56(5):915-27. doi: 10.1053/j.ajkd.2010.06.022 [published Online First: 
2010/10/05] 
113. Singh AK, Farag YM, Mittal BV, et al. Epidemiology and risk factors of chronic 
kidney disease in India - results from the SEEK (Screening and Early 
Evaluation of Kidney Disease) study. BMC nephrology 2013;14:114. doi: 
10.1186/1471-2369-14-114 [published Online First: 2013/05/30] 
114. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic 
kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. 
 277 
 
Lancet 2008;371(9631):2173-82. doi: 10.1016/s0140-6736(08)60952-6 
[published Online First: 2008/07/01] 
115. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-
based data on the global burden of chronic kidney disease in 2010. Kidney Int 
2015;88(5):950-7. doi: 10.1038/ki.2015.230 [published Online First: 
2015/07/30] 
116. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm.  
117. http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-
ch8-kidn.pdf.  
118. Arora P, Vasa P, Brenner D, et al. Prevalence estimates of chronic kidney disease 
in Canada: results of a nationally representative survey. CMAJ : Canadian 
Medical Association journal = journal de l'Association medicale canadienne 
2013;185(9):E417-23. doi: 10.1503/cmaj.120833 [published Online First: 
2013/05/08] 
119. Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk 
in patients with chronic kidney disease. Current opinion in nephrology and 
hypertension 2004;13(1):73-81. [published Online First: 2004/04/20] 
120. Portoles J, Gorriz JL, Rubio E, et al. The development of anemia is associated to 
poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC 
nephrology 2013;14:2. doi: 10.1186/1471-2369-14-2 [published Online First: 
2013/01/09] 
121. Thomas M, Tsalamandris C, MacIsaac R, et al. Anaemia in diabetes: an 
emerging complication of microvascular disease. Current diabetes reviews 
2005;1(1):107-26. [published Online First: 2008/01/29] 
122. Horl WH. Anaemia management and mortality risk in chronic kidney disease. 
Nat Rev Nephrol 2013;9(5):291-301. doi: 10.1038/nrneph.2013.21 [published 
Online First: 2013/02/27] 
123. Astor BC, Muntner P, Levin A, et al. Association of kidney function with 
anemia: the Third National Health and Nutrition Examination Survey (1988-
1994). Archives of internal medicine 2002;162(12):1401-8. [published Online 
First: 2002/06/22] 
124. Herzog CA, Muster HA, Li S, et al. Impact of congestive heart failure, chronic 
kidney disease, and anemia on survival in the Medicare population. Journal of 
cardiac failure 2004;10(6):467-72. [published Online First: 2004/12/16] 
125. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes 
Care 2009;32(7):1320-6. doi: 10.2337/dc08-0779 [published Online First: 
2009/07/01] 
126. Smith RE, Jr. The clinical and economic burden of anemia. The American 
journal of managed care 2010;16 Suppl Issues:S59-66. [published Online 
First: 2010/03/20] 
127. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the 
United States. PLoS One 2014;9(1):e84943. doi: 
10.1371/journal.pone.0084943 [published Online First: 2014/01/07] 
128. van Nooten FE, Green J, Brown R, et al. Burden of illness for patients with non-
dialysis chronic kidney disease and anemia in the United States: review of the 
literature. Journal of medical economics 2010;13(2):241-56. doi: 
10.3111/13696998.2010.484307 [published Online First: 2010/05/05] 
129. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines 
for the management of anaemia in patients with chronic renal failure. Nephrol 
Dial Transplant 2004;19 Suppl 2:ii1-47. [published Online First: 2004/06/23] 
 278 
 
130. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 
KDIGO Clinical Practice Guideline for Anemia in CKD. American journal of 
kidney diseases : the official journal of the National Kidney Foundation 
2013;62(5):849-59. doi: 10.1053/j.ajkd.2013.06.008 [published Online First: 
2013/07/31] 
131. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic 
renal insufficiency. American journal of kidney diseases : the official journal 
of the National Kidney Foundation 2001;38(4):803-12. doi: 
10.1053/ajkd.2001.27699 [published Online First: 2001/09/29] 
132. Li Y, Zhang W, Ren H, et al. Evaluation of anemia and serum iPTH, calcium, 
and phosphorus in patients with primary glomerulonephritis. Contributions to 
nephrology 2013;181:31-40. doi: 10.1159/000348636 [published Online First: 
2013/05/22] 
133. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for 
anemia in chronic kidney disease: 2007 update of hemoglobin target. 
American journal of kidney diseases : the official journal of the National 
Kidney Foundation 2007;50(3):471-530. doi: 10.1053/j.ajkd.2007.06.008 
[published Online First: 2007/08/28] 
134. Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of 
dialysis in the United States. Kidney Int 2001;60(5):1875-84. doi: 
10.1046/j.1523-1755.2001.00002.x [published Online First: 2001/11/13] 
135. Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated 
with suboptimal care before initiation of dialysis in the United States. J Am 
Soc Nephrol 1999;10(8):1793-800. [published Online First: 1999/08/14] 
136. Toto RD. Anemia of chronic disease: past, present, and future. Kidney Int Suppl 
2003(87):S20-3. [published Online First: 2003/10/09] 
137. 1999 World Health Organization-International Society of Hypertension 
Guidelines for the Management of Hypertension. Guidelines Subcommittee. 
Journal of hypertension 1999;17(2):151-83. [published Online First: 
1999/03/06] 
138. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes 
mellitus provisional report of a WHO consultation. Diabetic medicine : a 
journal of the British Diabetic Association 1998;15(7):539-53. doi: 
10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s [published 
Online First: 1998/08/01] 
139. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of 
five European countries: association with morbidity and mortality in the 
Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial 
Transplant 2004;19(1):121-32. [published Online First: 2003/12/13] 
140. Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and end-stage renal disease in 
patients with type 2 diabetes and nephropathy. Kidney Int 2004;66(3):1131-8. 
doi: 10.1111/j.1523-1755.2004.00863.x [published Online First: 2004/08/26] 
141. Clement FM, Klarenbach S, Tonelli M, et al. An economic evaluation of 
erythropoiesis-stimulating agents in CKD. American journal of kidney 
diseases : the official journal of the National Kidney Foundation 
2010;56(6):1050-61. doi: 10.1053/j.ajkd.2010.07.015 [published Online First: 
2010/10/12] 
142. Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of 
maintaining higher hemoglobin targets with erythropoietin in hemodialysis 
 279 
 
patients. Kidney Int 2003;64(1):295-304. doi: 10.1046/j.1523-
1755.2003.00079.x [published Online First: 2003/06/06] 
143. Yarnoff BO, Hoerger TJ, Simpson SA, et al. The Cost-Effectiveness of Anemia 
Treatment for Persons with Chronic Kidney Disease. PLoS One 
2016;11(7):e0157323. doi: 10.1371/journal.pone.0157323 [published Online 
First: 2016/07/13] 
144. Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in 
Chinese patients with nondialysis chronic kidney disease: First multicenter, 
cross-sectional study. Medicine 2016;95(24):e3872. doi: 
10.1097/md.0000000000003872 [published Online First: 2016/06/17] 
145. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in 
patients with chronic kidney disease. Current medical research and opinion 
2004;20(9):1501-10. doi: 10.1185/030079904x2763 [published Online First: 
2004/09/24] 
146. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar 
recombinant human erythropoietin induces the production of neutralizing 
antibodies. Kidney Int 2011;80(1):88-92. doi: 10.1038/ki.2011.68 [published 
Online First: 2011/03/25] 
147. Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet 
and survival in a Greek population. The New England journal of medicine 
2003;348(26):2599-608. doi: 10.1056/NEJMoa025039 [published Online 
First: 2003/06/27] 
148. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the 
seven countries study. American journal of epidemiology 1986;124(6):903-15. 
[published Online First: 1986/12/01] 
149. Buckland G, Gonzalez CA, Agudo A, et al. Adherence to the Mediterranean diet 
and risk of coronary heart disease in the Spanish EPIC Cohort Study. 
American journal of epidemiology 2009;170(12):1518-29. doi: 
10.1093/aje/kwp282 [published Online First: 2009/11/12] 
150. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle 
factors, and 10-year mortality in elderly European men and women: the HALE 
project. JAMA 2004;292(12):1433-9. doi: 10.1001/jama.292.12.1433 
[published Online First: 2004/09/24] 
151. Martinez-Gonzalez MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, et al. 
Adherence to Mediterranean diet and risk of developing diabetes: prospective 
cohort study. BMJ (Clinical research ed) 2008;336(7657):1348-51. doi: 
10.1136/bmj.39561.501007.BE [published Online First: 2008/05/31] 
152. Psaltopoulou T, Naska A, Orfanos P, et al. Olive oil, the Mediterranean diet, and 
arterial blood pressure: the Greek European Prospective Investigation into 
Cancer and Nutrition (EPIC) study. The American journal of clinical nutrition 
2004;80(4):1012-8. [published Online First: 2004/09/28] 
153. Rumawas ME, Meigs JB, Dwyer JT, et al. Mediterranean-style dietary pattern, 
reduced risk of metabolic syndrome traits, and incidence in the Framingham 
Offspring Cohort. The American journal of clinical nutrition 2009;90(6):1608-
14. doi: 10.3945/ajcn.2009.27908 [published Online First: 2009/10/16] 
154. Buckland G, Bach A, Serra-Majem L. Obesity and the Mediterranean diet: a 
systematic review of observational and intervention studies. Obesity reviews : 
an official journal of the International Association for the Study of Obesity 
2008;9(6):582-93. doi: 10.1111/j.1467-789X.2008.00503.x [published Online 
First: 2008/06/13] 
 280 
 
155. Kastorini CM, Milionis HJ, Esposito K, et al. The effect of Mediterranean diet on 
metabolic syndrome and its components: a meta-analysis of 50 studies and 
534,906 individuals. Journal of the American College of Cardiology 
2011;57(11):1299-313. doi: 10.1016/j.jacc.2010.09.073 [published Online 
First: 2011/03/12] 
156. Bloomfield HE, Koeller E, Greer N, et al. Effects on Health Outcomes of a 
Mediterranean Diet With No Restriction on Fat Intake: A Systematic Review 
and Meta-analysis. Annals of internal medicine 2016;165(7):491-500. doi: 
10.7326/m16-0361 [published Online First: 2016/07/19] 
157. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a 
cultural model for healthy eating. The American journal of clinical nutrition 
1995;61(6 Suppl):1402S-06S. [published Online First: 1995/06/01] 
158. Higgins J. Cochrane Handbook for Systematic Reviews of Interventions.Version 
5.1.0. 2011 
159. Newcombe RG. Two-sided confidence intervals for the single proportion: 
comparison of seven methods. Statistics in medicine 1998;17(8):857-72. 
[published Online First: 1998/05/22] 
160. Woodward M (ed). Epidemiology: design and data analysis. 2nd edn. Boca 
Raton, Florida, USA: Chapman and Hall/CRC Press 2005 
161. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by 
a simple, graphical test. BMJ (Clinical research ed) 1997;315(7109):629-34. 
[published Online First: 1997/10/06] 
162. WHO (September, 2011) Cardiovascular Diseases, Fact Sheet Number 317.  
163. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing 
countries. Circulation 1998;97(6):596-601. [published Online First: 
1998/03/11] 
164. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-
rich diet in secondary prevention of coronary heart disease. Lancet 
1994;343(8911):1454-9. [published Online First: 1994/06/11] 
165. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular 
disease with a Mediterranean diet. The New England journal of medicine 
2013;368(14):1279-90. doi: 10.1056/NEJMoa1200303 [published Online 
First: 2013/02/26] 
166. Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. Lancet 
2005;366(9483):354-6. doi: 10.1016/s0140-6736(05)67006-7 [published 
Online First: 2005/08/02] 
167. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice 
to men with angina: results of a controlled trial. European journal of clinical 
nutrition 2003;57(2):193-200. doi: 10.1038/sj.ejcn.1601539 [published Online 
First: 2003/02/07] 
168. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on 
progression of coronary artery disease in high risk patients (Indo-
Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 
2002;360(9344):1455-61. doi: 10.1016/s0140-6736(02)11472-3 [published 
Online First: 2002/11/16] 
169. Ng GW, Chan UM, Li PC, et al. Can a Mediterranean diet reduce the effects of 
lipodystrophy syndrome in people living with HIV? A pilot randomised 
controlled trial. Sexual health 2011;8(1):43-51. doi: 10.1071/sh09065 
[published Online First: 2011/03/05] 
 281 
 
170. Toobert DJ, Glasgow RE, Strycker LA, et al. Biologic and quality-of-life 
outcomes from the Mediterranean Lifestyle Program: a randomized clinical 
trial. Diabetes Care 2003;26(8):2288-93. [published Online First: 2003/07/29] 
171. Polonsky WH. Understanding and assessing diabetes-specific quality of life. 
Diabetes Spectrum 2000;13(1):36-41. 
172. Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. 
Reliability and validity in a patient population. Medical care 1988;26(7):724-
35. [published Online First: 1988/07/01] 
173. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, et al. Mediterranean diet, 
stroke, cognitive impairment, and depression: A meta-analysis. Annals of 
neurology 2013;74(4):580-91. doi: 10.1002/ana.23944 [published Online 
First: 2013/05/31] 
174. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence 
to the Mediterranean diet on health: an updated systematic review and meta-
analysis. The American journal of clinical nutrition 2010;92(5):1189-96. doi: 
10.3945/ajcn.2010.29673 [published Online First: 2010/09/03] 
175. Grosso G, Mistretta A, Frigiola A, et al. Mediterranean diet and cardiovascular 
risk factors: a systematic review. Critical reviews in food science and nutrition 
2014;54(5):593-610. doi: 10.1080/10408398.2011.596955 [published Online 
First: 2013/11/23] 
176. Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al. Meta-analysis 
comparing Mediterranean to low-fat diets for modification of cardiovascular 
risk factors. The American journal of medicine 2011;124(9):841-51.e2. doi: 
10.1016/j.amjmed.2011.04.024 [published Online First: 2011/08/23] 
177. Rees K, Hartley L, Flowers N, et al. 'Mediterranean' dietary pattern for the 
primary prevention of cardiovascular disease. The Cochrane database of 
systematic reviews 2013;8:CD009825. doi: 
10.1002/14651858.CD009825.pub2 [published Online First: 2013/08/14] 
178. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-
style diet on cardiovascular risk factors: a randomized trial. Annals of internal 
medicine 2006;145(1):1-11. [published Online First: 2006/07/05] 
179. Paraskevi Detopoulou CAD, Smaragdi Antonopoulou. Mediterranean diet in a 
new perspective: A Systematic review for its benefits regarding mortality and 
cardiovascular disease and potential protective mechanisms. Hellenic Journal 
of Nutrition & Dietetics 2013;Vol 4(1):27-43. 
180. Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and 
endothelial function: a systematic review and meta-analysis of intervention 
trials. Nutrition, metabolism, and cardiovascular diseases : NMCD 
2014;24(9):929-39. doi: 10.1016/j.numecd.2014.03.003 [published Online 
First: 2014/05/03] 
181. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements 
in prevention of cardiovascular disease: systematic review and meta-analysis 
of randomised controlled trials. BMJ (Clinical research ed) 2013;346:f10. doi: 
10.1136/bmj.f10 [published Online First: 2013/01/22] 
182. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle 
management to reduce cardiovascular risk: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Journal of the American College of Cardiology 2014;63(25 Pt B):2960-84. 
doi: 10.1016/j.jacc.2013.11.003 [published Online First: 2013/11/19] 
 282 
 
183. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular 
disease prevention in clinical practice (version 2012). The Fifth Joint Task 
Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representatives of nine societies and by invited experts). European heart 
journal 2012;33(13):1635-701. doi: 10.1093/eurheartj/ehs092 [published 
Online First: 2012/05/05] 
184. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ (Clinical 
research ed) 2006;332(7541):563-4. doi: 10.1136/bmj.332.7541.563 
[published Online First: 2006/03/11] 
185. United States Renal Data System - 2017 USRDS Annual Data Report  
186. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular 
disease in chronic renal disease. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 1998;32(5 Suppl 3):S112-
9. [published Online First: 1998/11/20] 
187. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes 
among a population with chronic kidney disease in a large managed care 
organization. Archives of internal medicine 2004;164(6):659-63. doi: 
10.1001/archinte.164.6.659 [published Online First: 2004/03/24] 
188. Johnson DW. Evidence-based guide to slowing the progression of early renal 
insufficiency. Internal medicine journal 2004;34(1-2):50-7. [published Online 
First: 2004/01/30] 
189. Modi GK, Jha V. The incidence of end-stage renal disease in India: a population-
based study. Kidney Int 2006;70(12):2131-3. doi: 10.1038/sj.ki.5001958 
[published Online First: 2006/10/26] 
190. Australian Bureau of Statistics. Australian health survey: First results 2011-12. 
2012. Report No:4364.0.55.001.  
191. Jun M PV, Cass A. Intensive glycemic control and renal outcome. In KN Lai and 
SCW Tang (editors), Diabetes and the Kidney. Contributions to Nephrology. 
Basel, Karger vol 170; 196-208.  
192. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic 
review and meta-analysis. Journal of the American College of Cardiology 
2012;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049 [published Online First: 
2012/10/23] 
193. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants 
of cardiovascular disease in endstage renal disease (SPACE): randomised 
placebo-controlled trial. Lancet 2000;356(9237):1213-8. [published Online 
First: 2000/11/10] 
194. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces 
cardiovascular events in patients with end-stage renal failure: a randomized, 
controlled trial. Circulation 2003;107(7):992-5. [published Online First: 
2003/02/26] 
195. Jun M, Jardine MJ, Gray N, et al. Outcomes of extended-hours hemodialysis 
performed predominantly at home. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 2013;61(2):247-53. doi: 
10.1053/j.ajkd.2012.08.032 [published Online First: 2012/10/06] 
196. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-
enzyme inhibitor benazepril on the progression of chronic renal insufficiency. 
The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal 
Insufficiency Study Group. The New England journal of medicine 
 283 
 
1996;334(15):939-45. doi: 10.1056/nejm199604113341502 [published Online 
First: 1996/04/11] 
197. Randomised placebo-controlled trial of effect of ramipril on decline in 
glomerular filtration rate and risk of terminal renal failure in proteinuric, non-
diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi 
Epidemiologici in Nefrologia). Lancet 1997;349(9069):1857-63. [published 
Online First: 1997/06/28] 
198. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and 
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The 
New England journal of medicine 2001;345(12):861-9. doi: 
10.1056/NEJMoa011161 [published Online First: 2001/09/22] 
199. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the 
role of blood pressure control, proteinuria, and angiotensin-converting enzyme 
inhibition: a patient-level meta-analysis. Annals of internal medicine 
2003;139(4):244-52. [published Online First: 2003/09/11] 
200. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. The New England journal of 
medicine 2004;351(13):1296-305. doi: 10.1056/NEJMoa041031 [published 
Online First: 2004/09/24] 
201. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of 
randomized controlled trials in nephrology. J Am Soc Nephrol 
2004;15(2):411-9. [published Online First: 2004/01/30] 
202. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and 
prognosis of chronic kidney disease: a KDIGO Controversies Conference 
report. Kidney Int 2011;80(1):17-28. doi: ki2010483 [pii] 
10.1038/ki.2010.483 [published Online First: 2010/12/15] 
203. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship 
of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 
2006;17(8):2275-84. doi: 10.1681/ASN.2005121273 
204. Odden MC, Whooley MA, Shlipak MG. Depression, stress, and quality of life in 
persons with chronic kidney disease: the Heart and Soul Study. Nephron 
Clinical practice 2006;103(1):c1-7. doi: 10.1159/000090112 
205. Campbell KH, Huang ES, Dale W, et al. Association between estimated GFR, 
health-related quality of life, and depression among older adults with diabetes: 
the Diabetes and Aging Study. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 2013;62(3):541-8. doi: 
10.1053/j.ajkd.2013.03.039 
206. Urquhart-Secord R, Craig JC, Hemmelgarn B, et al. Patient and Caregiver 
Priorities for Outcomes in Hemodialysis: An International Nominal Group 
Technique Study. American journal of kidney diseases : the official journal of 
the National Kidney Foundation 2016;68(3):444-54. doi: 
10.1053/j.ajkd.2016.02.037 
207. Sautenet B, Tong A, Manera KE, et al. Developing Consensus-Based Priority 
Outcome Domains for Trials in Kidney Transplantation: A Multinational 
Delphi Survey With Patients, Caregivers, and Health Professionals. 
Transplantation 2017;101(8):1875-86. doi: 10.1097/TP.0000000000001776 
208. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related 
quality of life research to support labeling and promotional claims in the 
United States. Qual Life Res 2000;9(8):887-900. 
 284 
 
209. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on 
renal replacement therapy: a systematic review and meta-analysis. Value 
Health 2008;11(4):733-41. doi: 10.1111/j.1524-4733.2007.00308.x 
210. Ware JE, Jr. SF-36 health survey update. Spine (Phila Pa 1976) 
2000;25(24):3130-9. 
211. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure 
of health from the SF-36. J Health Econ 2002;21(2):271-92. 
212. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity 
and Lifestyle Study (AusDiab)--methods and response rates. Diabetes 
research and clinical practice 2002;57(2):119-29. [published Online First: 
2002/06/14] 
213. KDIGO. Clinical Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease. Kidney international Supplement 2013;3(1) 
214. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. Medical care 
1992;30(6):473-83. 
215. Ware JE SK, Kosinski M, Gandek, B. SF-36 Health Survey. Manual and 
interpretation guide. : Boston: The Health Institute, New England Medical 
Center 1993. 
216. Norman R, Viney R, Brazier J, et al. Valuing SF-6D Health States Using a 
Discrete Choice Experiment. Med Decis Making 2014;34(6):773-86. doi: 
10.1177/0272989X13503499 
217. Porter AC, Lash JP, Xie D, et al. Predictors and Outcomes of Health-Related 
Quality of Life in Adults with CKD. Clin J Am Soc Nephrol 2016;11(7):1154-
62. doi: 10.2215/CJN.09990915 
218. Park JI, Baek H, Kim BR, et al. Comparison of urine dipstick and 
albumin:creatinine ratio for chronic kidney disease screening: A population-
based study. PLoS One 2017;12(2):e0171106. doi: 
10.1371/journal.pone.0171106 
219. Okubo R, Kai H, Kondo M, et al. Health-related quality of life and prognosis in 
patients with chronic kidney disease: a 3-year follow-up study. Clinical and 
experimental nephrology 2014;18(5):697-703. doi: 10.1007/s10157-013-0901-
x 
220. Park JI, Baek H, Jung HH. CKD and Health-Related Quality of Life: The Korea 
National Health and Nutrition Examination Survey. American journal of 
kidney diseases : the official journal of the National Kidney Foundation 
2016;67(6):851-60. doi: 10.1053/j.ajkd.2015.11.005 
221. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and 
estimates of utility in chronic kidney disease. Kidney Int 2005;68(6):2801-8. 
doi: 10.1111/j.1523-1755.2005.00752.x 
222. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining 
responsiveness and minimally important differences for patient-reported 
outcomes. Journal of clinical epidemiology 2008;61(2):102-9. doi: 
10.1016/j.jclinepi.2007.03.012 
223. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change 
in health-related quality of life. Journal of clinical epidemiology 
2003;56(5):395-407. 
224. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life 
data in CKD patients receiving treatment for anemia. Kidney Int 
2009;75(1):15-24. doi: 10.1038/ki.2008.414 
 285 
 
225. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important 
differences in health status measures: a general approach with illustration to 
the Health Utilities Index Mark II. Pharmacoeconomics 1999;15(2):141-55. 
226. Johnson DW, Jones GR, Mathew TH, et al. Chronic kidney disease and 
measurement of albuminuria or proteinuria: a position statement. Med J Aust 
2012;197(4):224-5. 
227. Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and 
reporting of urinary albumin excretion. Clin Chem 2009;55(1):24-38. doi: 
10.1373/clinchem.2008.106567 
 
